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ABSTRACT 
  Cytochrome P450 2J2 (CYP2J2) is membrane bound enzyme that is highly expressed in the 
cardiovascular system and brain where it mediates the metabolism of polyunsaturated fatty 
acids into oxygenated bioactive metabolites. This enzyme is most well-known for the 
conversion of arachidonic acid into epoxyeicosatrienoic acids (EETs) regioisomers, 14,15-, 
11,12-, 8,9-, and 5,6-EET that mediate vasodilatory, pro-angiogenic and anti-inflammatory 
effects. More recently, CYP2J2 has been identified as a key enzyme for the metabolism of 
omega-3 fatty acids, such as eicosapentanoic acid (EPA) and docosahexaenoic acid (DHA), 
producing epoxygenated metabolites that provide cardioprotective benefits.  
  The biochemical study of the CYP2J2 mediated metabolism of xenobiotics and endogenous 
fatty acids have been difficult due to challenges with protein expression and solubilization. 
To circumvent these issues, a series of N-terminal modifications were introduced in the 
CYP2J2 N-terminus that enabled heterologous expression in E. coli. Importantly, to address 
the propensity of CYP2J2 to aggregate in solution, each construct was incorporated into the 
native membrane bilayers of nanodiscs for rigorous spectroscopic and functional studies. 
Notably, all N-terminal constructs were stably bound within the nanodisc bilayers, which 
prompted efforts to elucidate additional motifs that impart membrane binding. These 
observations were further explored in a study using molecular dynamics simulations which 
revealed CYP2J2 membrane insertion at the F-G loop, through hydrophobic residues Trp-235, Ille-
236, and Phe-239. To explore the role of these residues, three F-G loop mutants were prepared 
from the truncated CYP2J2 construct (Δ34), which included Δ34-I236D, Δ34-F239H and Δ34-
I236D/F239H. Interestingly, the expression of the CYP2J2 F-G loop mutants in E. coli were shown 
to be localized to the cytosolic fraction at a greater percentage relative to construct Δ34  while 
functional characterization revealed that the double mutant, Δ34-I236D/F239H, exhibited the 
greatest solubility while maintaining native-like enzymatic activity. Further, the membrane 
insertion characteristics were examined by monitoring CYP2J2 Trp-quenching fluorescence 
spectroscopy upon binding nanodiscs containing pyrene phospholipids. Relative to the Δ34 
construct, all three F-G loop mutants exhibited lower Trp quenching indicating reduced membrane 
insertion.  
  The original CYP2J2 expression and characterization studies enabled metabolic screening of 
endogenous polyunsaturated fatty acid (PUFA) derived substrates that included derivatives of AA, 
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EPA and DHA. Notably, these efforts resulted in the discovery of the CYP2J2-nanodisc mediated 
oxygenation of omega-6 derived endocannabinoids, thereby revealing a previously unknown 
metabolic pathway. The endocannabinoids, anandamide (AEA) and 2-arachidonylglycerol (2-
AG), are endogenous lipid mediators that are agonists of cannabinoid receptor-1 (CB1) and 
cannabinoid receptor-2 (CB2) with effects similar to the active ingredient of marijuana. Reactions 
of CYP2J2 with AEA formed four AEA-epoxyeicosatrienoic acids, whereas incubations with 2-
AG yielded detectable levels of only two 2-AG epoxides. Additionally, 2-AG was shown to 
undergo enzymatic oxidative cleavage to form AA through a NADPH-dependent reaction with 
CYP2J2 and cytochrome P450 reductase.  
  The demonstrated ability of CYP2J2 to oxygenate AEA and 2-AG raised questions whether 
CYP2J2 could also accommodate the omega-3 derived endocannabinoids, eicosapentaenoic 
ethanolamide (EPEA) and docosahexaenoic ethanolamide (DHEA), as substrates. Indeed, 
subsequent metabolism studies of CYP2J2 with EPEA/DHEA revealed the production of a new 
class of ω-3 derived metabolites that we termed the omega-3 endocannabinoid epoxides – 
epoxyeicosatetraenoic-ethanolamide (EEQ-EA) and epoxydocosapentaenoic-ethanolamide (EDP-
EA). These newly discovered endogenous metabolites share structural similarity to both their 
endocannabinoid and epoxide parent compounds, with potential to exert physiological effects 
mediated through both signaling pathways. Both EEQ-EAs and EDP-EAs were endogenously 
present in rat brain and peripheral organs as determined via LC-MS/MS with 19,20-EDP-EA also 
detectable in pooled human plasma. Using LC-MS/MS we demonstrated the direct production of 
these lipids by recombinant human CYP2J2 epoxygenase, rat brain microsomes and activated BV-
2 microglia cells when supplemented with the parent EPEA or DHEA lipids. The discovery of 
these metabolites prompted a panel of in vitro assays to provide a first ever examination of their 
biological effects. Most notably, upon LPS stimulation of BV-2 microglia cells, both 17,18-EEQ-
EA and 19,20-EDP-EA decreased pro-inflammatory IL-6 and nitric oxide whilst increasing anti-
inflammatory IL-10. Additional studies revealed that these metabolites exerted anti-angiogenic 
effects in HMVEC cells, vasodilatory properties in bovine coronary arteries and reciprocally 
regulated platelet aggregation in washed human platelets. Taken together, the following thesis 
details new methods for the study of CYP2J2 within the membrane bilayers of nanodiscs. These 
techniques were used to reveal a new role for CYP2J2 in the metabolism of endocannabinoids into 
novel endocannabinoid metabolites with important physiological functions in the heart and brain. 
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CHAPTER I: DISSERTATION OVERVIEW 
  In biology, membrane proteins are embedded within the cell membrane bilayer. These membrane 
bound proteins are broadly classified into signaling receptors, ion channels and metabolic enzymes 
that are utilized throughout all kingdoms of life. Traditionally, membrane proteins have constituted 
one of the most difficult classes of proteins to characterize due to issues with stability, extraction, 
expression, functionality and data reproducibility. Thus, continual and incremental improvements 
in the methodologies necessary to probe the characteristics of these membrane proteins are an 
active area of research. Additionally, the structural differences among the different types of 
membrane proteins (e.g. enzyme vs. receptor) require targeted efforts to elucidate the nuances of 
each particular class of membrane proteins.  
  The following dissertation explores the biochemical, biophysical and metabolic pathway of 
human cytochrome P450 2J2 (CYP2J2), a membrane bound enzyme. This heme containing 
enzyme is the most highly expressed cytochrome P450 in the cardiovascular system and provides 
essential homeostatic functions via the metabolism of polyunsaturated fatty acids (PUFAs) into 
bioactive metabolites. Due to the intransigent nature of this enzyme, considerable efforts were 
expended to develop the methods that would later enable screening for previously unknown 
endogenous substrates of CYP2J2, thus providing new insights into the mechanisms by which 
CYP2J2 maintains homeostatic balance. 
  The dissertation is divided into a total of seven chapters with the corresponding figures, tables 
and references located at the end of each chapter. In Chapter II, I briefly review the literature that 
is relevant to what is known about the biochemistry and physiological significance of CYP2J2. 
Chapter III is an original research article that probes how the hydrophobic N-terminal membrane 
anchoring domain affects CYP2J2 expression in E. coli and functional activity in the membrane 
bilayers of nanodiscs [PMID: 23661295]. Importantly, this chapter provided the method to express 
the proteins that facilitated the other studies in this thesis. Of particular note we find that the native 
membrane bilayer and not the enzyme N-terminus is important for native-like activity. In Chapter 
IV, we show that additional hydrophobic residues of the F-G loop also are important for membrane 
binding capabilities of CYP2J2 [PMID: 26232558]. Using pyrene-phospholipids incorporated into 
the membrane bilayers of nanodiscs, we were able to experimentally demonstrate that hydrophilic 
mutation of key residues in the F-G loop significantly decrease the depth of insertion of CYP2J2 
and impart peripheral binding membrane protein characteristics.  
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  In Chapters V and VI, we show that CYP2J2 rapidly oxygenates a particular class of lipids known 
as the endocannabinoids into bioactive metabolites. Endocannabinoids are PUFA derived 
signaling molecules 2that have similar effects as Δ9-tetrahydrocannabinol, the active ingredient of 
cannabis. Specifically, in Chapter V we demonstrate that the omega-6 endocannabinoids, 
anandamide and 2-arachidonoylglycerol, are substrates for CYP2J2 [PMID: 25277139]. In short, 
CYP2J2 produced 2-AG and AEA epoxides that were previously demonstrated have greater 
binding affinity to cannabinoid receptors, thus revealing an unknown metabolic pathway in the 
heart. In Chapter VI, we demonstrated that CYP2J2 also oxygenates the omega-3 
endocannabinoids, EPEA and DHEA, to produce a newly discovered class of metabolites with 
unknown functions. In addition to the biosynthetic routes of formation of these metabolites, 
another major focus of this chapter was to determine the biological effects of the primary 
metabolites produced by CYP2J2.  
  Chapter VII includes methods employed in our lab in two successful collaborations with Prof. 
Andrew Smith and Prof. Michael Malkowski that utilized membrane scaffold protein and 
phospholipids to solubilize nanoplatelets and nanodiscs to solubilize and stabilize cyclooxygenase-
2, respectively.  
  Taken together, the following dissertation reports on the expression and solubilization of 
recombinant human CYP2J2 and the capacity of this enzyme to metabolize endogenous substrates 
such as polyunsaturated fatty acids and endocannabinoids. All three published original research 
articles utilize innovative nanodisc technology that were used to incorporate CYP2J2 in discoidal 
(~10 nm diameter) membrane bilayers as well as be employed in fluorescence applications. The 
two original projects on endocannabinoid metabolism comprise efforts to map the CYP2J2 
metabolic pathway using targeted lipidomics. While the physiological significance of these 
pathways have yet to be fully explored, these studies provide the critical basis for which additional 
animal studies are to be built upon as well as new targets for pharmacological intervention in 
disease pathologies.   
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CHAPTER II: INTRODUCTION TO CYP2J2 EPOXYGENASE 
 2.1 CYP2J2 overview. Cytochrome P450s (CYPs) are a superfamily of heme containing enzymes 
that are widespread throughout all kingdoms of life (1). In humans, these enzymes mediate 
oxidation of xenobiotics, hormones and fatty acids which provide essential detoxifying, 
reproductive and homeostatic functions, respectively (2). Historically, the mechanism and 
specificity of CYPs located in the liver (hepatic) were investigated due to their relevance in drug 
pharmacokinetics and pharmacodynamics. More recently, the role(s) of extrahepatic CYPs, 
especially those in the brain and heart, has become an active area of research as their physiological 
effects are critical in states of health and disease. One particular enzyme, human CYP2J2 
epoxygenase, has emerged as an essential regulator of cardiovascular health, vascular tone and 
hemostasis (3, 4). Notably, the dysregulation of this enzyme is implicated in a wide-range of 
pathophysiological conditions such as cancer (5), obesity (6) and heart disease (4). 
  2.2 CYP2J2 endogenous expression. CYP2J2 was successfully cloned and expressed by Zeldin 
and co-workers in 1996 (7), and since has emerged as a critical extrahepatic CYP for general 
homeostasis in the human body. CYP2J2 is the only member of the CYP2J subfamily expressed 
in humans. Moreover, there are few existing CYP2J2 single nucleotide polymorphisms (SNPs), 
thus suggesting that alteration of the enzyme’s typical functions significantly decreases overall 
fitness (8). This supposition is supported by studies that showed CYP2J2 overexpression promotes 
preeclampsia (9), and cancer (5, 10) whereas under expression is implicated in obesity (6, 11, 12). 
As mentioned above, CYP2J2 is the most highly expressed CYP in the cardiomyocytes that 
comprise the myocardium and is most well recognized for its role in controlling cardiovascular 
function (7, 8, 13). CYP2J2 is also highly expressed within the aortic arch and more generally 
within the epithelium that lines the vascular system with levels comparable to CYPC28 and 
CYP2C9 epoxygenase. Together these P450s comprise the CYP epoxygenase pathway in the 
cardiovascular system. In addition to the cardiovascular system, CYP2J2 was found within 
adipocytes (6), reproductive tissues (9), renal vasculature (14) and gastrointestinal tracts (15). 
Additionally, a recent report found that CYP2J2 is one of the primary CYPs in the brain with high 
expression in astrocytes as well as the hippocampus and total mRNA transcripts accounting for 
20% of total brain CYP transcripts (16).  
  2.3 CYP2J2 biochemistry and metabolism of dietary fatty acids. The general biochemical 
mechanism of CYP2J2 is thought to follow that of the classical P450 catalytic cycle. In short, 
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substrate binds to a heme prosthetic group in the enzymatic active site, resulting in ferrous (FeII) 
conversion to a high spin state (FeIII) and subsequent transfer of the first electron transfer via 
cytochrome P450 reductase (CPR) and NADPH. This step is followed by molecular oxygen (O2) 
binding and a second reduction, mediated by CPR and NADPH, to form a ferric-peroxo species 
(FeIII-O2
2-) that undergoes two protonation steps to form an unstable Fe-OOH2 reactive species 
that enables catalytic oxidation of carbon (17). Notably, the interactions of CYP2J2 and CPR are 
of interest as there are important protein-protein interactions that are thought to regulate enzyme 
activity and kinetics (18). During the P450 cycle there is potential for generation of reactive oxygen 
species (ROS) through catalytic shunts that can result in tissue damage and disease. Notably, 
CYP2J2 exhibits protection against ROS damage when compared to other cardiovascular P450s 
such as CYP2C8 and CYP2C9 (19, 20). Many questions persist concerning the biochemical 
mechanisms by which CYP2J2 mediates these protective properties through regulation of ROS. 
Particularly, whether CYP2J2 affords these benefits through differential CYP-CPR interactions, 
more efficient regulation of the P450 catalytic cycle or generation of anti-oxidant metabolites 
remain unknown.    
  CYP2J2 exerts its effects by converting dietary polyunsaturated fatty acids (PUFAs) into 
bioactive monooxygenated eicosanoids that, along with CYP2C8 and CYP2C9, comprise the third 
branch of the eicosanoid cascade (21). Eicosanoids are bioactive lipid signaling molecules 
generated by enzymes of the cyclooxygenase (COX), lipoxygenase (LOX) and CYP epoxygenase 
pathways (21).  Collectively, the eicosanoids constitute one of the most complex pathways in the 
human body, with hundreds of known interrelated bioactive lipid species (22).  
  Recent attention has shifted towards elucidating the epoxide metabolites of CYP2J2 due to their 
potency, biological actions and physiological significance. Importantly, there is strong evidence 
that suggests this mechanism is mediated, in part, through an unknown GPCR receptor, thus the 
identification of the ‘epoxyeicosanoid’ receptor is an active area of research (23). The class of 
metabolites produced by CYP2J2 and their known pharmacology are discussed below.  
  2.4 CYP2J2 metabolism of dietary omega-6 arachidonic acid. Arachidonic acid (AA) is an 
omega-6 dietary PUFA that is found at high levels in meats, cheese, eggs and vegetable oil (24). 
Notably, the eicosanoid cascade is commonly referred to as the ‘arachidonate cascade’ due to the 
reflection that AA is the predominant substrate for enzymes of this metabolic pathway. Upon 
dietary consumption, AA is esterified in membrane phospholipids until cytosolic phospholipase 
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A2 (cPLA2) is activated to catalyze AA hydrolysis from the phospholipid bilayer (23). AA can be 
oxygenated into a diverse range of metabolites that are generally pro-inflammatory when 
metabolized by enzymes of the COX and LOX pathways and anti-inflammatory when utilized by 
enzymes of the CYP pathway (4). Of particular focus are the metabolites produced by CYP2J2 
due their maintenance of homeostasis and potential for pharmacological interventions.   
  CYP2J2 utilizes molecular oxygen and two NADPH electrons to convert AA into 10 unique 
regio- and stereo-isomers that exhibit differing biological actions (Figure 2.1A-B). When 
considering regioselectivity, CYP2J2 exhibits catalytic preference for the terminal olefin of AA 
resulting in the predominant production of the (±) 14,15-EET regioisomer followed by the 
sequential production of (±) 11,12-EET, 8,9-EET and 5,6-EET (Figure 2.1A). Importantly, the 
EET regioisomers are comprised of R,S and S,R epoxide enantiomers that have different 
bioactivities and are also differentially produced by CYP epoxygenase enzymes (25). For instance, 
CYP2J2 was shown to produce the active R,S 14,15-EET stereoisomer at 72% whereas the 
remaining EETs were produced in a ~50:50 racemic mixture (R,S vs S,R) (7).  
  Upon production by CYP2J2, EETs are either re-incorporated in the plasma membrane or remain 
in solution to exert autocrine and paracrine biological actions until inactivation via hydrolysis (26). 
The re-incorporation of EETs into the plasma membrane is mediated by isozymes of the fatty acid 
binding protein (FABP) family, which esterify EETs within phospholipids for long-term storage 
and sequestration of their bioactivity (27). Importantly, it has been estimated that at rest, 
approximately 80-90% of total EETs are stored within the membrane until a signaling event 
triggers it release by PLA2 (28). Upon EET enzymatic production or release from the membrane, 
EET inactivation is primarily mediated by soluble epoxide hydrolase (sEH), which acts to 
hydrolyze the epoxide bond producing vicinal diols. While the vicinal diols have been shown to 
retain some biological activity, their potency is greatly diminished as compared to the epoxides 
(29). 
  2.5 EETs pharmacology and biological effects. EETs are autocrine and paracrine lipid 
mediators that elicit vasodilatory, anti-inflammatory and pro-angiogenic effects that provide 
beneficial cardiovascular effects (26, 29). These actions are thought be facilitated through a 
number of extracellular and intracellular channels and receptors. One of the primary pathways 
involves an omega-6 epoxy eicosanoid g-coupled protein receptor (GPCR) that remains 
undetermined and controversial within the CYP epoxygenase field of research  (23). Accumulating 
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evidence suggests that this putative EET receptor is a Gαs-coupled GPCR that activates adenylyl 
cyclase resulting in cyclic adenosine monophosphate (cAMP) accumulation and secondary 
signaling events (25, 30, 31). Additional direct modes of action are mediated through nuclear 
receptors such as peroxisome proliferator-activated receptor gamma (PPARγ) (32) as well as 
transient vanilloid receptor 4 (TRPV4) (33). While the complex pleiotropic signaling pathways of 
EETs are far being elucidated, the ultimate biological effects have been the focus of rigorous 
physiological studies. 
  One common biological effect of all EET regioisomers is the ability to activate large-conductance 
Ca2+-activated K+ channels (BKCa), effectively hyperpolarizing the membrane and mediating 
vasodilation (29). Importantly, because the EETs are stored the plasma membrane and released as 
a result of phospholipase activation, they are classified as endothelium-derived hyperpolarizing 
factors (EDHFs) (33). Notably, there is mounting evidence to support the cross-talk of the EETs 
with other EDHFs (e.g. adenosine and nitric oxide), to act in concert to properly maintain vascular 
tone in response to changes in blood pressure, heart rate and sympathetic and parasympathetic 
regulation (34, 35). Additionally, vasodilatory mechanisms of EETs include direct activation of 
TRPV4 resulting in Ca2+ influx and complex formation with BKCa channels (36, 37). However, it 
should be noted that direct EET (14,15-, 11,12-, 8,9- and 5,6-) activation of BKCa channels have 
also been shown to potentiate the Ca2+ mediated activation of these channels. These physiological 
effects have been elicited with pharmaceutical agents to inhibit sEH to prolong EET in vivo half-
life for the treatment of cardiovascular disease and other vascular disorders (21).  
  EETs exert potent anti-inflammatory effects in the endothelium, heart and brain via inhibition of 
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), and heme oxygenase-1 
(HO-1) (29, 38). Importantly, it is likely that the anti-inflammatory effects are dependent on the 
tissue and expression of the diverse range of receptors thought to mediate EET activity (Figure 
2.1B) (39). Thus, given the importance of the CYP epoxygenase pathway in the heart and 
vasculature, most studies have focused on EET anti-inflammatory effects in endothelial cells and 
myocytes. For example, in endothelial cells EETs were shown to inhibit leukocyte migration 
through potent inhibition of VCAM-1 and to a lesser extent inhibition of E-selectin and ICAM-1 
expression after LPS stimulation (38). Interestingly, these effects are independent of the 
vasodilatory effects mediated by BKCa inhibition providing evidence of EET pleiotropic activity 
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(38). The anti-inflammatory effects have also been confirmed in neonatal cardiomyocytes after 
LPS stimulation, in part, through activation of the PPARγ nuclear receptor (40).  
  Angiogenesis is important for normal homeostatic functions as well as pathological tumor growth 
and cancer metastasis. The mechanisms by which the EETs promote angiogenesis are far from 
being fully understood. A previous study demonstrated that the pro-angiogenic effects are 
mediated, in part, through EET binding and cleavage of heparin-binding epidermal growth factor-
like growth factor (HB-EGF) (41). More specifically, 14,15-EET activation of metalloproteinase 
cleavage resulted in epidermal growth factor (EGF) ligand release and EGFR mediated 
angiogenesis that was reversible with metalloproteinase inhibitors (41).  
  Not surprisingly, it is tempting to generally group the EETs as a single class of lipid mediators. 
However, this is an inaccurate assumption as the pharmacology between stereo- and regioisomers 
exhibits subtle differences in potency and effects depending on the target tissue/organ. For 
example, for activation of the putative EET receptor, the 14,15-EET R,S-stereoisomers are active 
whereas the S,R-stereoisomers are inactive (25). Moreover, differences between EET regioisomer 
anti-inflammatory activity have been demonstrated, with 11,12-EET showing the greatest 
inhibition of TNF-alpha induced vascular cell adhesion molecule (VCAM-1) in endothelial cells 
followed by 8,9-EET, 5,6-EET and 14,15-EET (38). It should also be considered that the EETs 
may demonstrate cross-talk with other eicosanoid pathways. Specifically, 5,6-EET is a substrate 
for enzymes of the COX pathway which produce thromboxane-like metabolites with 
vasoconstrictive properties (42).  
  2.6 CYP2J2 metabolism of dietary omega-3 fatty acids. The capacity of CYP2J2, and other 
CYP epoxygenases, to directly convert EPA and DHA into potent vasodilatory and anti-arrhythmic 
metabolites is thought to provide many of the beneficial cardiovascular effects associated with 
dietary omega-3 fatty acids (43). As shown in Figure 2.2B-C, CYP2J2 converts EPA and DHA 
into EEQ and EDP regio-and stereoisomers, respectively. Relative to AA the substrate preference 
for EPA and DHA were reported at 17-fold and 4-fold greater, respectively (43). The preferred 
site of oxygenation is the terminal PUFA olefin, predominantly producing, 17,18-EEQ from EPA 
and 19,20-EDP from DHA (Figure 2.2B-C). The physiological significance of this pathway was 
further highlighted in a study where EPA and DHA supplementation in humans resulted in 
significant increase of EEQ and EDP metabolites with no apparent increase in metabolites from 
the COX and LOX pathways (44). Taken together, there is significant biochemical and clinical 
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evidence to support that dietary supplementation with omega-3 fatty acids alters the eicosanoid 
profile in the body, in part, through interactions with CYP2J2. Many of these metabolites are yet 
to be identified and characterized. As discussed in Chapter VI, we characterized a new class of 
omega-3 derived bioactive metabolites produced by CYP2J2 thereby revealing a previously 
unknown metabolic pathway. 
  2.7 EEQ and EDP pharmacology and biological effects. The details concerning the 
pharmacology of the EEQ and EDP metabolites are poorly understood relative to the EETs. Initial 
assumptions that these epoxy-containing PUFAs would have similar actions as their EET 
counterparts have generally proved inaccurate. More specifically, the EEQ and EDP metabolites 
have vastly different potencies and sometimes even opposing biological effects when compared to 
the EETs. For example, while the EETs have been shown to produce pro-angiogenic effects, the 
EEQs and EDPs are anti-angiogenic and blocked cancer growth and metastasis (45). Even when 
considering instances where the general biological effects are the same, there are significant 
differences in the efficacy among PUFA epoxide classes. For instance, both 17,18-EEQ and 19,20-
EDP are profoundly anti-arrhythmic whereas 14,15-EET exhibits much weaker activity (43). 
Given, the contrary effects of the EETs relative to EEQs/EDPs it is tempting to hypothesize that 
there is unidentified omega-3 epoxide receptor, yet studies attempting to elucidate this receptor 
are lacking. This notion is supported by evidence that the 14,15-EEZE inhibitor does not block the 
actions of the 17,18-EEQ and required EEQ specific antagonists (46). Moreover, the EDPs were 
shown to exhibit the most potent vasodilatory activities, with the 13,14-EDP metabolite activating 
BKCa channels with 1000-fold greater potency than 14,15-EET (47).    
  2.8 CYP2J2 roles in health and disease. The potential significance of CYP2J2 expression in 
the cardiovascular system and other tissues of the body can be reasonably deduced by 
understanding the general biological actions of the EET, EEQ and EDP metabolites. However, it 
is necessary to demonstrate the CYP2J2 physiological significance in vivo to fully understand the 
role of CYP2J2 in states of health and disease. When examining related isozymes across species 
there are ‘CYP2J2-like’ isozymes in larger animals such as porcine and bovine. Bovine and sheep 
CYP2J isoforms share 75% and 77% homology with human CYP2J2, respectively (48). Moreover, 
microsomes prepared from bovine and porcine myocardium as well as recombinant human 
CYP2J2 nanodiscs all were shown to epoxygenate AA as well as arachidonate containing 
endocannabinoids (48). Interestingly, sheep CYP2J preferentially hydroxylates AA into 20-, 19- 
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and 18-HETES (~86% of total product) followed by 14,15-, 11,12-, 8,9- and 5,6-EET (~14% of 
total product) (49). In contrast, rodent species such as rats and mice have 10 subfamily CYP2J 
isozymes (CYP2J-5,6,7,8,9,11,12,13,14,15) but lack a comparable CYP2J2 isozyme, making 
comparative species studies more difficult (50).  This limitation has largely been overcome with 
the use of a transgenic mice with localized over-expression of CYP2J2 in the cardiomyocytes (ɑ-
MHC-CYP2J2) as well as within the cardiovascular endothelium (Tie-CYP2J2) for use in various 
models of disease (13, 19). Additional approaches include the use of primary human myocyte 
cultures as well as the use of CYP2J2 specific inducers and inhibitors as a model of CYP2J2 
cardiotoxicity (51). Further approaches have included the transfection and subsequent expression 
of CYP2J2 into specific cellular systems (52).     
  The importance of CYP2J2 for the maintenance of cardiovascular homeostasis became apparent 
upon the FDA approval of a new non-brain penetrating H1 antagonist (Terfenadine) with off-target 
effects that included ventricular arrhythmias (53). One of these effects included potent inhibition 
of CYP2J2 which efficiently hydroxylates terfenadine to form hydroxyl-terfenadine (54). 
Terfenadine was ultimately pulled from the market due to cardiotoxicity related side effects which 
prompted many to hypothesize it was due in part to inhibition of CYP2J2 mediated metabolism of 
PUFAs. Notably, the CYP2J2 metabolite hydroxyl-terfenadine was later released and is devoid of 
the cardiotoxic effects of its predecessor. The cardioprotective benefits of CYP2J2 have been 
explored in several models of cardiotoxicity (51). For example, transgenic mice with the cardiac-
specific overexpression of CYP2J2 ameliorated doxorubicin-induced cardiotoxicity (55). In a 
separate study these transgenic mice were shown to provide treatment of ischemia-reperfusion 
injury in the heart through increased expression of phosphor-p42/p44 mitogen-protein kinase 
(MAPK) pathway (13). In another cardioprotective pathway CYP2J2 overexpression counteracted 
electrical remodeling in mechanical and chemically induced cardiac hypertrophy (56). These 
effects are postulated to be due to EETs collective regulation of Ca2+, K+ and Na+-channels which 
provided electrical stability in part through maintaining gap junction integrity resulting in anti-
arrhythmic effects (56, 57). 
  Not surprisingly, CYP2J2 expression provides anti-inflammatory effects, presumably through the 
production of EET, EEQ and EDP metabolites. This was demonstrated in mouse aortic endothelial 
cells transfected with the pcDNA3.1/CYP2J2 plasmid which inhibited homocysteine induced 
metalloproteinase-9 activation of NFκB (52). Subsequent studies showed that CYP2J2 expression 
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promotes activation of peroxisome proliferator activated receptor-alpha (PPARα) in monocyte 
derived macrophages (58). The profound influence of CYP2J2 on macrophages was recently 
confirmed in a study that utilized adenovirus to overexpress CYP2J2 in mice to ameliorate LPS-
induced cardiac dysfunction (59). Mechanistic studies demonstrated that 11,12-EET promotes 
macrophage polarization from the pro-inflammatory M1 phenotype to the anti-inflammatory M2 
phenotype (59). As previously mentioned, CYP2J2 produces significantly fewer pro-inflammatory 
reactive oxygen species (ROS) when compared with CYP2C8 and CYP2C9. This characteristic 
has pathophysiological implications as the CYP2C9 production of ROS caused inflammation and 
CYP2C8 production of ROS increased susceptibility to ischemia-reperfusion injury despite the 
CYP production of EETs that theoretically oppose these events (19, 20). Thus, the production of 
bioactive epoxide metabolites by CYP2J2 likely proceeds much more efficiently with fewer side 
products that may counteract the beneficial effects of EETs, EEQs and EDPs.  
  The recognition of CYP2J2 and its metabolites’ anti-inflammatory effects have far reaching 
implications as nearly every disease pathology involves some component of inflammation. For 
instance, excess adipose tissue in obesity is associated with increased pro-inflammatory cytokines 
that have been shown to confer insulin resistance (60). Strikingly, CYP2J2 expression ameliorated 
inflammatory cytokines and insulin resistance associated with type II diabetes in mice (11). These 
reports were consistent with additional literature that revealed the expression of CYP2J2 in 
endothelial cells reversed vessel fat deposits and vascular disease in part by attenuation of heme 
oxygenase-1 (HO-1) (61). Interestingly, CYP2J2 is down-regulated in subcutaneous adipose tissue 
in obese people and may contribute to low levels of 25-hydroxy-vitamin D in these patients (6). 
Moreover, overexpression of CYP2J2 in mice fed a high fat diet resulted in significant decrease of 
hyperlipidemia in part through activation of AMPK and PPARα pathways (12).  
  Despite the apparent ameliorating benefits provided by CYP2J2 over-expression in pathologies 
that involve inflammatory and hypertensive characteristics, there are a number of diseases that are 
exacerbated by CYP2J2 overexpression. Most notably, CYP2J2 has been identified as an enzyme 
that drives tumor growth and metastasis. This was first reported in a study that found upregulation 
of CYP2J2 in 77% of human carcinoma tissues and shown to promote the neoplastic phenotype 
(62). The importance of CYP2J2 was further confirmed through synthesis of CYP2J2 specific 
terfenadone inhibitors that potently inhibited cancer growth using MDA-MB-435 cancer cells in 
vitro and in an in vivo murine tumor xenograft models of cancer (63). The CYP2J2 antagonist 
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mechanisms were found to be a result of caspase-3 activity and enhanced tumor cell apoptosis 
which inhibited growth and prevented metastasis (63). The effects are not surprisingly attributed 
to the mitogenic and pro-angiogenic effects of the EETs that are produced by a number of CYP 
epoxygenses. A separate disease in which CYP2J2 has been specifically implicated is in 
preeclampsia (9). As previously mentioned CYP2J2 is highly expressed in reproductive tissues 
such as the placenta, likely due to its production of pro-angiogenic and pro-growth metabolites. A 
recent report found that CYP2J2 overproduction of 5,6-EET and its subsequent conversion by 
COX-2 is largely responsible for the hypertensive and potentially life-threatening characteristics 
of preeclampsia (9).    
  2.9 CYP2J2 summary. Studies examining the physiological role(s) of CYP2J2 epoxygenase in 
health and disease have continually increased since the discovery of this extrahepatic CYP in 1996. 
Many characteristics set CYP2J2 apart from the traditional detoxifying hepatic CYPs, with the 
major being that CYP2J2 contains a significantly narrower hydrophobic active site that confers 
unique regioselectivity relative to the major liver CYPs (64). Additionally, liver CYPs generally 
exhibit much faster xenobiotic and endogenous substrate turnover with greater production of ROS 
than CYP2J2. However, despite the relatively slow turnover of the metabolism of endogenous 
fatty acids by CYP2J2, the scientific community has come to appreciate that this enzyme regulates 
complex homeostatic function through the generation of EETs that require enzymatic precision. 
Thus, the formation of these metabolites most likely represents a far more elegant mechanism for 
control of the many delicate homeostatic processes within organs, such as the heart, kidneys and 
brain. Therefore, similar to the steroid-synthesizing P450s, the enzymatic expression levels rather 
than the catalytic turnover are likely the prominent mechanism for metabolic control in each 
respective organ.    
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2.10 FIGURES 
 
Figure 2.1. CYP2J2 mediated metabolism of arachidonic acid into bioactive EETs.  (A) Using 
molecular oxygen and NADPH, CYP2J2 converts arachidonic acid (AA) as a substrate to form 10 
different metabolites consisting of two hydroxylated regioisomers (20-, and 19-HETE) as well as 
8 different epoxide stereo- and regioisomers (S,R and R,S) 14,15-, 11,12-, 8,9-, and 5,6-EET. (B) 
(R,S) EET regioisomers are autocrine and paracrine pleiotropic  lipid mediators with biological 
effects that include angiogeneis (red pathway), anti-inflammation (blue pathway) and vasodilation 
(grey pathway).  The mechanisms of angiogenesis (red pathway) are mediated through activation 
of metalloproteinases (MMPs) which produce EGFRs and activate heparin binding growth factor 
(HGFR) and/or via the putative EET receptor. The vasodilatory actions (grey pathway) are 
mediated by multiple mechanisms that include activation of transient receptor potential cation 
channel 4 (TRPV4) and calcium influx, direct or indirect activation of large conductance calcium 
gated potassium channels (BKca), and/or activation of the putative EET receptor. The anti-
inflammatory effects (blue pathway) are mediated through activation of nuclear receptors such as 
the peroxisome-proliferator activated recetor gamma (PPARγ) and/or activation of the putative 
EET receptor).29,30,31,32,33,41  
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Figure 2.2. CYP2J2 oxygenation regioselectivity of omega-6 and omega-3 fatty acids. (A) The 
omega-6 arachidonic acid is oxygenated by recombinant CYP2J2 with specific regioselectivity 
dependent on olefin position. The 14,15-EET metabolite is the predominant product and is formed 
through epoxygenation of the 14,15-olefin as shown in red. (B) The omega-3 eicosapentaenoic 
acid is oxygenated by recombinant CYP2J2 to form at least 4 different epoxide metabolites. The 
predominant metabolite, 17,18-EEQ is formed through epoxygenation of the 17,18-olefin as  
shown in red. (C) The omega-3 docosahexaenoic acid is a substrate for CYP2J2 and was reported 
to form at five regioisomers with the predominant isomer epoxygenated at the 19,20-olefin as 
shown in red.  
 
 
 
1. AA regioselectivity experimentally determined in-house via LC-MS/MS. 
2. EPA and DHA regioselectivity as previously reported by Arnold et. al.43 
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CHAPTER III: FUNCTIONAL STUDIES OF N-TERMINALLY 
MODIFIED CYP2J2 EPOXYGENASE IN NANODISCS 
 
3.1 ABSTRACT 
  CYP2J2 epoxygenase is a membrane bound cytochrome P450 that converts omega-3 and omega-
6 fatty acids into physiologically active epoxides. In this chapter, we present a comprehensive 
comparison of the effects of N-terminal modifications on the properties of CYP2J2 with respect 
to the activity of the protein in model lipid bilayers using Nanodiscs. We demonstrate that the 
complete truncation of the N-terminus changes the association of this protein with the E.coli 
membrane but does not disrupt incorporation in the lipid bilayers of Nanodiscs. Notably, the 
introduction of silent mutations at the N-terminus was used to express full length CYP2J2 in E. 
coli while maintaining wild-type functionality. We further show that lipid bilayers are essential for 
the productive use of NADPH for ebastine hydroxylation by CYP2J2. Taken together, it was 
determined that the presence of the N-terminus is not as critical as the presence of a membrane 
environment for efficient electron transfer from cytochrome P450 reductase to CYP2J2 for 
ebastine hydroxylation in Nanodiscs. This suggests that adopting the native-like conformation of 
CYP2J2 and cytochrome P450 reductase in lipid bilayers is essential for effective use of reducing 
equivalents from NADPH for ebastine hydroxylation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1Reprinted, with permission, from McDougle DR§, Palaria A§, Magnetta E, Meling DD, Das A*. Functional studies 
of N-terminally modified CYP2J2 epoxygenase in model lipid bilayers. Protein Sci. 2013 Jul;22(7):964-79. PMID: 
23661295 
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3.2 INTRODUCTION 
Eicosanoids are signaling molecules that mediate inflammation in the body and are implicated 
in many disorders including cancer, arthritis and cardiovascular disease (1). One class of 
eicosanoid synthesizing cytochrome P450s, known as the CYP epoxygenases catalyzes the 
epoxidation and/or hydroxylation of various dietary polyunsaturated fatty acids (PUFAs) and 
xenobiotics (2, 3). CYP2J and CYP2C are the two primary mammalian subfamilies that comprise 
the CYP epoxygenases. In humans, CYP2J2 is highly expressed in cardiac myocytes and the 
endothelium of coronary arteries where it plays significant roles in cardiovascular diseases and 
inflammation (4-7). This enzyme catalyzes the metabolism of arachidonic acid (AA) into 
epoxyeicosatrienoic acids (EETs).  These metabolites are stereo- and regio-isomers that exert 
isomer specific anti-inflammatory, vasodilatory and pro-angiogenic effects (8, 9). Additionally, 
CYP2J2 catalyzes the conversion of the omega-3 fatty acids into physiologically active products 
(5). Both the omega-3 and omega-6 fatty acid metabolites are known dilators of the 
microvasculature and are essential for heart homeostatic equilibrium (5, 10).  
Recently, CYP2J2 has also been found to be relevant in both cancer and preeclampsia 
pathophysiology (11-14). EETs are recognized as major promoters of angiogenesis and 
consequently enhance tumor cell survival (12, 13, 15, 16). In a study by Jiang and coworkers  
CYP2J2 was found to be predominantly localized in tumor cells when compared to the adjacent 
normal tissue samples (16). Additionally, Zeldin and co-workers recently found that EETs 
stimulate extensive multiorgan metastasis and escape from tumor dormancy in several cancer 
models (12). In preeclampsia, CYP2J2 was found to be highly upregulated in placental tissues and 
administration of CYP2J2 inhibitors reversed preeclampsia-associated symptoms in women (11). 
Hence, the development of drugs inhibiting CYP2J2 has tremendous pharmaceutical potential for 
the prevention of cancer metastasis and preeclampsia (11, 14, 17, 18).   
CYP2J2 also plays an important role in the first pass metabolism of astemizole, terfenadine and 
ebastine and is essential for understanding the pharmacokinetic and pharmacodynamic 
relationships of these drugs in the body (19, 20). Thus, to begin to elucidate the structure-function 
relationships of pharmaceutically relevant CYP2J2, we expressed the protein with high yields in 
E. coli and focused on understanding the role of the N-terminus of CYP2J2 in association with 
lipid bilayers and in ebastine hydroxylation activity.   
19 
 
The N-termini of membrane bound cytochrome P450s have been shown to play an important 
role in lipid association, protein-protein interactions and substrate access. There are many reports 
of the hydrophobic N-terminal domain mediating the P450 membrane binding association (21-24). 
Based on this observation, a soluble and monomeric form of CYP2C5 was engineered by deleting 
the N-terminal membrane-spanning region (25, 26). Additionally, the N-terminus of CYP1A2 was 
shown to be involved in membrane anchoring and N-terminal modifications had an effect on the 
catalytic activity (27). Interestingly, it was also demonstrated that membrane insertion of CYP1A2 
was promoted by the presence of anionic phospholipids and this association with membrane is 
dependent on the N-terminus of CYP1A2 (28). In addition to playing a role in association with 
membrane, the N-terminus can be involved in P450-P450 interactions (29). Tracy and coworkers 
demonstrated that the hydrophobic N-terminus binding domains of CYP2C9 and CYP3A4 are 
involved in heterodimer complex formation and truncation of the N-terminus of CYP2C9 led to 
the abolition of inhibition by CYP3A4 (30). In separate studies it was hypothesized that the N-
terminal domain might be critical for orientation of the protein into the lipid bilayer (31). Thus, 
the N-terminus affects the localization on the membrane and can influence orientation and activity. 
Although the N-terminus is considered to be responsible for membrane association, one cannot 
always obtain a soluble protein by simply truncating the N-terminus. This is likely due to the 
presence of additional hydrophobic residues, which contribute to membrane association. The other 
regions thought to be involved in membrane anchoring are the F′ and G′ helices and F-G loop. 
Hence, it is strongly believed that membrane lipid molecules may play an important role in gating 
the entrance of substrates and/or release of products implying that the ligand entrance pathways 
are likely partially immersed in the membrane (32, 33).  
Here we use Nanodiscs for rigorous biochemical interrogation of CYP2J2 and the role of N-
terminus in membrane association and activity. Nanodiscs are nanoscale lipid bilayers that are 
surrounded by a membrane scaffold protein (34-36). Incorporation of a CYP protein into 
Nanodiscs mimics the endogenous membrane environment of the protein, producing a 
macromolecule amenable to several important biochemical and biophysical assays hitherto 
reserved for soluble proteins. Nanodiscs have proven to be excellent for the solubilization and 
mechanistic investigation of many diverse membrane protein systems. Moreover, this technology 
has enabled the stabilization of membrane proteins both in solution (37-41) and on surfaces (40, 
42-45).  
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Herein we functionally characterize CYP2J2 in model lipid bilayer Nanodiscs. We demonstrate 
the role of the N-terminus in association with the E.coli membrane and with the lipid bilayers of 
Nanodiscs. We further evaluate whether lipid bilayers are essential for the productive use of 
NADPH and product formation by CYP2J2.   
Notably, we introduce silent mutations at the N-terminus to express full length CYP2J2 in E. 
coli while maintaining wild-type functionality (46).  The full-length CYP2J2 provides a nearly 
identical wild-type construct for comparison to the N-terminus truncated constructs being explored 
in this work. While some of the results corroborate more anecdotal results for other P450s, this 
present study presents a more thorough and comprehensive comparison of the effects of N-terminal 
modifications on the properties of CYP2J2 in native-like lipid bilayers with respect to membrane 
association and activity.  
3.3 MATERIALS AND METHODS 
Materials. Human CYP2J2 cDNA was obtained from OriGene (Catalog No. SC321730). PCR 
reagents and other enzymes for molecular biology were purchased from Invitrogen. Qiagen kits 
were used to purify the plasmid DNA from bacterial cells and from agarose gels. The bacterial 
strains used were E.coli XL1 Blue obtained from Agilent and DH5α from Invitrogen. Ampicillin, 
arabinose, chloramphenicol, IPTG and Ni-NTA resin were bought from Gold Biotechnology. δ-
Aminolevulinic acid was bought from Frontier Scientific. NADPH and NADP were obtained from 
P212121.com. 3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonate (CHAPS) was 
acquired from BioVision Inc. 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) was 
purchased from Avanti Polar Lipids, Inc.  Amberlite XAD 2 was acquired from Supelco.  Nanosep 
MF (0.2 µM) and Amicon Ultra (10,000 MWCO) centrifugal filters were procured from Millipore. 
Arachidonic acid and ebastine were obtained from Cayman Chemical.  The protein standards – 
thyroglobulin, ferritin, bovine serum albumin and cytochrome c were purchased from Sigma.  All 
other materials and reagents used were purchased from Sigma and Fisher Scientific. 
Design of CYP2J2 constructs and cloning into pCWori+ vector. CYP2J2 cDNA obtained from 
OriGene was cloned into the pCWori vector. All the constructs were grown in the presence of 
chaperonin system hence “G” is used for all constructs. Construct 1-M2G: The amino acid 
sequence of this construct is similar to the wild type amino acid sequence except for the 
substitution of the second amino acid residue leucine (CTC) by alanine (GCT). Construct 2- 
M2SMG: The sequence of this construct is similar to M2G with the introduction of silent mutations 
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in the 3rd, 4th and 6th codons to make them AT rich and thereby minimizing the free energy of 
the mRNA secondary structure formation. The ΔG of first 7 codons at N terminus of M2SMG is -
1.69, ΔG of WT = -4.27 and ΔG of construct M2G = -3.94. Values were obtained using RNAFold 
WebServer (47, 48). Note that M2G and M2SMG share identical primary sequences but differ in 
N-terminus codon usage. Construct 3-M2D5HG – This construct was designed not only to increase 
the yields of expression of human CYP2J2 but also for maintaining the association of this protein 
with lipid bilayers. Therefore in this construct we have replaced the first five amino acids from the 
N-terminus with a hydrophilic sequence AKKTSS and maintained most of the original 
hydrophobic sequence (49). Construct 4-M2D19HG – In order to optimize and enhance the 
expression while preserving some part of the hydrophobic region to interact with membranes we 
deleted codons, 2 to 19, from the N-terminus and inserted the hydrophilic sequence AKKTSS. 
Insertion of a hydrophilic sequence in combination with truncation of a major part of the native 
hydrophobic sequence has been shown to give higher protein expression. Construct 5-M2D34G 
was engineered with the goal of enhancing yield and making the protein soluble and suitable for 
crystallization and structural determination by X-ray diffraction studies (50, 51). It has been shown 
previously that deletion of the first 34 amino acids with a hydrophilic region naturally following 
this deletion increases the yields of CYP2J2 protein in E. coli. (52). In all the constructs we added 
a penta-his tag to the C-terminus to facilitate purification using metal chelating affinity columns.  
The different constructs of the CYP2J2 gene were prepared and amplified by PCR using the 
appropriate sets of primers listed in supplementary material (Table 3.2). The PCR conditions are 
also mentioned. CYP2J2 gene has an internal NdeI site. Hence, an AseI site was introduced within 
the forward primer. AseI site overhangs are compatible with the overhang produced from digesting 
NdeI site in the vector. Therefore all of the constructs had an AseI restriction site in the forward 
primer along with the various N-terminal modifications. The reverse primer incorporated a penta 
His tag and an XbaI restriction site at the C-terminus. The amplified CYP2J2 genes were digested 
with AseI-XbaI and then ligated with the NdeI-XbaI digested pCWori vector and co-transformed 
with chaperonin plasmid pTGro7 into DH5α competent cells. pTGro7 encodes for the GroEL-
GroES gene and is selected via chloroamphenicol resistance. Transformed colonies were 
confirmed for the presence of the respective constructs by DNA sequencing.   
Expression and purification of CYP2J2. Double transformant colonies containing the CYP2J2 
gene and pTGro7 gene were cultured in 30 mL of Luria Bertani (LB) media with chloroamphenicol 
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(20 µg/ml) and ampicillin (100 µg/ml) at 37ᵒC and 250 rpm overnight. 5 mL of this culture was 
used to inoculate 500 mL of Terrific Broth (TB) media supplemented with trace elements, 
ampicillin (100 µg/ml) and chloramphenicol (20 µg/ml). The culture was grown for 2.5 hours at 
37ᵒC and 220 rpm. Delta-aminolevulinic acid (500 µl of 0.5 mM) was then added and the culture 
was grown for another 2h at 26ᵒC and 160 rpm. After reaching a target absorption (A600 = 1.2), 1 
mM of Isopropyl β-D-1-thiogalactopyranoside (IPTG) was added to induce protein expression. In 
addition 2g of arabinose was added to each 500 mL  culture (53). The cultures were grown for 44 
h and then the cells were harvested by centrifugation. The cell pellet was resuspended in buffer 1 
(100 mM potassium phosphate pH 7.4, 20% glycerol, 6mM magnesium chloride, 0.1mM 
dithiothreitol (DTT) and 0.2 mM phenylmethanesulfonylfluoride (PMSF), approximately 1mg 
each of DNase and RNase). The cells were sonicated on ice for 6 cycles of 1 minute with breaks 
of 1 minute at an output of 4, 40% duty cycle with a Heat Systems Ultrasonics (Qsonica, Newtown, 
CT) sonicator. This was followed by centrifugation at 35,000 RPM at 4ᵒC for 45 min using a 
Beckman ultracentrifuge (Beckman Coulter, Brea, CA). The supernatant was collected to 
quantitate protein in the soluble fraction. The membrane fraction pellet was resuspended in a 
solubilization buffer 2 (100mM potassium phosphate pH 7.4, 20% glycerol, 200 mM sodium 
chloride, 0.1mM dithiothrietol and 1% CHAPS) for 3-5 h at 4ᵒC. This was further centrifuged at 
4ᵒC and 35,000 RPM for 45 min to obtain the supernatant, which contained the target membrane 
protein. The supernatant was then loaded onto a Ni-NTA column equilibrated with the column 
buffer 3 (100 mM potassium phosphate pH 7.4, 20% glycerol and 0.5% CHAPS). The column was 
washed with 5 column volumes of the wash buffer (100 mM potassium phosphate pH 7.4, 20% 
glycerol, 0.5% CHAPS and 20 mM imidazole). It was further washed with 4 column volumes of 
ATP containing buffer 4 (100 mM potassium phosphate pH 7.4, 20% glycerol and 0.5% CHAPS, 
5 mM ATP, 10 mM magnesium chloride, 150 mM potassium chloride) to remove the GroEL which 
may be bound to the CYP proteins (54). Finally the protein was eluted with 4 column volumes of 
the elution buffer (100mM potassium phosphate pH 7.4, 20% glycerol, 0.5% CHAPS and 200 mM 
imidazole). The eluted protein was concentrated and buffer exchanged to remove imidazole using 
Amicon centrifugal filters (10,000 MWCO) and stored at -80ᵒC.  
Characterization of CYP2J2. CYP2J2’s purity was analyzed using 10% SDS-PAGE where it 
separated as a single band with an Rz ratio (A417 nm/A280 nm) of 1.3 or higher obtained by 
measuring the UV-Visible spectra. CYP2J2 concentration was measured by carbon monoxy 
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difference spectra as described previously by Omura and Sato using an extinction coefficient of 
91 mM–1 cm–1 (55). The protein content from both cytosol and membrane fractions were 
quantified. For CO analysis we modified the Omura and Sato method by purging a 500µl aliquot 
of the buffer exchanged sample with nitrogen for 20 min and then adding 10-20 µL of dithionite 
solution anaerobically. This was then used for CO addition and monitored using a Cary Bio 300 
UV-Vis spectrophotometer (Agilent Technologies, Santa, Clara CA). The difference spectra were 
recorded to quantify the protein as well as to assess the quality of the protein.  
Oligomerization States of detergent solubilized CYP2J2 using size exclusion chromatography. 
Size exclusion chromatography (SEC) was performed using a Superdex 200 10/300 column (GE 
Life Sciences, Piscataway NJ) coupled with a high performance liquid chromatography (HPLC) 
system consisting of an Alliance 2695 analytical separation module (Waters, Milford MA) and a 
Waters 996 photodiode diode array detector (Waters, Milford MA). The different CYP2J2 
constructs were loaded individually at 15 µM on the SEC column and were run with an isocratic 
mobile phase consisting of 100 mM of potassium phosphate buffer (pH 7.4) containing 150 mM 
sodium chloride and 0.1 mM EDTA at 0.5ml/min flow rate. The oligomerization states of the 
CYP2J2 constructs were estimated using a standard curve plotted using thyroglobulin (669 kDa), 
ferritin (440 kDa), BSA (67 kDa) and cytochrome c (14 kDa) as standards. 
Expression and purification of cytochrome p450 reductase. A 10 ml volume of starter culture 
(grown from a single colony for 18-20 hours at 37ᵒC and 220 rpm) was used to inoculate 1L of LB 
media supplemented with ampicillin and riboflavin. The culture was grown at 37ᵒC and 220 rpm 
for 4 h (O.D. was 0.8-1). Expression of the reductase was induced by adding IPTG (1 ml of 1 mM) 
and growing the culture at 30-33ᵒC and 220 rpm for 18-20 h. Cells were harvested by centrifuging 
at 4000 rpm for 15 min. in a JA-10 rotor (Beckman Coulter, Brea, CA) at 4ᵒC. The pellet was 
resuspended in 500 ml of cold lysozyme buffer (75 mM Tris pH 8.0, 0.25 M sucrose, 0.25 mM 
EDTA and 0.02 mg/ml lysozyme) and allowed to stir at 4ᵒC for 30min. The spheroplasts were 
obtained by centrifuging at 4000 rpm for 30 min. in the JA-10 rotor at 4ºC and then resuspended 
in 40 ml of lysis buffer (50 mM Tris pH 8.0 and 1mM PMSF) at 4ºC for 30min. Sonication was 
carried out on ice with 5 cycles of 30 seconds with 1 minute breaks. Membranes were isolated by 
centrifuging at 30000 rpm for 30 min. at 4ºC in a Ti-45 rotor. This membrane pellet was then 
solubilized in 40 ml of column buffer (50 mM Tris pH 7.7, 0.1 mM EDTA 0.1 mM DTT and 20% 
glycerol) containing 0.2% Triton for an hour at 4ºC. Subsequent centrifugation at 30000 rpm for 
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30 min. at 4ºC in a Ti-45 rotor (Beckman Coulter, Brea, CA) gave the protein in the supernatant 
fraction which was then loaded onto a 2’5’ADP Agarose column equilibrated with the column 
buffer. The column was then washed with 10 column volumes (c.v.) of the wash buffer (100ml of 
column buffer containing 2 mM adenosine) and eluted with 5 c.v. of the elution buffer (50ml of 
column buffer containing 2 mM NADP or 2 mM AMP). To remove the detergent and obtain high 
purity of protein, the eluate was passed through a DEAE column equilibrated with the wash buffer, 
washed with 10 column volumes of the wash buffer and eluted with 5 column volumes of the 
elution buffer. The final eluate was concentrated and the CPR concentration was measured with a 
Cary Bio 300 UV-Vis spectrophotometer (Agilent Technologies, Santa, Clara CA) at 456 nm. 
Purified CPR was characterized by measuring the cytochrome c reduction for 10 min. at 550nm in 
a solution of 1 ml of 0.3 M potassium phosphate buffer pH 7.4 containing 50 µM cytochrome c, 
50 µM NADPH and 2 µM of the purified CPR. The purified reductase was stored at -80ºC. 
Assembly of CYP2J2-Nanodiscs. The lipid, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine 
(POPC) solubilized using 100 mM cholate, was added to the membrane scaffold protein MSP1D1 
(65:1 ratio) and allowed to mix at 4ᵒC for 1 hour. To assemble the Nanodiscs with the protein, 
CYP2J2 in 100 mM potassium phosphate pH 7.4, 20% glycerol, 0.5% CHAPS was added to the 
mixture at a CYP:MSP ratio of 1:15 and allowed to mix for an additional hour. Amberlite beads 
were then added to the final mixture to remove the detergent overnight at 4ºC. The mixture was 
separated from the beads by filtration. The resulting solution was concentrated, loaded onto a SEC 
column and the protein incorporated Nanodiscs peaks were collected and concentrated. The 
concentrated CYP2J2-ND complex was stored at -80ºC in the presence of 10% glycerol.  
Assembly of CYP2J2-CPR Nanodisc complex for activity assay. The assembly the CYP2J2 and 
CPR into a single macromoleculer complex was achieved following previously described methods 
(56).  Briefly, CYP2J2 and CPR was incubated in a 1:1.5 ratio in 0.1% (v/v) cholate for one hour 
at 4ºC prior to being added to the detergent solubilized MSP1E3D1- and POPC mixture described 
above.   The final molar ratio of the mixture contained a CYP2J2/CPR/MSP1E3D1(-)/POPC ratio 
of 0.1:0.15:1:130.  Amberlite beads were then added to the final mixture to remove the detergent 
overnight at 4ºC.  For the isolation of Nanodiscs containing both CPR and CYP2J2 the filtered 
solution was passed through an ADP agarose column to selectively bind CPR and eluted with 2.5 
mM NADP phosphate buffer (7.4). The eluent was then passed through a Ni-NTA column to 
selectively bind the his-tagged CYP2J2 protein and eluted phosphate buffer (7.4) containing 200 
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mM imidazole.  The eluent was concentrated and then loaded on a SEC column where the 
relatively large Nanodisc containing both CPR and CYP was confirmed by the elution time at 
~21.5 minutes. The final reconstitution molar ratio of all components was 0.1:0.2:240:120:1 
CYP2J2/CPR/cholate/POPC/MSP1E3D1(–)). The 1:1 ratio of CYP2J2 and CPR was confirmed 
with a UV-Vis scan using the respective absorbance of CYP2J2 at 417 nm (ε = 110 mM-1 cm-1) 
and CPR at 456 nm (ε = 24 mM-1 cm-1).  
Preparation of CYP2J2 and CPR in a 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine 
(POPC) reconstituted system. The in vitro activity of CYP2J2 and the redox partner CPR were 
assessed in a standard phospholipid reconstituted system following previously described 
methodology (57).  The lipids were prepared by reconstituting POPC in 100 mM phosphate buffer 
(pH 7.4) containing 100 mM sodium cholate to a final lipid stock concentration of 10 mM.  The 
solution was then dispersed by sonication until clarity was achieved prior to mixing with the 
proteins.  The detergent solubilized POPC stock was then added at a final concentration of 50 µM 
into a cuvette containing 0.6 µM CPR and 0.2 µM CYP2J2 and incubated at 37ºC for five minutes 
prior to use in the NADPH oxidation and ebastine hydroxylation assay.    
Stability of CYP2J2-Nanodiscs. The effect of N-terminal modifications on association of 
CYP2J2 with lipid bilayers of Nanodiscs was investigated by monitoring the stability of CYP2J2-
Nanodiscs at 4ºC using SEC-HPLC. Samples containing CYP2J2 N-terminal mutants incorporated 
into Nanodiscs were prepared with 50 mM POPC, 290 nmol of MSP1T2(-) (MSP1T2 His-tag was 
cleaved using TEV protease) (58) and 29 nmol of CYP2J2 as described above. Ni-NTA affinity 
column was used to remove empty Nanodiscs from CYP2J2-Nanodiscs mixture since the CYP2J2 
constructs contained a His-tag but the MSP1T2(-) did not. Samples were aliquoted and stored in 
100 mM phosphate buffer (pH 7.4) at 4ºC and analyzed over a period of 7 days with an isocratic 
gradient consisting of a 100 mM phosphate buffer (pH 7.4) mobile phase over a 60 minute period.  
The CYP2J2-ND assembly was monitored at 417 nm and 280 nm. Overall stability of M2SMG-
ND, M2D5HG-ND, M2D19HG-ND and M2D34G-ND were calculated from the integrated areas 
of each time point relative to the initial injection for each respective construct. The day 0 and day 
7 samples were also evaluated for stability using a CO binding assay as described above.  
Binding titration of CYP2J2-Nanodiscs with ebastine. The binding of ebastine to CYP2J2 
constructs was calculated by monitoring the spin state shift using a Cary Bio 300 UV-Vis 
spectrophotometer (Agilent Technologies, Santa, Clara CA).  Two constructs, M2SMG and 
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M2D19HG, were incorporated into Nanodiscs and purified using methods listed above.  Samples 
contained 2-5 µM of CYP2J2-ND, 100 mM phosphate buffer (pH 7.4) and ebastine.  Ebastine was 
added incrementally from a 10 mM ethanol stock with the final concentration of ethanol not 
exceeding 1%. The absorption spectra were measured between 800 and 200 nm after each ebastine 
titration.  Spectra were plotted and analyzed in Origin Lab (Origin Lab Inc., Northhampton, MA)   
For each titration the characteristic Type I spectral shift difference, from a low spin to a high spin 
state, were calculated (by measuring difference A386-A417) and plotted against the ebastine 
concentration.  The data were then fitted using the Hill equation (Eq. 1).  Additionally, the percent 
of high spin was calculated using a standard MATLAB subroutine.        
(Equation 1) ΔA = Amax Sn / (Ksn + Sn) 
Where ∆A is the absorbance difference at 386 nm and 417 nm, Amax is the amplitude 
corresponding to maximal spin shift, Ks is the spectral dissociation constant, S is the substrate 
concentration and n is the Hill coefficient. The ebastine binding data fit n=1 better than n=2, 
therefore for final fitting a single binding isotherm was used. The calculated spectral binding 
constants are averages of three independent experiments. 
NADPH activity assays. CYP2J2 NADPH oxidation rates were examined native-like in 
membrane bound systems (Nanodiscs) and detergent solubilized systems (0.1% CHAPS). The 
NADPH oxidation rates were measured using kinetics mode in a Cary 300 UV-Vis spectrometer 
(Agilent Technologies, Santa Clara, CA).  Incubation mixtures were calculated in the presence of 
saturating concentrations of substrate (arachidonic acid or ebastine) and electron donor (NADPH). 
The incubation mixtures contained 100 mM phosphate buffer (pH 7.4), 150 pmol CPR, 50 pmol 
of CYP2J2 N-terminal mutant and either arachidonic acid (70 µM) or ebastine (50 µM).  Samples 
were equilibrated at 37˚C for 5 minutes prior to reaction initiation with 200 µM NADPH (total 
volume 250 µL).  NADPH oxidation was monitored for ten minutes at 340 nm and the slope was 
used to determine the absorption change over time. The NADPH consumption rate was calculated 
using an extinction coefficient of 6.22 mM-1cm-1. Reactions were quenched and products of the 
reaction were further analyzed as given in the next section (59).  
Ebastine hydroxylation assay. CYP2J2 N-terminal mutant ebastine metabolism rates were 
examined in membrane bound systems (Nanodiscs) and detergent solubilized systems (0.1% 
CHAPS). Saturating concentrations of the substrate (ebastine) and electron donor (NADPH) were 
used to calculate the reaction Vmax (nmol/min/nmol of CYP) for each respective CYP2J2 N-
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terminus mutant. The incubation mixture for ebastine hydroxylation was the same as above. After 
a ten minute incubation period, the reaction was terminated with 100 µL of ice cold acetonitrile 
and then spiked with the internal standard terfenadine (100 ng/ml). The reactions were stopped at 
10 minutes to minimize secondary metabolite formation  Quenched samples were centrifuged at 
10,000 rpm for 15 minutes on a desktop mini-centrifuge (Eppendorf AG Hamburg, Germany).  A 
100 µL sample of supernatant was flash frozen for hydroxyebastine concentration determination 
via LC/MS/MS analysis. Each construct assay was completed in duplicate or greater. Rates and 
coupling efficiency (%) are reported as the mean ± SE. 
Liquid chromatography- tandem mass spectrometry for quantitation of ebastine and 
hydroxyebastine. Liquid chromatography-tandem mass spectrometry (LC/MS/MS) was employed 
for quantitation of ebastine, hydroxyebastine and terfenadine parent ions [M + H]+ and their 
corresponding fragment ions.  The LC/MS/MS system consisted of a Waters Alliance 2795 
analytical high performance liquid chromatography separation module (Waters, Milford, MA) 
coupled with an electrospray ionization mass spectrometer (Waters Quattro Ultima, Waters, 
Milford, MA) operated in positive mode.  Samples were analyzed using a reversed-phase C18, 1.3 
Å, 2.1 mm x 20 mm and 2.5 µm pore size column (Waters, Milford, MA). The solvent system was 
composed of two solutions: solvent A (95% H2O, 5% acetonitrile (ACN) and 0.1% formic acid 
(FA)) and solvent B (5% H2O and 95% ACN, and 0.1% FA). The 10 min gradient LC separation 
included 8 steps: (1) 90–80% solvent A in 0–1 min (linear); (2) 80–65% solvent A for 1–4 min 
(linear); (3) 65% solvent A for 4-5 min (isocratic); (5) 65-50% solvent A for 5-7 min (linear); (6) 
50% solvent A for 7-8 min (isocratic); (7) 50-90% solvent A for 8-9 min (linear); and (8) 90% 
solvent A for 9-10 min (isocratic).  
The MRM data acquisition consisted of monitoring the following analytes in positive mode 
using these transitions (parent ion → fragment ion, cone voltage, collision voltage) ebastine (470.4 
→ 167.0, 30 eV, 30 eV and 470.4 → 203.1, 30 eV, 30 eV), terfenadine (472.4 → 57.2, 30 eV, 35 
eV and 472.4 → 436.3, 30 eV, 25 eV) and hydroxyl-ebastine (486.4 → 167.0, 30 eV, 30 eV and 
486.4 → 219.1, 30 eV, 30 eV) all with 100 ms dwell time. Quantitation of ebastine and 
hydroxyebastine was determined using the peak areas normalized to the internal standard 
(terfenadine 100 ng/ml) from a previously calculated standard curve. Analytical data was 
processed using Waters Mass Lynx software (version 4.1).  
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Modeling of CYP2J2. The primary amino acid sequence of M2D34G was used as input to 
generate a 3-dimensional model of CYP2J2 created using the Phyre Web server (60).  The resulting 
pdb file was used as input for the Orientations of Proteins in Membranes (OPM) database (61) to 
generate a model of M2D34 binding with a membrane (Figure 3.4B).  
3.4 RESULTS AND DISCUSSION 
Construction of CYP2J2 N-deletion mutants. The native human CYP2J2 gene was obtained 
from Origene. The Kyte-Doolittle hydropathy plot for CYP2J2 (Figure 3.6) shows that 
approximately the first 33 amino acids form the hydrophobic membrane-spanning domain. From 
literature, it is known that removal of hydrophobic regions from the N-terminus increases the 
yields of expression of cytochrome P450s (26, 49). Therefore we prepared five different CYP2J2 
constructs with varying N-terminal modifications for the purpose of increasing the yield of 
expression without eliminating their ability to associate with the lipid bilayers. The different N-
terminally modified CYP2J2 constructs are listed in Figure 3.1A and the list of primers used for 
each respective construct are represented in the supplementary data (Table 3.2). The N-terminal 
modifications made to the CYP2J2 constructs are the following. [1] Replaced the second codon in 
the gene sequence with Ala (GCT), as many E. coli genes controlled by the lacZ operator have 
been found to contain this codon (62, 63). [2] Incorporated silent mutations in the first 5 to 7 
codons to render them both AT rich and to minimize the free energy of mRNA secondary structure 
(47, 48, 63, 64). [3] Truncated part or all of the hydrophobic (membrane spanning) region of the 
N-terminus as done previously (22). [4] Incorporated hydrophilic sequence AKKTSS into the N-
terminus (65, 66).  
One complication in the molecular cloning of CYP2J2 was the presence of an internal NdeI site 
in the gene (67). We circumvented this problem by using an easy and elegant method of digesting 
the CYP2J2 gene with a different enzyme, AseI, which produced an overhang compatible with the 
NdeI digested fragment and enabled ligation producing the desired constructs.  
Heterologous expression of CYP2J2 in E. coli. All the constructs of CYP2J2 were transformed 
into DH5alpha cells along with the pTGro7 plasmid encoding for the expression of the GroEL-
GroES chaperonin system (68). The average yields obtained after Ni-NTA column purification 
from each of the constructs are shown in Figure 3.1B. The overall protein expression yields 
corresponded to the size of the N-terminal deletion with yields following: 
M2D34G>M2D19HG>M2D5HG~M2SMG. The protein expression yields of the full-length 
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CYP2J2 significantly varied for constructs M2G and M2SMG with yields of 1-2 nmol/L and 27 
nmol/L of purified protein, respectively. Interestingly, both M2G and M2SMG are full-length 
proteins similar to wild type CYP2J2 with a single substitution (Leu2Ala) at the 2nd amino acid in 
the N-terminal domain (Figure 3.1A). The difference between these two constructs was the 
introduction of silent mutations at the 3rd, 4th and 6th codons of M2SMG that increased expression 
20-fold as represented in Figure 3.1B. Thus, we were able to greatly enhance the expression of full 
length CYP2J2 (M2SMG) with the introduction of silent mutations at the N-terminus thereby 
minimizing the free energy of the mRNA secondary structure formation (ΔG of M2G = -3.94; ΔG 
of M2SMG = -1.69) as calculated in the methods section. The expression of full length CYP2J2 
in high yields was essential to fully elucidate the role of the N-terminus of CYP2J2 in membrane 
binding and association with its redox partner cytochrome P450 reductase.  
The complete truncation of the N-terminal hydrophobic region in the M2D34G construct 
resulted in the protein being located in the soluble fraction at a much higher percentage (~40%) 
than the proteins expressed from other constructs (Figure 3.1B). M2D19HG, which was modified 
by truncating 19 N-terminal amino acids, was primarily purified from the E. coli membrane 
fraction (~85%). This indicated that the additional 14 hydrophobic amino acids of D19HG 
provided a much stronger membrane anchor for association during purification when compared to 
M2D34G. 
Oligomerization Studies. The oligomerization states of the different constructs were estimated 
by size exclusion chromatography. In Figure 3.2C, we see that the N-terminal hydrophobic regions 
of M2SMG and M2D5HG induce significantly greater oligomeric states with predominant 
retention times at 22 min and a much smaller peak at 30 min. The N-terminal truncations of 
M2D19HG exhibited a different elution profile with two predominant oligomeric states at 22 min 
and 31 min.  Most dramatically, the N-terminal deletions of M2D34G produced a large monomeric 
state at 31 min with a smaller aggregated peak at 19 min. The overall quantity and stokes radius 
for the larger oligomeric states corresponded closely with the size of the N-terminus, thus 
following the pattern M2SMG~M2D5HG>M2D19HG>M2D34G. 
Spectrophotometric characterization of CYP2J2 N-terminus mutants and substrate binding 
assay. The purified oxidized CYP2J2 constructs were analyzed using UV-visible spectra. All the 
constructs had typical peaks at 417 nm and the α and β bands (Q-bands) at 536 nm and 570 nm 
respectively. The proteins were reduced and the Fe(II) CO spectra was measured for each of the 
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constructs (55). Figure 3.2B shows the Fe(II)-CO spectra of all the different constructs. They all 
exhibited prominent peak at 450 nm with little to no presence of a peak at 420 nm. This confirmed 
that the axial-thiolate ligand was retained and suggested maintenance of a typical P450 fold for 
this motif in the active site. 
Spectroscopic substrate binding assay. Typically for drug metabolizing and steroid synthesizing 
human cytochrome P450s, binding substrate produces a spin state shift accompanied by the shift 
of Soret from 417 nm to 393 nm (40, 56, 69). To probe the active site of a full-length versus 
truncated CYP2J2, we studied the substrate binding in Nanodiscs. CYP2J2 is primarily expressed 
in the human heart where its main function is the conversion of arachidonic acid (AA) into EETs 
by epoxidation.  Using this assay, we did not detect an observable spectral spin state change for 
AA binding.  However, we did measure a modest increase in NADPH consumption rates (data not 
shown) that indicated binding of the substrate.  Additionally, Zeldin and colleagues previously 
determined the in vitro metabolism rate of AA (70). In contrast, the other epoxygenases (CYP2C8 
and CYP2C9) directly interact with AA, as evidenced by a 27% spin state change for CYP2C8 
(71, 72). However, this is not unprecedented as there are several examples where substrate binding 
does not substantially change the spin state for substrates capable of being metabolized. For 
instance, CYP3A4 metabolizes erythromycin despite a minor spin state shift (5-10%) upon binding 
(40). 
CYP2J2 is also involved in the metabolization of certain drugs including ebastine, astemiozole 
and terfenadine (73, 74). We measured the UV-Vis spectra of ebastine binding to CYP2J2. As 
shown in Figure 3.3A, type I substrate-binding spectra is obtained upon titration with ebastine. 
This is also true for binding of terfenadine to CYP2J2 (data not shown). The spectral dissociation 
constant of ebastine binding to the two constructs of CYP2J2 were calculated to be 7.3 ± 1.9 µM 
for M2SMG and 6.8 ± 0.7 µM for M2D19HG. This reveals that the spectral dissociation constant 
is likely to be independent of the N-terminus composition of CYP2J2 in Nanodiscs. Unlike other 
drug metabolizing P450s, the binding of ebastine fits to a single substrate binding equation and 
does not exhibit cooperativity. 
Association of CYP2J2 with lipid bilayers. Nanodiscs are native-like lipid bilayer membranes 
that have been used to stabilize membrane proteins in solution. We assembled the different N-
terminal variants of CYP2J2 into Nanodiscs in order to: (a) functionally stabilize the cytochrome 
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P450s, (b) study the stability of the association of different CYP2J2 constructs with the lipid 
bilayers over time, (c) and assess the role of lipid bilayers in controlling the function of P450s.  
The N-terminus of membrane-bound native CYP2J2 is hydrophobic and is thought to be 
involved in association with the membranes. We analyzed the P450 content of the different N-
terminally modified CYP2J2 constructs in both the soluble and membrane fractions of E.coli cells 
(Figure 3.1B). We found that M2D34G CYP2J2 (complete N-terminus truncation) was purified 
from both soluble (40%) and membrane fraction (60%) while M2SMG CYP2J2 (full length) was 
primarily obtained from the membrane fraction (96%) as seen in Figure 3.1B.  The membrane 
fraction of M2D34G still contained the majority of protein indicating the intrinsic membrane 
binding affinity was not completely abolished. These results suggested the solubility of the protein 
was increasing due to the truncation of N-terminal hydrophobic residues similar to other membrane 
bound CYPs (25).          
To evaluate if the N-terminus modifications conferred stable association with lipid bilayers, we 
measured the stability of the CYP2J2-Nanodisc complex over a period of seven days at 4ºC using 
size exclusion chromatography. The CYP2J2-Nanodiscs peak eluted at 26 minutes (flow rate is 
0.5 mL/min) and was measured by monitoring the absorbance at 417 nm. The area under the peak 
was integrated and used to quantitate percent loss of the CYP2J2-Nanodisc complex. Over 7 days 
at 4ºC there was loss of ~10-25% of the starting amount of CYP2J2-Nanodiscs (Figure 3.4D).  We 
did not observe the formation of an empty Nanodisc peak or free CYP2J2 in solution indicating 
the macromolecular complex was likely precipitating upon dissociation and lost in the pre-
filtration step of this assay.  
Interestingly, despite the truncation of 34 amino acid residues in the M2D34G construct we 
obtained stable Nanodiscs comparable to that of the full length M2SMG. Surprisingly, M2D19HG 
demonstrated the greatest stability over the same time course. Thus, the trends observed when 
purifying proteins from cell lysates do not directly translate to in vitro protein-membrane 
associated systems in standard conditions. These observations indicated that additional residues 
separate from the N-terminus were also responsible for membrane association. To explore this 
further, we modeled CYP2J2 in membranes using Phyre and OPM software (60, 61). We found 
that similar to other membrane binding CYPs, the A helix, F-G loop and F′-G′ helices contain 
hydrophobic groups that likely aid in the association of this protein with the membrane (Figure 
3.4B). These residues provide interesting targets for additional mutations to further explore the 
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membrane binding properties of CYP2J2 and engineer a soluble and monomeric CYP2J2 
construct. 
Additionally, we measured the P450 content by CO binding at the beginning and end of 7 days 
to gauge CYP2J2 functionality. The Fe(II)-CO P450 formation at the beginning (day one) and end 
(day seven) of the time course produced 100% P450 (data not shown), indicating that all the  
proteins in Nanodiscs retained the typical P450 protein fold with the heme-thiolate motif intact 
when stored at 4ºC. 
CYP2J2 activity and role of membranes.  We further studied the role of the N-terminus of 
CYP2J2 in modulating the activity of the protein with respect to the rate of NADPH oxidation and 
ebastine hydroxylation. The rate of steady-state NADPH consumption was measured for the four 
constructs in the presence/absence of ebastine in a three different systems - detergent solubilized 
system, phospholipid reconstituted system and incorporated into Nanodiscs.  
Additionally, the enzymatic activities of CYP2J2 constructs were determined in the three 
systems by measuring the rate of ebastine hydroxylation (59, 75). We measured the ebastine 
hydroxylation activity of the protein to determine whether the protein is using the transferred 
electrons from NADPH for a productive pathway to generate desired products or using them 
unproductively in generating unwanted reactive oxygen species (76). We measured the coupling 
efficiency, which is defined as the ratio of rate of product formation to the rate of NADPH 
oxidation (Figure 3.5). These experiments provided insight of the role of N-terminus and that of 
membranes in controlling the NADPH oxidation and ebastine hydroxylation in CYP2J2-CPR 
system.   
NADPH oxidation, product formation and coupling efficiency in CYP2J2:CPR-Nanodiscs.  
The Nanodisc rates reported here are for a co-incorporated 1:1 homogeneous complex of 
CYP2J2:CPR (56). On average, for the CYP2J2:CPR-Nanodiscs substrate free form the rate of 
NADPH consumption was ~10 nmol/min/nmol for the four constructs. When a saturating 
concentration of ebastine was added, a doubling of the NADPH oxidation rate was observed, in 
the range of 20.3-27.1 nmol/min/mol. Notably, in this defined lipid membrane system we observed 
similar NADPH oxidation rates for all the constructs; with M2D19HG:CPR-ND exhibiting a 
slightly higher consumption rate. Taken together, when the ratio of CYP2J2:CPR was equal and 
incorporated into membrane bilayers we do not detect a significant difference in the NADPH 
turnover rates for the constructs.  
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To gauge functionality, we measured the ebastine hydroxylation activity of this system as given 
in table 1 for M2SMG, M2D5HG, M2D19HG and M2D34G.  Due to the narrow range of product 
formation it was necessary to calculate the coupling efficiencies in order to directly compare the 
four constructs in this system. The coupling efficiencies in Nanodiscs for M2SMG: CPR, 
M2D5HG:CPR, M2D19HG:CPR and M2D34G:CPR were  determined to be 17.0 ± 0.8, 17.1 ± 
0.7, 16.5 ± 0.9 and 13.6 ± 1.3 %, respectively.  We considered each of these efficiencies to be very 
similar, with a slight reduction in the efficiency of M2D34G. Overall, these coupling efficiencies 
were approximately 6-fold greater than the detergent solubilized system and 3-fold greater than 
the phospholipid reconstituted system (Table 3.1). This shows that interaction of CYP2J2 and CPR 
in a membrane environment plays a more important role in controlling the coupling efficiency as 
compared to the N-terminus hydrophobic domain of CYP2J2.  
NADPH oxidation, product formation and coupling efficiency in a phospholipid reconstituted 
system. In the absence of substrate the phospholipid reconstituted system provided a range of 
NADPH consumption rates (31.8-65.1 nmol/min/nmol) that followed the extent of the N-terminal 
truncation. Likewise, in the presence of excess substrate a similar trend in NADPH oxidation was 
observed (69-121 nmol/min/nmol). However, the ebastine hydroxylation rates for all the constructs 
were similar (Table 3.1). Interestingly, the NADPH oxidation rates and ebastine hydroxylation 
rates for the M2SMG and M2D5HG constructs with the majority of the N-terminus intact were 
nearly identical indicating a similar association with CPR within the reconstituted system. The 
M2D19HG construct consumed a marginally higher amount of NADPH yet produced the highest 
amount of product when compared to the other constructs.  Strikingly, M2D34G while consuming 
a relatively high level of NADPH produced the lowest level of product. The coupling efficiencies 
of this lipid reconstituted system for M2SMG, M2D5HG, M2D19HG and M2D34G were 
calculated to be 6.1 ± 0.2, 6.1 ± 0.7, 6.2 ± 0.4 and 2.5 ± 0.3 %, respectively. Thus, within this 
reconstituted system the presence of the full or partially truncated N-terminal domain exhibited 
similar utilization of NADPH for ebastine hydroxylation. Moreover, it would indicate that despite 
the different oligomerization states of the different N-terminus constructs, the three constructs’ 
orientation with the exogenous CPR lead to the formation of a productive complex. However, the 
fully truncated M2D34G construct exhibited a more than a two-fold decrease in efficiency 
suggesting that the formation of a productive complex between the two proteins is significantly 
reduced in the absence of the N-terminus. The extent of the analysis is hindered without a 
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comprehensive understanding of the complexes formed within the POPC reconstituted system. 
However, sufficient evidence is present to suggest that in absence of a uniform membrane bilayer 
environment, the N-terminus is important for productive interaction with CPR.          
NADPH consumption, product formation and coupling efficiency in a CYP2J2-detergent 
solubilized system. For detergent solubilized CYP2J2, there was a dramatic increase of NADPH 
consumption when ebastine was added and like the phospholipid reconstituted system the rates 
ranged from 44.9 nmol/min/nmol of protein for M2D5HG to 142.5 nmol/min/nmol for the 
M2D34G mutant. Interestingly, the differences in the NADPH consumption rates in this system 
followed the order of the N-terminal truncations M2D34G>M2D19HG>M2SMG~M2D5HG.   
The functional activity of the constructs was measured in the detergent solubilized system (Table 
3.1).  We found that the rate of product formation correlated with the rate of NADPH consumption 
observed. This observation was reinforced upon calculation of the coupling efficiencies for the 
different constructs. Notably, the coupling efficiencies containing all or part of the N-terminus 
used NADPH with the same efficiency whereas the fully truncated construct exhibited ~50% 
reduction. 
NADPH consumption using arachidonic acid as a substrate. We also determined that the rate 
of NADPH oxidation in the presence of excess AA increases marginally (~1.5 fold) above the 
substrate-free system (data not shown). Overall, the NADPH oxidation rate with AA and ebastine 
bound to CYP2J2 was slower as compared to other CYPs bound to substrate.(77) In CYP3A4, the 
presence of a spin state changing substrate can significantly affect NADPH oxidation rates, for 
instance the rate in the absence of the substrate is 25 nmol/min/nmol whereas in the presence of 
the substrate and a spin state change it can reach 272 nmol/min/nmol. Thus, the modest 1.5-fold 
increase in NADPH consumption during AA metabolism by CYP2J2 in detergents and Nanodiscs 
affirms the previous observation that AA does not produce a spin state change. Previously 
Guengerich and co-workers have shown a strong correlation between the steady-state NADPH 
oxidation rate and the first electron transfer which can be related to the degree of spin state change 
(78) (79).  
Comparison of ebastine hydroxylation rate of CYP2J2 isolated from different systems. We 
compared the ebastine hydroxylation rates of the E.coli expressed protein to previous recombinant 
human CYP2J2 expressed in mammalian, yeast and insect cells. The values obtained had a range 
of ebastine hydroxylation rates in the different microsomal preparations (73,74,80). Previous 
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studies using mammalian COS-1 and insect baculovirus cells yielded rates (Vmax) of 5.5 and 8.1 
nmol/min/nmol, respectively (73, 80).  The ebastine hydroxylation rates using yeast microsomes 
exhibited a relatively high Vmax of 40.1 nmol/min/nmol possibly due to different post-
translational modifications in these systems (74). In this work, the E. coli expressed CYP2J2 
constructs in Nanodiscs exhibited similar catalytic rates to what was reported for microsomal 
preparations of CYP2J2 from insect and mammalian expression systems. Specifically, the turnover 
numbers of CYP2J2-CPR-Nanodisc systems were the most similar when compared to the 
aforementioned systems.  
Within the Nanodisc system we were able to control the oligomerization state of CYP2J2:CPR 
and incorporate these proteins in a 1:1 ratio in a defined lipid membrane environment. This model 
system enabled us to deconstruct the complex interactions of the N-terminally modified CYPs, 
which revealed in the membrane lipid bilayer of Nanodiscs, the NADPH consumption rates and 
coupling ratio were quite similar for the different constructs. This suggests that when the different 
N-terminal constructs of CYP2J2 are incorporated into lipid bilayers they adopt orientations and 
conformations that enable similar interactions with CPR. Alternatively, in the detergent and 
phospholipid reconstituted system, the truncation of the N-terminus leads to the increased NADPH 
oxidation rates and reduced coupling efficiency. It is difficult to delineate the exact factors 
affecting these rates in detergents and phospholipid reconstituted systems in absence of detailed 
knowledge of the macromolecular protein complex in these systems.   
In Nanodiscs, the dual incorporation of CPR and CYP favors a more productive alignment of 
the two proteins’ redox centers via electrostatic interactions as found in  other P450 systems (81-
83). Additionally, it is possible that the complementary charge interactions of the incorporated 
CPR with CYP2J2 could be prompting a more productive orientation in membrane, especially for 
fully N-terminus truncated M2D34G. Our data show strong evidence that the presence of 
membrane environment is more critical than the presence of N-terminus for efficient electron 
transfer from NADPH to CYP2J2 orchestrated by CPR. This suggests the adoption of the native-
like conformation in lipid bilayers is essential for effective use of reducing equivalents from 
NADPH.  
3.5 CONCLUSIONS 
In this work, we significantly enhanced the expression of full length CYP2J2 in E. coli with the 
introduction of silent mutations at the N-terminus of the protein.  The expression of full length 
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CYP2J2 in high yields was essential to elucidate the role of the N-terminus of CYP2J2 in substrate 
binding, electron transfer and association with its redox partner cytochrome P450 reductase. We 
demonstrated that with the successful use of hydrophilic motifs and truncations of the N-terminal 
domain dramatically increases CYP2J2 expression in E.coli. All of the constructs expressed 
exhibited close to 100% P450 content indicating the maintenance of a typical P450 protein fold. 
Binding assays revealed that the Kd of binding of ebastine to M2D20HG and M2SMG was similar 
thus showing that the N-terminus does not affect the binding of this substrate to the protein.  
We further studied the association of CYP2J2 with lipid bilayers. During purification we 
observed 40% of the fully truncated M2D34G construct was found in the soluble fraction. 
However, when the four constructs were incorporated into Nanodiscs, we observed sufficient 
incorporation and stability over a week at 4ºC and found that the N-terminus is not a key 
determinant of membrane association in CYP2J2. Therefore we concluded that the association of 
CYP2J2 with lipid bilayers is mediated by other residues besides the N-terminus. 
The NADPH consumption and ebastine hydroxylation functionality of each construct was 
investigated in a detergent solubilized system, phospholipid reconstituted system and CYP2J2-
CPR-Nanodiscs. The coupling efficiencies were calculated to compare enzyme productivity and it 
was found that the CYP2J2-CPR Nanodisc system was approximately six-fold more efficient than 
the detergent solubilized system and three-fold more efficient than the phospholipid reconstituted 
system. 
We concluded that the N-terminus does not interfere with effective coupling of NADPH 
oxidation with ebastine hydroxylation when the protein is in the membrane environment. However 
in a detergent solubilized system or phospholipid-reconstituted system, an intact N-terminus is 
required for effective coupling. This suggests that in Nanodiscs, the protein is in a more native-
like membrane environment. Additionally, the proteins are monomeric and are effectively 
interacting with their redox partner CPR. Thus the membrane environment likely facilitates the 
proper docking of CPR to CYP2J2.  
This present study incorporates novel findings with respect to comparing the effects of N-
terminal modifications on the properties of CYP2J2 and its ability to interact with its redox partner 
CPR in the lipid bilayers of Nanodiscs.   
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3.7 FIGURES AND TABLES  
              
Figure 3.1. Design and Expression of CYP2J2 Mutants. (A) CYP2J2 wild type and design of 
N-terminal mutant constructs.  Boxed residues denote substitution of native Leu with Ala (GCT).  
Bolded residues represent introduction of AT rich silent mutations.  Underlined residues signify 
introduction of a hydrophillic motif.  Gaps represent deletion of N-terminal amino acids. (B) 
CYP2J2 N-terminal mutant expression and solubility in DH5alpha cells.  The bar graph denotes 
expression yields which were highly dependent on N-terminal modifications. The line plot 
signifies percentage of protein found in the soluble fraction during purification which largely 
corresponded to N-terminal truncations. 
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Figure 3.2. Characterization of CYP2J2 constructs.  (A)  CYP2J2 mutants were incorporated 
into Nanodiscs and purified using size exclusion chromatography-HPLC.  SDS-PAGE was used 
to verify successful isolation of each respective CYP2J2-ND.  The first column contains a protein 
ladder  standard showing that the molecular weight of  M2D19HG is close to the ~50-60 kDa 
standard and the scaffolding protein MSP1T2 has molecular weight close to ~24 kDa. The exact 
molecular weights were confirmed using ESI-MS.  (B) CO binding spectra were used to 
characterize each construct and gauge the protein folding after expression and purification.  Each 
construct exhibited ~100% P450 content which is indicative of a well-folded and functional CYP. 
(C) SEC-HPLC was applied to characterize CYP2J2 mutant oligomerization states in phosphate 
buffer (0.1 M). The CYP2J2 elution profile was produced by monitoring the heme absorbance at 
417 nm.  Using water soluble protein standards, we observed that the constructs monomeric state 
corresponded closely with N-terminal truncations and to followed 
M2SMG>M2D5HG>M2D19HG>M2D34G. 
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Figure 3.3. Ebastine-binding spectra were fitted to a single binding isotherm. (A) Difference 
spectra of D19HGND ebastine titration. Ebastine was added incrementally from 0 to 120 mM. (B, 
C) The change of absorbance (DA) from 393 to 417 nm was calculated for each titration and 
plotted against the corresponding ebastine concentration (mM). Data were fitted with Origin Lab 
to the single binding isotherm. A single binding isotherm was applied to calculate the Kd of 
M2SMG and M2D19HG, which were determined to be 7.3 ± 1.9 and 6.8 ± 0.7 mM, respectively 
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Figure 3.4. Incorporation of CYP2J2 constructs in Nanodiscs and stability assay. (A) Visual 
molecular dynamics (VMD) was used to construct a representative model of CYP2J2 incorporated 
into Nanodiscs (CYP2J2 model was obtained using Phyre). In the model, blue represents the 
membrane scaffolding protein (MSP1D1), the gray are the phospholipids, and the protein ribbon 
model is the CYP2J2 enzyme. (B) Membrane association of M2D34HG model. Highlighted 
residues in the A helical region (Trp48, Arg49, Leu50, Pro51, Phe52, Leu53, Phe57, Leu58, and 
Phe61), Lys122 in B′ helix and in the FG loop region (Trp235, Phe239, and Leu240) are predicted 
by OMP software to be associated with the lipid membrane. Predicted Gibbs free energy for this 
interaction is 13.8 kcal mol−1. (C) CYP2J2 constructs were incorporated into Nanodiscs and 
monitored at 417 nm SEC-HPLC. The single peak corresponds to homogeneous CYP2J2-
Nanodiscs. (D) The relative stability of each CYP2J2 construct incorporated into Nanodiscs was 
monitored using SEC-HPLC over a 7-day period at 4°C. The percent area of the 417-nm peak 
corresponding to heme absorption was monitored at the established CYP2J2-Nanodisc elution time 
(∼26 min). We observed a similar relative stability for each of the constructs with an approximate 
10–20% degradation over the time course. 
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Figure 3.5. Schematic of NADPH oxidation and ebastine hydroxylation by a CPR-CYP2J2 
Nanodisc complex. Electrons are shuttled from NADPH to CYP2J2 via cytochrome P450 
reductase redox centers (step 1). These electrons subsequently drive CYP2J2 P450 catalysis of 
ebastine to hydroxyebastine (step 2). Coupling efficiency is measured as the ratio of ebastine 
hydroxylation (step 2) over NADPH oxidation (step 1). 
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Figure 3.6.  Hydropathy plots of CYP2J2.  (A) CYP2J2 N-terminus (1-43 amino acids) and 
(B) Full-length CYP2J2 hydrophobicity. 
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Table 3.1. NADPH oxidation and ebastine hydroxylation rates of CYP2J2 constructs in 
detergent solubilized and membrane bound systems. Each of the four constructs were 
incorporated into Nanodiscs, reconstituted with lipids or solubilized in 0.1% CHAPS and used to 
measure NADPH consumption and hydroxyebastine product formation. The coupling efficiency 
was calculated by taking the ratio of ebastine hydroxylation measured using LC-MS/MS versus 
the NADPH Oxidation monitored via UV-Vis spectroscopy at 340 nm. 
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Table 3.2 List of all the primers used to perform PCR to generate the required modifications 
of the 2J2 gene. The reverse primer was common for all the constructs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
46 
 
3.8 REFERENCES 
1. Samuelsson, B. (2012) J Biol Chem 287, 10070-80. 
2. Hannemann, F., Bichet, A., Ewen, K. M., and Bernhardt, R. (2007) Biochim Biophys Acta 
1770, 330-44. 
3. Bernhardt, R. (2006) J Biotechnol 124, 128-45. 
4. Delozier TC, Kissling GE, Coulter SJ, Dai D, Foley JF, Bradbury JA, Murphy E, 
Steenbergen C, Zeldin DC, and Goldstein, J. (2007) Drug Metab Dispos. 35, 682-8. 
5. Westphal, C., Konkel, A., and Schunck, W. H. (2011) Prostaglandins Other Lipid Mediat. 
96, 99-108. 
6. Wang, H., Jiang, Y., Liu, Y., Lin, C., Cheng, G., Chen, X., Hao, B., Tan, W., Lin, D., and 
He, F. (2006) Clin Chim Acta 365, 125-8. 
7. Xiao, B., Li, X., Yan, J., Yu, X., Yang, G., Xiao, X., Voltz, J. W., Zeldin, D. C., and Wang, 
D. W. (2010) J Pharmacol Exp Ther 334, 784-94. 
8. Imig, J. D. (2012) Physiol Rev 92, 101-30. 
9. Imig, J. D., and Hammock, B. D. (2009) Nat Rev Drug Discov 8, 794-805. 
10. Zhang, Y., El-Sikhry, H., Chaudhary, K. R., Batchu, S. N., Shayeganpour, A., Jukar, T. O., 
Bradbury, J. A., Graves, J. P., DeGraff, L. M., Myers, P., Rouse, D. C., Foley, J., Nyska, 
A., Zeldin, D. C., and Seubert, J. M. (2009) Am J Physiol Heart Circ Physiol 297, H37-46. 
11. Herse, F., Lamarca, B., Hubel, C. A., Kaartokallio, T., Lokki, A. I., Ekholm, E., Laivuori, 
H., Gauster, M., Huppertz, B., Sugulle, M., Ryan, M. J., Novotny, S., Brewer, J., Park, J. 
K., Kacik, M., Hoyer, J., Verlohren, S., Wallukat, G., Rothe, M., Luft, F. C., Muller, D. 
N., Schunck, W. H., Staff, A. C., and Dechend, R. (2012) Circulation 126, 2990-9. 
12. Panigrahy, D., Edin, M. L., Lee, C. R., Huang, S., Bielenberg, D. R., Butterfield, C. E., 
Barnes, C. M., Mammoto, A., Mammoto, T., Luria, A., Benny, O., Chaponis, D. M., 
Dudley, A. C., Greene, E. R., Vergilio, J. A., Pietramaggiori, G., Scherer-Pietramaggiori, 
S. S., Short, S. M., Seth, M., Lih, F. B., Tomer, K. B., Yang, J., Schwendener, R. A., 
Hammock, B. D., Falck, J. R., Manthati, V. L., Ingber, D. E., Kaipainen, A., D'Amore, P. 
A., Kieran, M. W., and Zeldin, D. C. (2012) J Clin Invest 122, 178-91. 
13. Panigrahy, D., Greene, E. R., Pozzi, A., Wang, D. W., and Zeldin, D. C. (2011) Cancer 
Metastasis Rev 30, 525-40. 
14. Panigrahy, D., Kaipainen, A., Greene, E. R., and Huang, S. (2010) Cancer Metastasis Rev 
29, 723-35. 
15. Jiang, J. G., Chen, C. L., Card, J. W., Yang, S., Chen, J. X., Fu, X. N., Ning, Y. G., Xiao, 
X., Zeldin, D. C., and Wang, D. W. (2005) Cancer Res 65, 4707-15. 
16. Jiang, J. G., Ning, Y. G., Chen, C., Ma, D., Liu, Z. J., Yang, S., Zhou, J., Xiao, X., Zhang, 
X. A., Edin, M. L., Card, J. W., Wang, J., Zeldin, D. C., and Wang, D. W. (2007) Cancer 
Res 67, 6665-74. 
17. Lee, C. A., Jones, J. P., 3rd, Katayama, J., Kaspera, R., Jiang, Y., Freiwald, S., Smith, E., 
Walker, G. S., and Totah, R. A. (2012) Drug Metab Dispos 40, 943-51. 
18. Chen, C., Li, G., Liao, W., Wu, J., Liu, L., Ma, D., Zhou, J., Elbekai, R. H., Edin, M. L., 
Zeldin, D. C., and Wang, D. W. (2009) J Pharmacol Exp Ther 329, 908-18. 
19. Lee CA, Jones JP 3rd, Katayama J, Kaspera R, Jiang Y, Freiwald S, Smith E, Walker GS, 
and Totah, R. (2012) Drug Metab Dispos. 40, 943-51. 
20. Matsumoto S, Hirama T, Matsubara T, Nagata K, and Yamazoe, Y. (2002) Drug Metab 
Dispos. 30, 1240-5. 
47 
 
21. Skorupa, E., and Kemper, B. (1998) Methods Mol Biol 107, 251-66. 
22. Cosme, J., and Johnson, E. F. (2002) Methods Enzymol 357, 116-20. 
23. Williams, P. A., Cosme, J., Sridhar, V., Johnson, E. F., and McRee, D. E. (2000) J Inorg 
Biochem 81, 183-90. 
24. Hsu, P. Y., and Wang, L. H. (2003) Archives of Biochemistry and Biophysics 416, 38-46. 
25. Cosme, J., and Johnson, E. F. (2000) J Biol Chem 275, 2545-53. 
26. von Wachenfeldt, C., Richardson, T. H., Cosme, J., and Johnson, E. F. (1997) Archives of 
Biochemistry and Biophysics 339, 107-14. 
27. Kim, H. J., Lee, S. B., Guengerich, F. P., Park, Y. I., and Dong, M. S. (2007) Xenobiotica 
37, 356-65. 
28. Ahn, T., Guengerich, F. P., and Yun, C. H. (1998) Biochemistry 37, 12860-6. 
29. Davydov, D. R. (2011) Expert Opin Drug Metab Toxicol 7, 543-58. 
30. Praporski, S., Ng, S. M., Nguyen, A. D., Corbin, C. J., Mechler, A., Zheng, J., Conley, A. 
J., and Martin, L. L. (2009) J Biol Chem 284, 33224-32. 
31. Pernecky, S. J., Larson, J. R., Philpot, R. M., and Coon, M. J. (1993) Proc Natl Acad Sci 
U S A 90, 2651-5. 
32. Berka K, Hendrychová T, Anzenbacher P, and Otyepka, M. (2011) J Phys Chem A. 115, 
11248-55. 
33. Conner KP, W. C., Atkins WM. (2011) Arch Biochem Biophys. 50, 56-65. 
34. Denisov, I. G., and Sligar, S. G. (2011) Biochim Biophys Acta 1814, 223-9. 
35. Bayburt, T. H., and Sligar, S. G. (2010) FEBS Lett 584, 1721-7. 
36. Ritchie, T. K., Grinkova, Y. V., Bayburt, T. H., Denisov, I. G., Zolnerciks, J. K., Atkins, 
W. M., and Sligar, S. G. (2009) Methods Enzymol 464, 211-31. 
37. Leitz, A. J., Bayburt, T. H., Barnakov, A. N., Springer, B. A., and Sligar, S. G. (2006) 
Biotechniques 40, 601-612. 
38. Boldog, T., Grimme, S., Li, M., Sligar, S. G., and Hazelbauer, G. L. (2006) Proc Natl Acad 
Sci U S A 103, 11509-14. 
39. Nath, A., Atkins, W. M., and Sligar, S. G. (2007) Biochemistry 46, 2059-69. 
40. Das, A., Grinkova, Y. V., and Sligar, S. G. (2007) J Am Chem Soc 129, 13778-9. 
41. Das, A., and Sligar, S. G. (2009) Biochemistry 48, 12104-12. 
42. Tark, S. H., Das, A., Sligar, S., and Dravid, V. P. (2010) Nanotechnology 21, 435502. 
43. Marty, M. T., Das, A., and Sligar, S. G. (2012) Anal Bioanal Chem 402, 721-9. 
44. Das, A., Zhao, J., Schatz, G. C., Sligar, S. G., and Van Duyne, R. P. (2009) Anal Chem 81, 
3754-9. 
45. Zhao, J., Das, A., Zhang, X., Schatz, G. C., Sligar, S. G., and Van Duyne, R. P. (2006) J 
Am Chem Soc 128, 11004-5. 
46. Kim, D. H., Kim, K. H., Isin, E. M., Guengerich, F. P., Chae, H. Z., Ahn, T., and Yun, C. 
H. (2008) Protein Expr Purif 57, 188-200. 
47. Schauder, B., and McCarthy, J. E. (1989) Gene 78, 59-72. 
48. Stormo, G. D., Schneider, T. D., and Gold, L. M. (1982) Nucleic Acids Res 10, 2971-96. 
49. Richardson, T. H., Jung, F., Griffin, K. J., Wester, M., Raucy, J. L., Kemper, B., Bornheim, 
L. M., Hassett, C., Omiecinski, C. J., and Johnson, E. F. (1995) Archives of Biochemistry 
and Biophysics 323, 87-96. 
50. Poulos, T. L. (1996) Methods Enzymol 272, 358-68. 
51. Poulos, T. L. (1995) Curr Opin Struct Biol 5, 767-74. 
48 
 
52. Aiba, I., Yamasaki, T., Shinki, T., Izumi, S., Yamamoto, K., Yamada, S., Terato, H., Ide, 
H., and Ohyama, Y. (2006) Steroids 71, 849-56. 
53. Kagawa N, and Cao, Q. (2001) Arch Biochem Biophys. 393, 290-6. 
54. Joseph, R. E., and Andreotti, A. H. (2008) Protein Expr Purif 60, 194-7. 
55. Omura, T., and Sato, R. (1964) J Biol Chem 239, 2379-85. 
56. Denisov, I. G., Baas, B. J., Grinkova, Y. V., and Sligar, S. G. (2007) J Biol Chem 282, 
7066-76. 
57. Causey, K. M., Eyer, C. S., and Backes, W. L. (1990) Mol Pharmacol 38, 134-42. 
58. Kapust RB, Tözsér J, Fox JD, Anderson DE, Cherry S, Copeland TD, and Waugh, D. 
(2001) Protein Eng. 14, 993-1000. 
59. Kang W, Liu KH, Ryu JY, and Shin, J. (2004) J Chromatogr B Analyt Technol Biomed 
Life Sci. 813, 75-80. 
60. Kelley LA, and Sternberg, M. (2009) Nat Protoc. 4, 363-71. 
61. Lomize MA, Lomize AL, Pogozheva ID, and Mosberg, H. (2006) Bioinformatics. 22, 623-
5. 
62. Looman, A. C., Bodlaender, J., Comstock, L. J., Eaton, D., Jhurani, P., Deboer, H. A., and 
Vanknippenberg, P. H. (1987) Embo Journal 6, 2489-2492. 
63. Barnes, H. J., Arlotto, M. P., and Waterman, M. R. (1991) Proc Natl Acad Sci U S A 88, 
5597-601. 
64. Yamasaki, T., Izumi, S., Ide, H., and Ohyama, Y. (2004) J Biol Chem 279, 22848-56. 
65. DeVore NM, and Scott, E. (2012) Nature 482, 116-9. 
66. Fisher CW, Caudle DL, Martin-Wixtrom C, Quattrochi LC, Tukey RH, Waterman MR, 
and Estabrook, R. (1992) FASEB J. 6, 759-64. 
67. Messina, A., Nencioni, S., Gervasi, P. G., Gotlinger, K. H., Schwartzman, M. L., and 
Longo, V. (2010) Xenobiotica 40, 109-18. 
68. Xu Z, and Sigler, P. (1998) J Struct Biol. 124, 129-41. 
69. Sligar, S. G. (1976) Biochemistry 15, 5399-406. 
70. Wu, S., Chen, W., Murphy, E., Gabel, S., Tomer, K. B., Foley, J., Steenbergen, C., Falck, 
J. R., Moomaw, C. R., and Zeldin, D. C. (1997) J Biol Chem 272, 12551-9. 
71. Schoch, G. A., Yano, J. K., Sansen, S., Dansette, P. M., Stout, C. D., and Johnson, E. F. 
(2008) J Biol Chem 283, 17227-37. 
72. Schoch, G. A., Yano, J. K., Wester, M. R., Griffin, K. J., Stout, C. D., and Johnson, E. F. 
(2004) J Biol Chem 279, 9497-503. 
73. Matsumoto, S., Hirama, T., Matsubara, T., Nagata, K., and Yamazoe, Y. (2002) Drug 
Metab Dispos 30, 1240-5. 
74. Hashizume, T., Imaoka, S., Mise, M., Terauchi, Y., Fujii, T., Miyazaki, H., Kamataki, T., 
and Funae, Y. (2002) J Pharmacol Exp Ther 300, 298-304. 
75. Liu KH, Kim MG, Lee DJ, Yoon YJ, Kim MJ, Shon JH, Choi CS, Choi YK, Desta Z, and 
Shin, J. (2006) Drug Metab Dispos. 34, 1793-7. 
76. Denisov, I. G., Makris, T. M., Sligar, S. G., and Schlichting, I. (2005) Chem Rev 105, 2253-
77. 
77. Sulistyaningdyah WT, Ogawa J, Li QS, Maeda C, Yano Y, Schmid RD, and Shimizu, S. 
(2005) Appl Microbiol Biotechnol. 67, 556-62. 
78. Isin, E. M., and Guengerich, F. P. (2008) Anal Bioanal Chem 392, 1019-30. 
79. Fisher, M. T., and Sligar, S. G. (1985) Journal of the American Chemical Society 107, 
5018-5019. 
49 
 
80. Liu, K. H., Kim, M. G., Lee, D. J., Yoon, Y. J., Kim, M. J., Shon, J. H., Choi, C. S., Choi, 
Y. K., Desta, Z., and Shin, J. G. (2006) Drug Metab Dispos 34, 1793-7. 
81. Bridges, A., Gruenke, L., Chang, Y. T., Vakser, I. A., Loew, G., and Waskell, L. (1998) J 
Biol Chem 273, 17036-49. 
82. Shen, S., and Strobel, H. W. (1993) Archives of Biochemistry and Biophysics 304, 257-65. 
83. Shimizu, T., Tateishi, T., Hatano, M., and Fujii-Kuriyama, Y. (1991) J Biol Chem 266, 
3372-5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
50 
 
CHAPTER IV: INCORPORATION OF CHARGED RESIDUES IN THE CYP2J2 F-G 
LOOP DISRUPTS CYP2J2-LIPID BILAYER INTERACTION 
 
4.1 ABSTRACT  
  CYP2J2 epoxygenase is an extrahepatic, membrane bound cytochrome P450 (CYP) that is 
primarily found in the heart and mediates endogenous fatty acid metabolism. CYP2J2 interacts 
with membranes through an N-terminal anchor and various non-contiguous hydrophobic residues. 
The molecular details of the motifs that mediate membrane interactions are complex and not fully 
understood. To gain better insights of these complex protein-lipid interactions, we employed 
molecular dynamics (MD) simulations using a highly mobile membrane mimetic (HMMM) model 
that enabled multiple independent spontaneous membrane binding events to be captured. 
Simulations revealed that CYP2J2 engages with the membrane at the F-G loop through 
hydrophobic residues Trp-235, Ille-236, and Phe-239. To explore the role of these residues, three 
F-G loop mutants were modeled from the truncated CYP2J2 construct (Δ34) which included Δ34-
I236D, Δ34-F239H and Δ34-I236D/F239H. Using the HMMM coordinates of CYP2J2 the 
simulations were extended to a full POPC membrane which showed a significant decrease in the 
depth of insertion for each of the F-G loop mutants. The CYP2J2 F-G loop mutants were expressed 
in E. coli and were shown to be localized to the cytosolic fraction at a greater percentage relative 
to construct Δ34. Notably, the functional data demonstrated that the double mutant, Δ34-
I236D/F239H, maintained native-like enzymatic activity. The membrane insertion characteristics 
were examined by monitoring CYP2J2 Trp-quenching fluorescence spectroscopy upon binding 
pyrene phospholipids containing nanodiscs. Relative to the Δ34 construct, the F-G loop mutants 
exhibited lower Trp quenching and membrane insertion. Taken together, the results suggest that 
the mutants exhibit a different membrane topology in agreement with the MD simulations and 
provide important evidence towards the involvement of key residues in the F-G loop of CYP2J2. 
 
 
 
 
2Reprinted, with permission, from McDougle DR§, Baylon JL§, Meling DD, Kambalyal A, Grinkova YV, Hammernik 
J, Tajkhorshid E, Das A*. Incorporation of Charged Residues in the CYP2J2 F-G Loop Disrupts CYP2J2-Lipid 
Bilayer Interaction. BBA Biomembranes. 2015 Oct;1848(10):2460-70. PMID: 26232558 
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4.2 INTRODUCTION  
  The cytochrome P450 (CYP) superfamily is a class of heme-containing enzymes that are 
widespread throughout all kingdoms of life (1). In humans, CYPs mediate the biotransformation 
of both xenobiotics and endogenous substrates for homeostasis (2). Eukaryotic CYPs interact with 
membrane bilayers through an N-terminal anchor as well as various non-contiguous hydrophobic 
residues that constitute the monofacial membrane-binding domain (3, 4).  
  The CYP interaction with the membrane bilayer is a complex phenomenon that is an active area 
of both experimental and computational research. While seminal studies correctly identified the 
general nature of the protein-membrane binding and topology (5), more recent examples have 
elucidated the interactions at the molecular and atomistic levels (6-8). Notably, P450 interactions 
with membranes have been shown to regulate ligand binding mechanisms (9), membrane depth of 
insertion (10), redox potentials (11), enzyme stability (12), structure and orientation (6). 
Additionally, advanced computational approaches have revealed the dynamic nature of CYPs and 
how their hydrophobic motifs interact with the membrane bilayer (6, 8). Both experimental and 
computational approaches have revealed that CYPs are inserted within the membrane, with a 
partially imbedded active site and deeply immersed N-terminus and F-G loop (13, 14).  
  CYP2J2 is an extrahepatic human CYP that catalyzes the epoxidation of both omega-3 and 
omega-6 polyunsaturated fatty acids into a number of biologically active metabolites (15). 
Importantly, CYP2J2 is highly expressed in the myocardium and surrounding aortic epithelium 
where it has been shown to be a key regulator of cardiovascular homeostasis (16). The metabolism 
of arachidonic acid, an omega-6 polyunsaturated fatty acid, by CYP2J2 produces 8 unique regio- 
and stereoisomers known as epoxyeicostrienoic acids (EETs) that are collectively characterized as 
anti-inflammatory and vasodilatory lipid mediators (17).   
  CYP2J2 is anchored within the endoplasmic reticulum (2). The presence of the hydrophobic 
membrane binding domains of CYP2J2 complicates its use in many biochemical assays due to its 
inherent tendency to aggregate outside of the membrane environment. The disruption of the 
protein-membrane interactions affords solubility and enables structural elucidation through 
methods such as nuclear magnetic resonance (NMR) and high resolution x-ray crystallography. 
Currently, there are no reports of the successful solubilization and subsequent crystallization of 
any member of the CYP2J subfamily. However, this was achieved for other CYP2 family members 
including CYP2C5, CYP2A6, CYP2C8, CYP2C9 and CYP2D6 (4, 18-21). Specifically, soluble 
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isozymes were engineered through a combination of deletions and hydrophilic substitutions of 
targeted membrane binding regions that resulted in increased expression yields and protein 
homogeneity.  For example, the solubility of CYP2C5 was increased by substituting the N-
terminus (Δ28) with MAKKTSSKG, adding a four-residue histidine tag at the C-terminus and 
incorporating five substitutions at the membrane binding interface with the mutations N202H, 
R206E, I207L, S209G, and S210T (4).  Similarly, CYP2C9 N-terminal (Δ29) residues were 
replaced by MAKKTSSKGR, a four-histidine carboxy-tag and the seven amino acid mutations 
(K206E, I215V, C216Y, S220P, P221A, I222L and I223L) in the F-G loop (18).  Soon after, 
CYP2D6 was successfully crystallized by truncating the N-terminus, adding a four-histidine tag 
at the C-terminus and mutating the F-G loop Leu-230 and Lue-231 with a combination of 
hydrophilic residues (Asn, Lys, His, Gln, Arg, and Ser) (21). Importantly, these changes afforded 
some of the first structural insights of mammalian P450s through high resolution x-ray 
crystallography. However, membrane dissociation while maintaining the native functional 
characteristics is an essential, yet difficult step, in the field of CYP protein engineering.  
 The truncation of the membrane-spanning CYP N-terminus is the most widely used strategy to 
disrupt protein-membrane interactions (19-23). Indeed, we previously demonstrated that the 
complete truncation of the CYP2J2 N-terminus results in a construct with significantly increased 
solubility. Importantly, this truncated construct (Δ34-CYP2J2) exhibited similar substrate turnover 
rates as the full length CYP2J2 construct in model membranes (24). Notably, Δ34 maintained its 
membrane insertion despite the N-terminal truncation (24). Accumulating evidence suggests that 
the F-G loop of CYPs (Figure 4.1A and 4.3A) is an essential mediator of membrane binding (25).  
Additionally, the F-G loop is positioned at the mouth of the substrate access tunnels and is thought 
to control the rate of substrate access to the buried active site (26). Unlike the N-terminal motif, 
the non-conservative mutations within the F-G loop region often results in significantly altered 
enzymatic activity (27). Thus far, strategies have typically included random mutagenesis and 
substitution of alternative CYP chimeras which are typically an exercise of trial-and-error (28).  
    In this study, we used molecular dynamics (MD) simulations in conjunction with experimental 
studies to evaluate the role of the F-G loop of CYP2J2 in membrane binding and insertion. 
Previously, MD simulations have been used to study protein-membrane interactions of membrane-
bound CYPs (6-8, 13, 29, 30). Herein, we first employ a highly mobile membrane-mimetic 
(HMMM) model (31) to capture spontaneous binding of CYP2J2 to the membrane. The HMMM 
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model employs short-tailed lipids while an organic solvent replaces the hydrophobic core of the 
membrane, resulting in increased lipid mobility. Due to the enhanced lipid mobility, the model 
accelerates the association of proteins with the lipid bilayer, and has been successfully employed 
to capture membrane binding of a variety of peripheral and membrane proteins including the GLA 
domain (31), cytochrome P450 3A4 (6), talin (32), α-synuclein (33), synaptotagmin (34), and 
synaptobrevin (35). This approach enabled us to capture atomic level interactions between CYP2J2 
and the membrane. Importantly, these interactions were preserved when the short-tailed lipids 
were extended to a full POPC membrane. Secondly, after a membrane-bound model of CYP2J2 
was obtained, we studied the effect of F-G loop mutations on membrane-binding and insertion 
depth, by taking advantage of the enhanced lipid dynamics of the HMMM model.  
  To experimentally support the MD findings, hydrophilic residues were engineered in the CYP2J2 
F-G loop. Subsequent studies revealed the effects of the mutations on enzyme functionality, 
subcellular distribution and membrane binding characteristics. The details of the relative depth of 
insertion were explored by measuring the mutants’ intrinsic tryptophan fluorescence and energy 
transfer to pyrene phospholipids incorporated in lipid bilayers.  
  Determining the degree of the Trp-pyrene fluorescence resonance energy transfer (FRET) is a 
widely used method to probe the interaction of both peripheral and membrane proteins with 
membrane bilayers. Previously, liposomal systems were used to measure the Trp insertion of 
membrane proteins such as CYP3A4 (10) and CYP1A2 (36) as well as peripherally binding 
proteins such as cytochrome C (37) and 14-3-3γ (38). The use of nanodiscs in this application 
offers several advantages over traditional liposomal systems. Specifically, nanodiscs are nanoscale 
discoidal lipid bilayers that exhibit significantly enhanced stability and homogeneity relative to 
liposomal systems. Additionally, nanodiscs are more easily concentrated without aggregation and 
lack the typical scattering effects observed with liposomal systems (14, 24, 39). 
  Overall this work provides novel insights on the role of key residues in the CYP2J2 F-G loop and 
their effects on membrane binding and functional metabolism. The use of MD simulations 
provides high resolution interactions between the membrane and CYP2J2 F-G loop. 
Experimentally, the introduction of hydrophilic residues in the F-G loop provides essential 
functional data as well as an assay for membrane depth of insertion. Understanding the nuances of 
these interactions will enable new applications with other membrane bound CYPs.   
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4.3 MATERIALS AND METHODS  
  Materials. Ampicillin, arabinose, chloroamphenicol and IPTG were from Gold Biotechnology.  
NADPH and NADP were obtained from P212121.com. Protein standards—thyroglobulin, ferritin, 
bovine serum albumin, and cytochrome c, were purchased from Sigma.  Phospholipids 1-
palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) and 1-hexadecanoyl-2-(9Z-
octadecenoyl)-sn-glycero-3-phospho-L serine (POPS) were purchased from Avanti Polar Lipids. 
The phospholipid 1-hexadecanoyl-2-(1-pyrenedecanoyl)-sn-glycero-3-phosphocholine (PYR-PC) 
was obtained from Life Technologies. Amberlite XAD 2 was procured from Supelco. Nanosep 
MF (0.2 µM) and Amicon Ultra (10,000 MWCO) centrifugal filters were bought from Millipore. 
AA and ebastine were purchased from Cayman Chemical. All other materials and reagents used 
were purchased from Sigma-Aldrich and Fisher Scientific.  
  Molecular Dynamical Simulations: Preparation of HMMM membrane. The HMMM 
membrane was constructed starting from a solvated POPC membrane by shortening the lipid tails 
to only 5 carbons (31), while the remaining carbon atoms were converted to 1,1-dichloroethane 
(DCLE). This resulted in an HMMM membrane patch with two leaflets of short-tailed PC lipids 
at the interface of water and DCLE, as described in detail elsewhere (31). The solvated HMMM 
membrane contained 137 short-tailed PC lipids in each leaflet and 1,268 DCLE molecules, 
yielding a system with ~41,000 atoms. The solvated membrane mimetic system was energy 
minimized for 2,000 steps and simulated for 1 ns using an NPnAT ensemble with constant area, 
and with a target normal pressure and temperature of 1.0 atm and 310 K, respectively. A constant 
area of 10, 281 Å2 (101.4  101.4 Å2) was employed, yielding an area of 75 Å2 per lipid (AL), 
about 8% higher than the experimental AL for POPC membranes (40). Based on our experience 
with other peripheral proteins, a mild increase in AL (5-8%) can significantly accelerate membrane 
binding (31, 33). The resulting membrane was employed in all subsequent binding simulations of 
wild-type CYP2J2 and its mutants. To mimic the atomic distributions of a full lipid bilayer in the 
HMMM simulations more closely, a harmonic constraint along the z-axis (membrane normal) with 
a force constant k = 0.05 kcal·mol−1·Å−2 was applied to the carbonyl carbon atoms of the short-
tailed PC lipids . 
 CYP2J2 model and initial configurations. A homology model of the catalytic domain of 
CYP2J2, generously provided by Dr. D. Mansuy (Université René Descartes, Paris France), was 
employed as the starting structure of CYP2J2 for this study. The homology model was derived 
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using the available crystal structures of CYP2A6 (PDB: 1Z11), CYP2B4 (PDB: 2BDM), CYP2C5 
(PDB: 1NR6), CYP2C8 (PDB: 1PQ2), and CYP2D6 (PDB: 2F9Q) as templates, as previously 
described (41). The sequence identity of the template structures with CYP2J2 ranged from 41% to 
45%. The individual sequence identity of each template with CYP2J2 is as follows: CYP2A6: 
42%; CYP2B4: 45%; CYP2C5: 41%; CYP2C8: 42%; CYP2D6: 42%. Initially, the CYP2J2 
structure was relaxed by placing the enzyme in a water box with dimensions of 90  90  90 Å3, 
containing ~20,000 water molecules, generated with the SOLVATE plugin of VMD (42), and 
neutralized with 100 mM NaCl ions using the AUTOIONIZE plugin. The system was then energy 
minimized for 2,000 steps and simulated for 100 ps with the Cα atoms of the protein harmonically 
restrained (k = 1 kcal·mol-1·Å-2), and followed by 100 ns run with no constraints. The resulting 
structure of CYP2J2 was used as the initial structure for simulations.  
  For the membrane-binding simulations, wild-type CYP2J2 was placed ~10 Å above the surface 
of the HMMM membrane with different initial orientations (50° and 80° with respect to the z-
axis). Three initial systems were prepared for simulation, two of which started from the same initial 
orientation (80°). The resulting structure was further solvated using the SOLVATE plugin, and 
neutralized with 100 mM NaCl using the AUTOIONIZE plugin of VMD (42). Each of the three 
resulting initial systems consisted of a box with dimensions of 101.4  101.4  122.0 Å3 and 
containing ~120,000 atoms. The systems were energy minimized for 2,000 steps and relaxed 
k = 1 kcal·mol−1·Å−2), 
followed by 40 to 60 ns of production simulation. 
  To study the effect of F-G loop mutations on membrane binding of CYP2J2, the mutations I236D, 
F239H, and I236D/F239H were introduced in the last frame of each membrane-binding simulation 
of the wild-type CYP2J2. This approach allowed us to take advantage of the accelerated lipid 
dynamics to monitor changes in the membrane insertion of CYP2J2 induced by the mutations. The 
Asp residue in the mutants was modeled in its deprotonated (charged) form, while the His residue 
was modeled in its neutral form, to match the expected charge of these side chains at pH 7.4. The 
resulting systems were energy minimized for 1,000 steps and relaxed further for 100 ps with the 
k = 1 
kcal·mol−1·Å−2), followed by 40 to 50 ns of production simulation.  
  The resulting models of membrane-bound CYP2J2 and its mutants in the HMMM membrane 
were extended to a full POPC membrane, to perform additional simulations. A membrane-bound 
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model of the CYP2J2 for each case (wild-type and mutants) was adopted from the last frames of 
one of the HMMM membrane-binding simulations described above. The short-tailed lipid bilayer 
was transformed into a POPC bilayer by removing the DCLE molecules and adding the missing 
carbons of the lipid tails. The positions of the added lipid tail atoms were refined based on the 
coordinates of randomly selected lipid molecules obtained from a POPC bilayer equilibrated 
separately. During these steps, the positions of the lipid atoms already present in the HMMM 
membrane (headgroups and the initial five carbons of the lipid tails) were preserved, maintaining 
the original contacts established between the lipids and CYP2J2 during the HMMM simulations. 
The resulting POPC-bound CYP2J2 systems were then minimized for 2,000 steps and equilibrated 
for 100 ps while restraining all the protein and short-tailed lipids atoms with a force constant k = 
1 kcal·mol−1·Å−2 to allow relaxation of the the newly added lipid tail atoms. Following this step, 
the resulting wild-type and mutants systems were simulated without restraints for 70 to 100 ns. 
  Pyrene phospholipid partitioning in the membrane. In order to gain a more detailed 
description of the partitioning and orientation of pyrene molecules in a lipid bilayer, we performed 
another set of MD simulations.  A solvated POPC membrane containing one pyrene phospholipid 
in each leaflet was constructed to study the dynamics of pyrene in the membrane. A POPC 
molecule was employed as a template to generate the pyrene-attached phospholipid, by removing 
carbons from the acyl tail and replacing them by a pyrene moiety. The resulting system was then 
minimized for 1,000 step and simulated for 1 ns with the heavy atoms of the lipid head groups 
harmonically restrained (k = 1 kcal·mol−1·Å−2), except for the pyrene phospholipids. The step was 
then followed by a 50 ns production simulation.   
  Simulation conditions and protocols. All simulations were performed with NAMD2 (43) using 
the CHARMM27 (44) force field with cMAP corrections for the protein and CHARMM36 (45) 
for lipids. Parameters of the pyrene-attached phospholipid were derived by analogy from the 
CHARMM General Force Field (46, 47). The TIP3P model was used for water (48). The NPnAT 
ensemble at 1.0 atm and 310 K, with a constant area of 10,281 Å2 (101.4  101.4 Å2), was 
employed for all HMMM simulations. The POPC systems were simulated as an NPT ensemble at 
the same pressure and temperature. All simulations were performed with a time step of 2 fs. 
Constant pressure was maintained by the Nosé−Hoover Langevin piston method (49, 50) and 
constant temperature was maintained by Langevin dynamics with a damping coefficient γ of 0.5 
ps−1 applied to all atoms. A cutoff of 12 Å was used for nonbonded interactions, with a smoothing 
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function applied after 10 Å. The particle mesh Ewald (PME) method (51) was used for long-range 
electrostatic calculations with a grid density greater than 1 Å−3.       
  Heterologous expression and purification the CYP2J2 F-G loop constructs.  The N-
terminally truncated CYP2J2 construct (Δ34) was heterologously expressed and purified as 
described previously (24, 52). The mutations for the F-G loop plasmids were prepared using the 
reverse primers listed in Figure 4.7 and amplified by polymerase chain reaction (PCR) on the 
pCWori Δ34 plasmid in conjunction with the Δ34 forward primers. Each F-G loop mutant plasmid 
was co-transformed with the GroEL plasmid and grown in an overnight culture and used for 
inoculation of 1 L of terrific broth (TB) media supplemented with ampicillin (100 µg/mL) and 
chloramphenicol (20 µg/mL).  The culture was grown at 37˚C and 220 rpm for 2.5 hours and then 
supplemented with δ-aminolevulinic acid (0.5 mM) and maintained at 26˚C and 160 rpm for 2 
hours. Next the culture was induced with 1 mM of Isopropyl β-D-1-thiogalactopyranoside (IPTG) 
and 2g of arabinose and grown for an additional 44 hours. The cells were isolated via centrifugation 
for 10 min (2800 g) using a JA-10 rotor (Beckman Coulter, Brea CA) and sonicated in lysis buffer 
containing dithiothreitol (DTT), 0.2 mM phenylmethanesulfonylfluoride (PMSF), 5 mg DNase, 
and RNase. The membrane fraction was isolated via ultracentrifugation at 35,000 rpm from 30 
min Ti-45 rotor (Beckman) and the soluble fraction was collected for analysis of the CYP content.  
Protein was extracted using 1% cholate (w/v) and the supernatant layer containing CYP2J2 was 
obtained by ultracentrifugation 35,000 rpm from 30 min Ti-45 rotor (Beckman). The histidine 
tagged protein was further purified by running the supernatant through a Ni-NTA column and 
eluted with 0.1mM DTT, 0.1% (w/v) cholate, 100 mM KPi, 200 mM imidazole and 20% glycerol. 
CYP2J2 concentration was measured by carbon monoxide difference spectra as described below.  
  Purification of oligomeric CYP2J2 by size-exclusion chromatography. For the membrane 
binding studies, the resulting Ni-NTA eluent was further purified using size exclusion - high 
performance liquid chromatography (SEC-HPLC) on a semi-preparative Superdex 200 10/300 
column (GE Life Sciences, Piscataway, NJ) with a mobile phase consisting of 100 mM phosphate 
buffer (pH 7.4), 1 mM EDTA, 0.5 M NaCl, 2% glycerol and 0.1% cholate at a 0.5 ml/min flow 
rate. The predominant peak of each construct was collected and adjusted to contain 20% glycerol 
and concentrated using Amicon Ultra (10,000 MWCO) centrifugal filters (Millipore). The 
resulting protein concentration was quantified using a Micro BCA protein assay kit (Thermo Sci 
#23235). Next, the concentrated protein was examined for homogeneity (Figure 4.3C) by injecting 
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20 µL on a high resolution Superdex 75 10/30 SEC column (GE Life Sciences, Piscataway, NJ) 
with a mobile phase consisting of 100 mM phosphate buffer (pH 7.4), 1 mM EDTA, 0.5 M NaCl, 
2% glycerol and 0.1% cholate at a 0.5 ml/min flow rate. The oligomeric state of the CYP2J2 
constructs was estimated using the same mobile phase and Superdex 75 10/30 column and a 
standard curve plotted using thyroglobulin (669 kDa), ferritin (440 kDa), BSA (67 kDa), and 
cytochrome c (14 kDa) as protein standards (Figure 4.9). 
  Expression and purification of cytochrome P450 reductase. Cytochrome P450 reductase 
(CPR) from Ratticus norvegicus was expressed and purified as previously described (24).  
  Construction of ΔTrp-MSP1D1.  In order to obtain ΔTrp-MSP1D1, the EcoR1-Sac1 gene 
fragment of MSP1D1 was replaced by the synthetic gene fragment in which two tryptophan codons 
(TGG) were substituted by phenylalanine codons (TTC). An additional silent mutation was added 
to create new restriction site (Xba1) in order to facilitate the screening. Briefly, the 300 bp G-block 
fragment (synthesized by IDT DNA, Inc.) and MSP1D1 plasmid were digested with Eco R1 and 
Sac1 restriction endonucleases. After separation on agarose gel, the 5.7 kBp fragment of MSP1D1 
plasmid was ligated to synthetic insert using T4 ligase. After initial identification of the mutant 
clones by digestion mapping, the presence of the desired mutations and the absence of the 
unwanted ones were confirmed by DNA sequencing. MSP expression and purification was 
performed as described earlier (53). 
  Carbon monoxide binding assay.  The carbon monoxide binding characteristics of the 
constructs were measured after Ni-NTA purification using a modified version of Omura and Sato’s 
method (54) as described previously (24, 39, 55).  
  Guanidine hydrochloride induced denaturation of CYP2J2. The denaturation of CYP2J2 
protein was studied by measuring the change in Soret at 417 nm as a function of increasing 
concentration of Gd-HCl (0 to 6 M) as previously described (56).  Solutions containing varying 
concentrations of guanidinium hydrochloride were incubated with ~2 µM of CYP2J2 for 5 minutes 
before measuring their UV-vis spectra (800 – 300 nm). The resulting spectra were then processed 
using a MATLAB subroutine for determination of Soret absorbance changes. 
  Arachidonic acid metabolism assay for measurement of EETs. Incubations containing empty 
POPC-nanodiscs (10 µM), CYP2J2 (0.2 µM), CPR (0.6 µM) in 100 mM phosphate buffer (pH 
7.4) were incubated with concentrations of arachidonic acid (40 μM) near the critical micelle 
concentration. The mixture was equilibrated at 37°C for 10 min before reaction initiation with 200 
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µM NADPH (total volume 500 µL) and was allowed to react for 30 min. CYP2J2-Δ34 AA 
metabolism linearity over a one hour time course was previously confirmed (39). Samples were 
quenched upon extraction with an equal volume of ethyl acetate (3 times), dried under a steady 
stream of nitrogen and reconstituted in ethanol. Samples were analyzed using a 1200 series HPLC 
(Agilent Technologies, Santa Clara, CA) coupled to a 5500 QTRAP LC-MS/MS system (AB 
Sciex, Foster City, CA) for EET quantification using LC-MS/MS as previously described (39).  
  Assembly of POPC nanodiscs. POPC was solubilized with cholate (50 mM) and mixed with the 
membrane scaffold protein ΔTrp-MSP1D1 (devoid of Trp ε280 = 10,040 mM-1 cm-1) in a 65:1 ratio 
before rocking the mixture at 4°C for one hour. Nanodisc assembly was initiated upon removal of 
detergents using of Amberlite Biobeads (Supelco). The homogenous nanodisc assembly was 
isolated using SEC-HPLC with a Superdex 200 10/300 column (GE Life Sciences, Piscataway, 
NJ) and a mobile phase consisting of 100 mM phosphate buffer (pH 7.4) and a 0.5 ml/min flow 
rate. The isolated nanodiscs were then concentrated with Amicon Ultra (10,000 MWCO) 
centrifugal filters (Millipore) to a final concentration of 500 µM. 
  Assembly of POPC-PYR nanodiscs. Nanodiscs containing PYR-PC were prepared with the 
same methodology as the POPC nanodiscs with a minor adaptation. Specifically, the PYR-PC was 
added to the POPC mixture in a 1.5:98.5 molar ratio. The phospholipids were then mixed with 
MSP1D1 in a 65:1 ratio and allowed to equilibrate for 1 hour at 4°C before detergent removal with 
Amberlite Biobeads. The assembled nanodiscs were isolated using SEC-HPLC on a Superdex 200 
10/300 column (GE Life Sciences, Piscataway, NJ) with a mobile phase consisting of 100 mM 
phosphate buffer (pH 7.4) and a 0.5 ml/min flow rate (Figure 4.4B). Desired concentration of the 
incorporated PYR-PC was confirmed in solution spectrophotometrically at 342 nm using the molar 
extinction coefficient 42 mM-1 cm-1 (Figure 4.4B inset). 
  Assembly of POPC-PYR-POPS nanodiscs. Nanodiscs containing PYR-PC were prepared as 
described for the POPC-PYR nanodiscs, albeit with the addition of differing ratios of anionic 
phospholipids (POPS). Nanodiscs containing 30% and 60% POPS were prepared by mixing 
POPC/PYR/POPS in a molar ratio of 68.5:1.5:30 and 38.5:1.5:60, respectively. Each 
POPC/PYR/POPS mixture was added to MSP1D1 in a 65:1 ratio and allowed to equilibrate for 1 
hour at 4°C before detergent removal with Amberlite Biobeads. The assembled nanodiscs were 
isolated using SEC-HPLC on a Superdex 200 10/300 column (GE Life Sciences, Piscataway, NJ) 
with a mobile phase consisting of 100 mM phosphate buffer (pH 7.4) and a 0.5 ml/min flow rate 
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  Steady state fluorescence titration experiments. Steady state fluorescence measurements were 
performed using a K2 multi-frequency phase and modulation fluorometer (ISS, Urbana, IL, USA).  
Fluorescence experiments utilized purified monomeric CYP (1 µM), nanodiscs (50 µM), 100 mM 
phosphate buffer (pH 7.4) and 1 mM Na-EDTA maintained at 25°C with a circulating water bath. 
Emission spectra of the intrinsic fluorescence of the CYP interacting with nanodiscs were recorded 
from 300-400 nm with an excitation of 295 nm and bandwidths of 8 nm for both excitation and 
emission measurements. The maximal initial fluorescence (Fo) was measured by preparing 
samples containing CYP and ΔTrp-MSP1D1 POPC nanodiscs (50 µM), incubating for 10 min and 
recording the emission spectra. The quenched fluorescence measurement (F) was recorded after 
an incubation (10 min) of individually preparing samples containing CYP with pyrene nanodiscs 
(50 µM) comprised of ΔTrp-MSP1D1 POPC, ΔTrp-MSP1D1 POPC/POPS (70:30), or ΔTrp-
MSP1D1 POPC/POPS (40:60). A parallel sample devoid of CYP was recorded after each 
measurement and subsequently subtracted from the main spectra using Vinci 2 software (Urbana, 
IL, USA). Samples were analyzed for changes in the Trp fluorescent maxima (λmax) as well as for 
the ratio of changes in the initial fluorescent intensity (Fo) and final fluorescence (F). 
  Data analysis Data were analyzed and presented as means ± standard error. Data were collected 
multiple times and were analyzed for statistical significance using a Student’s paired t test where 
*p < 0.05, **p < 0.01, and ***p < 0.001. 
4.4 RESULTS AND DISCUSSION  
  Molecular dynamics simulations - membrane-bound form of CYP2J2. In order to generate a 
membrane-bound model of CYP2J2 which would allow us to better understand the key lipid-
protein interactions involved in membrane binding of the protein, we performed three independent 
-CYP2J2 placed above a phosphatidyl 
choline (PC) HMMM lipid bilayer. The aim was to capture the spontaneous membrane binding 
and insertion of the protein into lipid bilayer in unbiased simulations. Owing to the enhanced lipid 
dynamics of the membrane model, spontaneous membrane binding of the catalytic domain of 
CYP2J2 was consistently observed during these simulations (Figure 4.1). The analysis of the three 
resulting simulations reveals a similar behavior in terms of depth of insertion and orientation in 
the membrane of CYP2J2 (Figure 4.1B and Figure 4.5). The resulting binding pose of CYP2J2 
suggests that the enzyme can interact with the membrane through hydrophobic residues located in 
the F-G loop region, in particular residues Trp-235, Ille-236 and Phe-239. During the simulations, 
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these side chains were observed to insert in the membrane (i.e., positioning below the reference 
plane defined by the PO4 level) (Figure 4.1B). The N-terminal loop formed containing residue 
Trp-48 is also observed to insert into the membrane after binding (Figure 4.1B).  
  Starting from the HMMM membrane-bound models of CYP2J2, the short-tailed lipids (with five 
carbons in each tail) were extended to full POPC lipids (see Methods), resulting in a model of 
CYP2J2 bound to a POPC membrane as shown in Figure 4.1A. The extended model simulation 
shows that the main interactions observed in the HMMM model are preserved, and Trp-48, as well 
as residues Trp-235, Ile-236 and Phe-239 located in the F-G loop remain inserted in the membrane 
(inserted below the PO4 level) (Figure 4.1B and Figure 4.5). In order to test the convergence of the 
membrane-bound models of CYP2J2, we characterized the orientation that the enzyme with 
respect to the lipid bilayer by calculating the heme tilt angle, defined as the angle between the 
heme plane (defined as the plane containing the four porphyrin nitrogen atoms) and membrane 
normal (z-axis). In the three extended POPC simulations, the heme tilt angle converges to values 
~50°, suggesting a convergent membrane-bound pose for CYP2J2 (Figure 4.6). The orientation 
that CYP2J2 adopts in the membrane is similar to that reported for other membrane-bound CYPs, 
measured both from experiments and from simulations, which are reported to be around 60 to 70° 
(6, 57). 
  Simulation of pyrene partitioning in the membrane. We performed experiments to evaluate 
the interaction of the mutated CYP2J2 proteins with membranes by measuring the Trp quenching 
by pyrene phospholipids inserted into the homogeneous lipid bilayer. Therefore, in order to 
identify potential interactions between a pyrene molecule attached to a phospholipid and the 
membrane-bound CYP2J2, we performed a separate simulation of a POPC membrane containing 
a single pyrene phospholipid in each leaflet for 50 ns in the absence of CYP2J2. The goal was to 
characterize the distribution of the pyrene molecules within the lipid bilayer and use it to infer 
information on the potential interaction of the side chains of CYP2J2 with pyrene upon membrane 
binding based on the location of this moiety in the membrane. The distribution of the z-position 
for each molecule revealed that the pyrene moiety is located mainly in the hydrophobic core of the 
membrane, below the phosphate groups (Figure 4.1C). Despite being attached to their respective 
phospholipid tail, pyrene molecules are able to sample a wide range of insertion depth within the 
hydrophobic core of the membrane, as indicated by their wide z-position distributions. 
Interestingly, the insertion depth of CYP2J2 in the POPC membrane would allow for the side 
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chains of Trp-48 and Trp-235 to interact with the pyrene moiety located in the PYR-ND, as 
indicated by their z-position distributions (Figure 4.1C). The distribution of the z-position of each 
side chain shows that they both insert to a similar level around the PO4 level, with Trp-235 slightly 
more inserted than Trp-48. Therefore using PYR-ND one can delineate the membrane interactions 
of the CYP2J2 mutants with the lipid bilayer using experimental approaches as described later.   
  CYP2J2 construct design. The initial structural analysis and MD simulations suggested two 
hydrophobic residues in the F-G loop, Ile-236 and Phe-239, as putative membrane anchors (Figure 
4.1A and 4.3A). These sites were mutated to hydrophilic residues with the aim of altering 
membrane-binding characteristics by decreasing the overall hydrophobicity of this region. To this 
end, two single mutations, I236D (Δ34-I236D) and F239H (Δ34-F239H), as well as a construct 
containing both I236D and F239H (Δ34-double) were designed. Apart from the N-terminal anchor, 
the CYP F-G loop has been hypothesized to be the primary membrane-binding motif. This 
assumption is further supported by the observation that the greatest structural differences between 
the soluble prokaryotic CYPs and the membrane bound mammalian CYPs are found in the F and 
G helices and the F-G loop (58). Notably, CYP2D6 was successfully solubilized and crystallized 
by truncating the N-terminus and mutating the F-G loop Leu-230 and Leu-231 with a combination 
of hydrophilic residues that included I230D and I231R (21). Following a similar design strategy 
we mutated Ile-236 and Phe-239 to hydrophilic residues to examine the effects on solubility and 
functionality. Additionally, the close proximity of the naturally occurring Trp-235 to the mutated 
sites enabled membrane-binding studies using fluorescence spectroscopy.  
  Molecular dynamics simulations of membrane binding modes of the F-G loop mutants. We 
studied the effect of these specific F-G loop mutations on membrane binding of CYP2J2 by 
introducing the mutations in the membrane-bound models obtained from MD simulations. To 
achieve this, we used the final snapshot of each of the three HMMM membrane-binding 
simulations, introduced the mutations and performed production simulations on the system. This 
approach allowed us to monitor changes in the membrane insertion depth of the protein due to 
mutations in the F-G loop. Single mutations Δ34-I236D and Δ34-F239H, as well as double 
mutation Δ34-double were introduced in the membrane-bound CYP2J2, resulting in 3 models for 
each mutant, which were simulated individually between 40 and 50 ns.  
  The results of these simulations show that the mutations affect the insertion of the F-G loop to 
various degrees (Figure 4.2). The I236D mutation promotes the detachment of Trp-235 from the 
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membrane. In the cases were this mutation is introduced (I236D and 1236D/F239H), Trp-235 
moves from a fully inserted position to an average position that is above the PO4 and choline levels, 
with occasional detachment of the residue from the membrane (Figure 4.2A and 4.2B). In both 
cases, the position of Trp-235 side chain (above the phosphate level) is maintained upon the 
conversion of the HMMM membrane with short-tail lipids to a full POPC membrane (Figure 4.2A 
and 4.2B). In the POPC membrane, the average position of Trp-235 resulting from the I236D 
mutation is between 5 to 10 Å above the reference PO4 plane, as shown in Figure 4.2D. The F239H 
mutation, on the other hand, seems to have a smaller effect on Trp-235 insertion, causing only 
transient detachment of Trp-235 both in the short-tail lipid membrane and in the POPC membrane 
(Figure 4.2C), resulting on an average relative position that is close to the Trp-235 insertion in the 
wild type case (Figure 4.2D). Taken together, the simulations indicate that introducing mutations 
in the F-G loop results in a shallower membrane insertion of Trp-235 in the F-G loop when 
compared to the wild-type simulations. As discussed later, this was corroborated by an increased 
percentage of the mutants in the cytosolic fraction and fluorescence experiments where we 
measured CYP2J2 Trp quenching by membranes containing pyrene lipids. 
  Expression and purification of CYP2J2 F-G loop mutants. The growths of all constructs were 
performed in DH5alpha cells due their relatively slow growth and expression characteristics that 
improve the overall yields of functional P450 (52). We previously demonstrated that the N-
terminus truncated CYP2J2 construct (Δ34) exhibited greater solubility, yet still maintained its 
ability to insert in the membrane bilayers of nanodiscs (24). Interestingly, the percentage of protein 
found in the soluble fraction during purification corresponded to the number of F-G loop 
mutations. Specifically, the percentage of protein in the soluble fraction of Δ34-double, Δ34-
I236D, Δ34-F239H and Δ34 were 56.7%, 46.3%, 43.8% and 37.5%, respectively (Figure 4.3B). 
These results provide the expression and membrane binding characteristics of the CYP constructs 
in the E. coli membrane. The ratio of the membrane to soluble fraction of the protein only provides 
an indication of enzyme solubility and is not directly applicable to other systems such as model 
membranes and mammalian cells. Therefore we further explored the membrane insertion of these 
constructs using a Trp quenching assay in Nanodiscs as described later. 
 Spectral characterization, denaturation studies, and size-exclusion chromatography of the 
F-G loop mutants. The F-G loop mutants exhibited typical Soret and Q-bands similar to wild type 
CYP2J2 (data not shown). To investigate the potential heme-thiolate perturbations the mutants 
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were reduced (FeII) and bound with carbon monoxide. All constructs exhibited a prominent 451 
nm peak, albeit with some 420 nm peak, indicating that the charged mutations in the F-G loop did 
not largely perturb the heme-thiolate motif interactions and the common P450 fold (Figure 4.8).  
Furthermore, the stability of the mutants was assessed by performing guanidine hydrochloride 
denaturation studies using UV-Vis spectroscopy. The 417 nm Soret absorbance is attributed to the 
uniquely coordinated ferric (FeIII) heme. In the presence of increasing concentration of guanidine 
hydrochloride (Gd-HCl), the absorbance of the CYP at 417 nm decreased, indicating heme loss 
due to protein unfolding (56). The three constructs demonstrated comparable stability in Gd-HCl 
with a decrease in peak intensity of ~45%. The Δ34 construct exhibited less denaturation with an 
overall 30% decrease in the Soret peak intensity in the presence of 6M Gd-HCl (Figure 4.3D).  
  The range of oligomers formed from each mutant after Ni-NTA purification was examined using 
semi-preparative size exclusion chromatography All the constructs produced a predominant peak 
that eluted with a volume of ~15.5 ml on the Superdex 200 10/300 column (data not shown) using 
the conditions listed in the materials and methods. The primary oligomer was collected, 
concentrated and its homogeneity and molecular weight was assessed using a high resolution 
Superdex 75 10/30 column. As seen in Figure 4.3C, all the constructs show a single oligomer that 
corresponded to the monomeric form of the protein as measured using protein standards (Figure 
4.9). Taken together, the results suggest that the non-conservative mutations did not change the 
protein in regards to P450 fold, oligomeric state and stability.  
  Arachidonic acid metabolism.  Typically, random introduction of mutations in the F-G loop of 
CYPs alters their function as compared to the wild type construct (27). Therefore we examined the 
effect of the F-G loop mutation on the CYP2J2 mediated metabolism of arachidonic acid (AA) in 
the presence of a 50 µM concentration of empty POPC nanodiscs. As discussed in the steady state 
fluorescence section, a CYP to nanodisc stoichiometric ratio of 1:50 was chosen to ensure that the 
CYP construct was completely bound to nanodiscs. Under these conditions, the functional 
differences between CYP2J2 are results of differences in their ability to metabolize AA and not 
due to discrepancies between the membrane-bound and unbound states. AA is a slowly 
metabolized endogenous substrate that forms EET metabolites that are potent vasodilators and 
anti-inflammatory lipids (17, 59). The metabolism of AA is complex, as it produces four unique 
epoxide regio-isomers. Interestingly, the Δ34-I236D metabolism of AA was increased with a ~1.6 
greater catalytic efficiency of all regio-isomers when compared to Δ34 (Figure 4.3E). Conversely, 
65 
 
the function of Δ34-F239H was dramatically decreased relative to Δ34, indicating that the mutant’s 
native function has been altered. Notably, the Δ34-double construct produced the EET metabolites 
with similar catalytic efficiency to Δ34 as shown in Figure 4.3E. Interestingly, none of the 
mutations altered the ratio of the EET products produced by CYP2J2 (data not shown), which 
suggests that the active site was not drastically altered. 
  In both mammalian and bacterial systems, the F-G loop is an important regulator of substrate 
access channels (60). Moreover, this region has been shown to be flexible with open/closed 
conformations and provides the roof of the internal substrate-binding pocket which mediates 
substrate recognition (61). Recent evidence suggests that the conformation of the F-G loop and 
ligand type may alter ligand egress routes. Specifically, MD simulations predicted that the non-
helical CYP2C9 F-G loop would favor egress pathways through the membrane bilayer (62). In this 
work we demonstrate that single mutations in this region can alter the catalytic turnover 
characteristics of the epoxidation of arachidonic acid (Figure 4.3E). Interestingly, the enhanced 
catalytic functionality of Δ34-I236D or decreased activity of Δ34-F239H did not alter the enzyme 
regioselectivity and therefore cannot simply be rationalized based on their enhanced solubility or 
active site alteration. Rather these changes suggest that the introduction of the acidic residue either 
alters the loop conformation dependent egress pathways and/or substrate recognition sites.  
Notably, these effects are abolished in the Δ34-double construct, which restores wild-type activity. 
  While only a small amount of histidine is charged at its physiological pH, this may be an 
important stabilizing residue. The combination of an anionic and cationic residue introduction was 
selected for the crystallization of CYP2D6 due to its restoration of wild-type like activity (21). 
Importantly, these mutations were chosen as a practice of trial-and-error. The rational introduction 
of the double mutation in CYP2J2 F-G loop corroborates this strategy. However, MD simulations 
demonstrated that although there is a close interaction of the side-chains we failed to observe a 
salt-bridge formation (data not shown).  
  CYP2J2 construct membrane insertion into pyrene nanodiscs. To investigate the CYP2J2 
constructs’ insertion in the membrane bilayer, we measured the relative Trp quenching energy 
transfer between the protein monofacial Trp residues and pyrene phospholipids. To this end, we 
prepared nanodiscs with pyrene phospholipids (PYR-ND) using the ΔTrp-MSP1D1 construct in 
which Trp residues were mutated to Phe. As shown in Figure 4.4A, the Trp residues of the CYP2J2 
membrane binding region are predicted to interact with pyrene phospholipids incorporated in the 
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membrane bilayer. Using a POPC/PYR-PC molar ratio of 64:1 the expected PYR-PC was 1 pyrene 
molecule per nanodisc leaflet. Previously, pyrene-containing liposomes have been successfully 
employed to characterize membrane insertion properties of peripheral and integral CYP proteins 
(10, 63, 64). Here we demonstrate use of PYR-ND as a new iteration of this method with a few 
key advantages. Notably, the PYR-ND is a 10 nm discoidal lipid bilayer that is homogeneous 
(Figure 4.4B) and exhibits superior stability. Additionally, the nanodisc also enables 
stoichiometric control of the lipid compositions. 
 As previously discussed, MD simulations revealed that the pyrene moiety can sample a wide range 
of orientations just under the phospholipid heads in the membrane core. Upon insertion into the 
membrane bilayer the two residues, Trp48 and Trp235, were shown to interact with pyrene. Thus, 
in the presence of saturating concentrations of PYR-ND, the experiment is a measure of membrane 
depth of insertion of these fluorophores.  
  For the depth of insertion measurements, the CYP to PYR-ND (1:50) ratio was chosen based on 
fluorescence titrations that revealed that the overall Trp florescence was quenched with excess 
PYR-ND (data not shown). This has been previously detailed in other cases and is thought to 
reflect that there are two populations of Trp residues (65). Specifically, one population that 
interacts with the pyrene upon insertion and another population that is buried in the protein and is 
not substantially quenched (65). Therefore the relative extent of non-ideal Trp quenching is 
represented here by the quenched fluorescence (F) divided by the initial fluorescence (Fo).  
  The FRET transfer of energy is a dynamic quenching interaction. Evidence of a FRET between 
the Trp (donor) and pyrene (quencher) was observed upon titration of the CYP to a sample of 
PYR-ND. Specifically, a decrease in the Trp fluorescence of CYP is accompanied by an increase 
in the pyrene emission (Figure  4.4C). Using the PYR-ND system we examined the relative 
quenching of Trp fluorescence (F/Fo) as a function of both the mol% of anionic phospholipids 
(POPS) and the absence/presence of 0.5 M NaCl. The rationale of these two conditions used is 
explained below.  
  In the absence of anionic lipids, the differences among the CYP2J2 mutants F/Fo are subtle 
(Figure 4.4D). Specifically, Δ34, Δ34-I236D, Δ34-F239H and Δ34-double exhibited average F/Fo 
ratios of 0.82 ± 0.02, 0.848 ± 0.01, 0.845 ± 0.04 and 0.89 ± 0.01, respectively. These results suggest 
that the F-G loop mutants are oriented in a way that the Trp residues are not as deeply imbedded. 
Overall the quenching ratios reflect similar values observed with CYP3A4 binding to liposomes. 
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Specifically, when the Trp quenching properties of CYP3A4 were examined with in 
phosphatidylcholine (PC) vesicles containing 1.5 mol% of PYR-PC the initial F/Fo values were 
~0.85 (10). Conversely, in the case of CYP1A2, a negligible amount of quenching is observed 
with neutral phospholipid vesicles (36).  
  The presence of anionic lipids is known to induce both CYP conformational shifts as well as 
increased penetration into membrane bilayers (10, 36). Thus, we further examined the membrane 
insertion properties (relative F/Fo changes) of CYP2J2 when anionic lipids (POPS) were 
incorporated into the bilayers of nanodiscs (Figure 4.4D). When 30 mol% of POPS was substituted 
at the expense of POPC, we observed greatly enhanced differences among the F-G loop mutants 
and the Δ34 construct. Specifically, Δ34, Δ34-I236D, Δ34-F239H and Δ34-double exhibited 
average F/Fo ratios of 0.65 ± 0.03, 0.82 ± 0.002, 0.81 ± 0.01 and 0.84 ± 0.04, respectively. 
Interestingly, the differences among the F-G loop mutants and the Δ34 construct were the most 
pronounced when 60 mol% of POPS was incorporated into nanodiscs. For these experiments, Δ34, 
Δ34-I236D, Δ34-F239H and Δ34-double exhibited average F/Fo ratios of 0.52 ± 0.005, 0.74 ± 
0.02, 0.7 ± 0.03 and 0.82 ± 0.002, respectively. Thus, using a high percentage of anionic lipids we 
were able to affect the greatest changes between the Δ34 construct and the F-G loop mutants. 
While these results are only qualitative, the different membrane binding interactions induced by 
the presence of anionic lipids suggest that the hydrophobicity and charge of the F-G loop is 
important for POPS mediated depth of insertion. Specifically, these differences support the 
assumption that the enzyme topology is altered when the F-G loop is mutated with these 
hydrophilic residues. This conclusion is supported by the MD data that demonstrate these residues 
are putative membrane anchors and hydrophilic mutations detach this region from the leaflet.  
  To further explore the nature of the membrane depth of insertion, we examined the effect of a 
high concentration of NaCl on the F/Fo ratio when the 60 mol% POPS PYR-ND was employed to 
achieve the maximum membrane interaction of CYP2J2 (Figure 4.4E). Importantly, high salt 
concentrations effectively solubilize membrane proteins, altering their nature from an irreversibly 
membrane bound protein to a state of protein that can bind and dissociate in a peripheral manner 
(4). This effect was observed when the Δ34G construct was examined, with a decrease in the Trp 
quenching (F/Fo) from 0.52 to 0.71, for the no salt buffer to 0.5M NaCl buffer, respectively. 
Surprisingly, the presence of a high concentration of NaCl had little effect on the extent of Trp 
quenching for the F-G loop mutants which demonstrates the membrane insertion depth is 
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maintained despite the high salt concentration. Overall, the MD simulation results and sub-cellular 
localization in E. coli studies suggests that these proteins are peripherally binding in the no salt 
buffer. 
  Here we demonstrate that the subtle topology nuances between similar constructs and membrane 
depth of insertion can be measured using Trp quenching studies. While the fluorescence 
experiments only provide a relative measure of membrane insertion characteristics, this approach 
is an effective tool to understand how mutations, lipid composition and NaCl can alter the depth 
of insertion. 
4.5 CONCLUSIONS 
  In this work, we demonstrate that the CYP2J2 F-G loop region is an important protein-membrane 
interface that controls membrane insertion and substrate metabolism characteristics. The HMMM 
model simulations revealed that CYP2J2 interacts at the F-G loop through the Trp-235, Ille-236 
and Phe-239 residues. Importantly, these binding interactions and the protein orientation were 
preserved in the MD simulations when the short-tailed lipids were extended to POPC lipids. The 
effects of mutating the putative membrane anchors Ile-236 and Phe-239 with hydrophilic residues 
were also examined. These mutations significantly decrease the F-G loop depth of insertion when 
used in MD simulations. To experimentally corroborate these findings, four CYP2J2 constructs 
(Δ34, Δ34-I236D, Δ34-F239H and Δ34-double) were expressed in E. coli. Notably, the F-G loop 
mutant expression yields derived from the membrane fraction were substantially decreased and 
the protein was localized to the cytosolic fraction to a greater extent. While all constructs 
demonstrated sufficient P450 content and stability we observed significant differences in their 
functional metabolism. Wild-type activity was restored through the introduction of a double 
mutation F239H and I236D. Thus, we experimentally demonstrate that the insertion of CYP2J2 
into the membrane bilayers of PYR-ND is influenced by the overall hydrophobicity of the F-G 
loop. The relative membrane binding characteristics were experimentally derived by monitoring 
CYP2J2 Trp quenching after insertion into the membrane bilayers of PYR-ND. The N-terminal 
truncated construct Δ34-CYP2J2 exhibited membrane binding to a greater extent than the F-G 
loop mutants (Δ34-I236D and Δ34-F239H) suggesting a different enzyme topology in agreement 
with the MD simulations. 
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4.7 FIGURES AND TABLES 
 
 
Figure 4.1. Insertion of CYP2J2 into Membrane. (A) (Top) Membrane binding of CYP2J2 
captured with the HMMM membrane in 40 ns. The membrane-bound model of CYP2J2 was 
extended to a POPC membrane and simulated for another 100 ns.  The stick backbone of the heme 
is colored red, the F- and G- helices are blue with the remaining P450 colored light blue. Lipids 
are shown in stick representation. (Bottom) Residues Trp-48, Trp-235, Ile-236 and Phe-239, 
identified to interact with the membrane upon binding, are shown in stick representation. (B) (Top) 
Time series of the center of mass (COM) z-coordinate of the side chains Trp-48, Trp-235, Ile-236 
and Phe-239 for the HMMM and POPC membranes. A side chain is assumed to insert into the 
membrane when its COM z-position is below the reference plane defined by the COM z-position 
of the PO4. The black dashed lines indicate the time allowed for the grown POPC membrane to 
relax. The positions of the phosphorous (PO4) and nitrogen (choline) atoms of the lipids are show 
in in brown and gray, respectively. (Bottom) Time series of the heme tilt angle of CYP2J2 in the 
HMMM and POPC membranes. The red dashed line indicates the average for the heme tilt angle 
in the POPC membrane. (C) Distribution of the z-coordinate of pyrene molecules attached to 
phospholipids and of the Trp-48 and Trp-235 side chains, obtained from separate simulations. The 
dashed brown lines indicate the distribution of the z-coordinate PO4 group of each leaflet.  The 
location of pyrene and Trp side chains in the simulation is also shown. 
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Figure 4.2. Effect of F-G loop mutations in membrane-binding of CYP2J2. Time series of the 
COM z-position of side chains Trp-48, Trp-235, Ile-236 and Phe-239 for the HMMM and POPC 
membranes shown for (A) I236D/F239H mutant, (B) I236D mutant and (C) F239H mutant. For 
each case, the HMMM simulations were extended to a POPC membrane and simulated 80 ns. The 
black dashed lines indicate the time allowed for the extended POPC membrane to relax after 
conversion from HMMM. The positions of the phosphorous (PO4) and nitrogen (choline) atoms 
of the lipids are show in in brown and gray, respectively. (D) Average relative position of the COM 
z-coordinate of the side chains forming the F-G loop (residues 225 to 240) with respect to the 
reference plane defined by the COM z-position of the PO4. The average was taken from the last 
20 ns of simulations for each case. The error bars represent one standard deviation. 
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Figure 4.3. Biochemical characterization of the CYP2J2 F-G loop mutants. (A) 
Representation of the CYP2J2 Δ34 homology model. The stick backbone of the heme is colored 
red, the F- and G- helices are dark blue with the remaining P450 protein fold and helices colored 
light blue. The two residues selected for mutation (I236 and F239) are colored red on the F-G loop 
represented by cyan. (B) The three CYP2J2 mutants Δ34-I236D, Δ34-F239H and Δ34-double 
were recombinantly expressed in E. coli. The bar graph denotes expression yields purified from 
the membrane fraction whereas the line plot signifies percentage of CYP found in the soluble 
fraction during purification. (C) The size exclusion chromatography purified CYP2J2 protein was 
examined for homogeneity and elution volume with a high resolution Superdex 75 10/30 column  
(D) Changes to the stability of each CYP2J2 construct was assessed by monitoring the loss of the 
prosthetic heme monitored at 417 nm using UV-Vis spectroscopy in the presence of increasing 
concentrations of guanidine hydrochloride. (E) F-G loop mutant functionality was gauged by 
monitoring the metabolism of arachidonic acid (40 µM) using LC/MS/MS in a phospholipid 
reconstituted system. The rate of the conversion of arachidonic acid to total EET consisting of 
14,15-, 11,12-, 8,9- and 5,6-EET were determined for the wild-type construct and each of the three 
F-G loop mutants. In the arachidonic acid assay we did not observe statistical significance below 
p < 0.05 when using a paired, two-tailed student's t-test but did see a trend towards significance 
for Δ34-I236D and Δ34-F239H with p-values of 0.1 and 0.18, respectively. 
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Figure 4.4. Fluorescence studies with CYP2J2 F-G loop constructs. (A) Schematic of CYP2J2 
insertion into pyrene nanodiscs (PYR-ND). The F-G loop is located between the CYP2J2 F- and 
G-helices (represented in blue) and contains the Trp 235 residue, which interacts with the pyrene 
phospholipids (shown in cyan stick model) incorporated in the membrane bilayer of nanodiscs 
(phospholipids are grey and membrane scaffold protein is purple). (B) Size-exclusion HPLC 
chromatography of the PYR-ND. (Inset) Spectra demonstrating successful PYR-PC phospholipids 
incorporation into nanodiscs. (C) The relative membrane insertion characteristics of each construct 
were determined by measuring CYP2J2 Trp quenching. Fo (dashed line) is the Trp-fluorescence 
maximum CYP2J2 in the presence of POPC nanodiscs (lacking pyrene). F (solid line) is the 
quenched CYP2J2 Trp fluorescence due to insertion in pyrene nanodiscs. The dotted line 
represents the pyrene nanodisc fluorescence spectra (excitation 295 nm; emission 300-600 nm) in 
the absence of protein. (D) Trp fluorescence signals of CYP2J2 constructs were monitored in the 
presence of empty nanodiscs (F0) and presence of PYR-ND (F) to calculate F/Fo. The F/Fo was 
measured using PYR-ND containing POPS/POPC molar ratios of 0:100, 30:70 and 60:40. (E) The 
effect of 0.5M NaCl on F/Fo ratio was measured for each CYP2J2 F-G loop mutant using 60 mol% 
POPS PYR-ND 
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Figure 4.5. Effect of F-G loop mutations in membrane-binding of CYP2J2. Time series of the 
COM z-position of side chains Trp-48, Trp-235, Ile-236 and Phe-239 for the additional HMMM 
simulations for (Top) Δ34G-double mutant, (Middle) Δ34G-I236D mutant and (Bottom) Δ34G-
F239H mutant. The positions of the phosphorous (PO4) and nitrogen (choline) atoms of the lipids 
are show in in brown and gray, respectively. 
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Figure 4.6. Time series of the center of mass (COM) z-coordinate of side chains Trp-48, Trp-
235, Ile-236 and Phe-239 and the heme tilt angle for the additional HMMM binding 
simulations. Each simulation was extended to a POPC membrane. The black dashed lines indicate 
the time allowed for the grown POPC membrane to relax after conversion from the HMMM. The 
positions of the phosphorous (PO4) and nitrogen (choline) atoms of the lipids are show in brown 
and gray, respectively. (Bottom)  
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Figure 4.7. F-G Loop Mutant Primers.  The Δ34 forward primer was used in conjunction with 
each individual reverse primer listed above (5’ to 3’) and amplified on the pCWori wild-type 
CYP2J2 Δ34 plasmid for production of Δ34G-I236D, Δ34G-F239H and Δ34G-double plasmids.  
Site-directed mutagenesis was used for introduction of residue mutations as denoted by the 
underlined codons.   
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Figure 4.8. F-G Loop Mutant CO-Binding Spectra. Carbon-monoxide binding spectra were 
measured for each construct to examine perturbations of the heme-thiolate motif and overall 
maintenance of typical P450 protein folding. 
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Figure 4.9. Spherical protein mass standard curve. SEC-HPLC using a Superdex 75 10/35 and 
a mobile phase of 100 mM phosphate buffer (pH 7.4), 1 mM EDTA, 0.5 M NaCl, 2% glycerol and 
0.1% cholate at a 0.5 ml/min flow rate.  A standard curve was constructed by plotting the ratio of 
the elution volume (Ve) to void volume (Vo) against the log of the molecular weight of the standard 
to estimate the oligomerization state of CYP2J2. Protein standards included thyroglobulin (669 
kDa), ferritin (440 kDa), BSA (67 kDa), and cytochrome c (14 kDa) as standards. 
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CHAPTER V: ANANDAMIDE AND 2-ARACHIDONOYLGLYCEROL ARE 
SUBSTRATES FOR HUMAN CYTOCHROME P450 2J2 EPOXYGENASE 
 
5.1 ABSTRACT 
   The endocannabinoids, anandamide (AEA) and 2 -arachidonoylglycerol (2-AG) are arachidonic 
acid derivatives that are known to regulate human cardiovascular functions. CYP2J2 is the primary 
cytochrome P450 in the human heart and is most well-known for the metabolism of arachidonic 
acid (AA) to the biologically active epoxyeicosatrienoic acids (EETs). Herein we demonstrate that 
both 2-AG and AEA are substrates for metabolism by CYP2J2 epoxygenase in the model 
membrane bilayers of nanodiscs. Reactions of CYP2J2 with AEA formed four AEA-
epoxyeicosatrienoic acids (EET-EA) whereas incubations with 2-AG yielded detectable levels of 
only two 2-AG epoxides (EET-G).  Notably, 2-AG was shown to undergo enzymatic oxidative 
cleavage to form AA through a NADPH dependent reaction with CYP2J2 and cytochrome P450 
reductase (CPR). The formation of the predominant AEA and 2-AG epoxides were confirmed 
using microsomes prepared from the left myocardium of porcine and bovine heart tissues. The 
nuances of the ligand-protein interactions were further characterized using spectral titrations, 
stopped-flow small molecule ligand egress and molecular modeling. The experimental and 
theoretical data were in agreement which showed that substitution of the AA carboxylic acid with 
the 2-AG ester-glycerol changes the binding interaction of these lipids within the CYP2J2 active 
site leading to different product distributions. In summary, we present data for the functional 
metabolomics of AEA and 2-AG by a membrane bound cardiovascular epoxygenase. 
 
 
 
 
 
 
 
 
3Reprinted, with permission from Daniel R. McDougle, Amogh Kambalyal, Daryl D. Meling and Aditi Das. 
Endocannabinoids – Anandamide and 2- Arachidonoylglycerol are Substrates for Human Cytochrome P450 2J2 
Epoxygenase. J. Pharmacology and Experimental Therapeutics. 2014 Dec; 351(3):616-27. PMID:25277139 
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5.2 INTRODUCTION 
   The human body contains endogenous cannabinoids (endocannabinoids) that elicit similar 
effects as Δ9-tetrahydrocanabinol (THC), the principal component of cannabis. The two most well 
characterized endocannabinoids are anandamide (AEA) and 2-arachidonylglycerol (2-AG) that 
primarily exert their effects by activating the cannabinoid receptors - cannabinoid receptor 1 (CB1) 
and cannabinoid receptor 2 (CB2).  Dysregulation of the endocannabinoids have been implicated 
in a wide range pathologies including anxiety disorders, neurodegenerative diseases, obesity and 
heart disease (1). Therefore, a thorough understanding of all the potential metabolic pathways in 
the body is necessary to potentially target and alter these pathophysiological conditions.  
   Endocannabinoids are derivatives of arachidonic acid (AA) that are stored in the plasma 
membrane (Figure 5.1).  AA is the primary substrate for the eicosanoid synthesizing cascade that 
includes three branches -the cyclooxygenase (COX), lipoxygenase (LOX) and cytochrome P450 
epoxygenase (EPOX) pathways (2). Endocannabinoids provide substrate for the eicosanoid-
synthesizing cascade through both direct and indirect pathways. The indirect route is through the 
cleavage of either the AEA ethanolamide motif by fatty acid amide hydrolase (FAAH) or the 2-
AG glycerol motif by monoacylglycerol lipase (MAGL), which produces AA that can enter one 
of the three branches (2). Alternatively, AEA can directly enter each of the pathways and produce 
a diverse range of metabolites with different pharmacological properties when compared to the 
endocannabinoid parent compound.  Prior to this work, 2-AG was only shown to be a direct 
substrate of the COX and LOX pathways, although the 2-AG epoxide metabolites had been 
extracted from rat kidney, spleen and brain tissues (3). Recently it has been shown that 
endocannabinoids regulate human cardiovascular functions and are important for homeostasis 
(Pacher et al., 2009). Thus it is of interest to evaluate the metabolism of endocannabinoids by 
relevant heart enzymes. In this work, we reveal the nuances of the metabolism of 2-AG and AEA 
by the predominant EPOX enzyme in the heart, CYP2J2 epoxygenase. CYP2J2 is an extrahepatic 
cytochrome P450 that is highly expressed in the myocardium and surrounding aortic epithelium 
and has been shown to be an important regulator of cardiovascular function (4-6). CYP2J2 
produces potent lipid epoxide mediators derived from AA known as epoxyeicosatrienoic acids 
(EETs), that are involved in pain, inflammation, kidney and cardiovascular disease (7, 8). 
Additionally, the epoxygenases also produce hydroxyeicosatetraeonic acids (HETE) that are 
hydroxylated at the 19- or 20-Ω position of AA.  
86 
 
   Currently, there are no reports of the direct oxygenation of 2-AG by a CYP.  Previous studies 
with several recombinant P450 epoxygenases (CYP2C8, CYP2C11, and CYP2C3) failed to 
produce 2-AG epoxide metabolites (3). In this work, we show that CYP2J2 epoxygenase 
metabolizes 2-AG to form 11,12-EET-G and 14,15-EET-G.  Several reports have demonstrated 
the CYP mediated metabolism of AEA to 20-HETE-EA, 5(6)-, 8(9)-, 11(12)- and 14(15)-EET-
EAs by CYP3A4, CYP4F2, CYP4X1, CYP2B6 and CYP2D6 (9-12).  Notably, it was 
demonstrated that these new metabolites provide different pharmacological profiles when 
compared to the parent endocannabinoid. Herein we characterize the oxidation of 2-AG and AEA 
with the heart epoxygenase CYP2J2 using both recombinantly expressed CYP2J2 and heart 
microsomes.   
   Additionally, the activities of endocannabinoids are regulated through various activation and 
inactivation pathways. 2-AG is primarily inactivated through hydrolysis by MAGL (8). However, 
inhibition of this enzyme does not completely block the 2-AG conversion to AA (13). This 
indicates the presence of alternative pathways of attenuation. Here we demonstrate another 
potential pathway where 2-AG is converted to AA by CYP2J2 and other P450s. 
    In summary, we elucidate the nuances of binding and metabolism of AA and its derivatives, 
AEA and 2-AG, by CYP2J2 using LC-MS/MS, LC-MS, spectral titrations, small molecule ligand 
egress studies and molecular modeling. For all studies with recombinant protein we used nanodiscs 
(nanoscale lipid bilayers) to solubilize and stabilize membrane bound CYP2J2. Nanodiscs have 
been previously used to functionally stabilize membrane protein in solution and on surfaces (14-
19). Importantly, the use of these model membranes significantly reduced scattering and enabled 
spectroscopic characterization by increasing the solubility of the hydrophobic lipid substrates and 
membrane protein.    
5.3 MATERIALS AND METHODS 
  Materials. NADPH and NADP were obtained from P212121.com. 1-palmitoyl-2-oleoyl-sn-
glycero-3-phosphocholine (POPC) and 1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-
phospho-L serine (POPS), 1-heptadecanoyl-2-arachidonoyl-sn-glycero-3-[phosphoinositol-4',5'-
bisphosphate]  (PIP2) were purchased from Avanti Polar Lipids, Inc.  AA, 2-AG, AEA, AEA-d4, 
MS-PPOH, 14,15-EET, 11-12-EET, 8,9-EET, 5,6-EET, 16,17-EpDPE, 2-(14,15-
epoxyeicosatrienoyl glycerol), 14,15-EET ethanolamide was obtained from Cayman Chemical. 
Whole cow and porcine hearts were obtained fresh from the University of Illinois Meat Sciences 
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Laboratory. Polyclonal CYP2J2 antibody (catalog No. ABIN1529400) and the HRP conjugated 
donkey anti-rabbit antibody (Catalog No. ABIN101948) were purchased from antibodies-
online.com.  Recombinant CYP2C8 supersomes were purchased from BD Biosciences Gentest. 
The anti-oxidant butylated hydroxytoluene (BHT) was obtained from Sigma.  All other materials 
and reagents used were purchased from Sigma-Aldrich and Fisher Scientific. 
   Recombinant expression of CYP2J2 in E. coli.  The recombinant CYP2J2 (construct D34G) 
was expressed and purified as published previously (20, 21).  Briefly, DH5alpha cells containing 
the His-tagged and N-terminally truncated CYP2J2 plasmid and pTGro7 chaperonin plasmid were 
cultured in 30 mL of Luria Bertani (LB) media with chloroamphenicol (20 µg/mL) and ampicillin 
(100 µg/mL) at 37˚C and 250 rpm overnight. The resulting culture was used to inoculate 500 mL 
of Terrific Broth (TB) containing ampicillin (100 µg/mL) and chloroamphenicol (20 µg/mL).  The 
culture was grown at 37˚C and 220 rpm until reaching an O.D. = 1.0, then δ-aminolevulinic acid 
(500 µl of 0.5 mM) was added and then grown for 2h at 26˚C and 160 rpm.  1 mM of Isopropyl β-
D-1-thiogalactopyranoside (IPTG) and 2g of arabinose were added to each 500 mL culture for 
induction and subsequently grown for an additional 44 hours (Kagawa N and Cao, 2001).  The 
cells were harvested via centrifugation (2800 g for 10 min) using a JA-10 rotor (Beckman Coulter, 
Brea, CA) at 4˚C. The cells were then sonicated in lysis buffer (DTT, and 0.2 mM 
phenylmethanesulfonylfluoride (PMSF), 5 mg of DNase and RNase) before ultracentrifugation at 
140,000 g from 30 min Ti-45 rotor (Beckman) for membrane fraction isolation.  Protein was 
extracted from the membrane fraction using 1.0% (w/v) cholate and stirred at 4˚C for four hours. 
The membrane fraction was removed by ultracentrifugation (140,000 g) for 30 min with a Ti-45 
rotor (Beckman).  CYP2J2 was isolated from the supernatant by running the solution through a 
Ni-NTA column and eluting in 0.1% (w/v) cholate, 100 mM KPi, 200 mM imidazole and 20% 
glycerol with yields of ~150 nmol/L.   
    Expression and purification of cytochrome P450 reductase. Expression of the redox partner  
cytochrome P450 reductase (CPR) from Rattus norvegicus was described previously (20). Briefly, 
CPR starter cultures were used to inoculate 1L of LB supplemented with ampicillin (100 µg/mL) 
and riboflavin (1 mg/L) and grown for 4 hours at 37˚C and 220 rpm, before induction with IPTG 
(1 mL of 1 mM) and then grown for 18-20 hours at 33˚C and 220 rpm.  Upon harvesting the cells 
by centrifugation ( 2800 g for 10 min), the cells were treated with 500 mL of cold lysozyme buffer 
(75 mM Tris pH 8.0, 0.25 M sucrose, 0.25 mM EDTA and 0.02 mg/mL lysozyme) and allowed to 
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stir at 4˚C for 30 min. The resulting solution was centrifuged (2800 g for 10 min), and resuspended 
in 40 mL of lysis buffer (50 mM Tris pH 8.0 and 1mM PMSF) at 4ºC before sonication on ice (5 
cycles x 30 seconds) with 1-minute rests.  The membrane fraction was isolated via 
ultracentrifugation and solubilized in column buffer (50 mM Tris pH 7.7, 0.1 mM EDTA 0.1 mM 
DTT and 20% (v/v) glycerol) containing 0.2% (v/v) Triton x-100 for an hour at 4ºC. The solution 
was subjected to ultracentrifugation (140,000 g for 30 min) and the resulting supernatant was 
loaded onto 2’5’ADP Agarose, followed by detergent removal using a DEAE sepharose column.  
   Incorporation of CYP2J2 into Nanodiscs. Purified CYP2J2 was incorporated into the 
membrane bilayers of Nanodiscs as previously described with the only modification being the 
addition of POPS (20).  POPS and POPC lipid stocks were combined in chloroform in a 20:80 
molar ratio and dried down under a steady stream of N2. The lipid mixture was reconstituted with 
200 mM cholate in phosphate buffer (pH 7.4) and added to membrane scaffold protein MSP1D1(-
) in a 65:1 molar ratio and mixed at 4˚C for 1 hour.  Purified CYP2J2 (100 mM KPi (pH 7.4), 20% 
(v/v) glycerol, and 0.1% cholate) was added to the solution in a CYP2J2:MSP molar ratio of 1:10 
and mixed for several hours before detergent removal with Amberlite beads overnight. The 
CYP2J2-Nanodiscs were separated from empty Nanodiscs using a Ni-NTA column and eluted 
with 100 mM phosphate buffer containing 200 mM imidazole. Homogenous CYP2J2-ND 
populations were further purified using size-exclusion chromatography utilizing an Alliance 2695 
analytical separation module (Waters, Milford, MA) coupled to a Waters 996 photodiode diode 
array detector (Waters) and a semi-preparative Superdex 10/200 column (GE Healthcare) column. 
   Recombinant CYP2J2 metabolism assays containing arachidonic acid, anandamide and 2-
arachidonoyl glycerol.  Incubation mixtures containing CYP2J2-ND (0.2 µM) CPR (0.6 µM), 
0.1% (w/v) BHT in 100 mM phosphate buffer (pH 7.4) and either AA, AEA or 2-AG (500 µL 
total volume) were equilibrated at 37ºC for five minutes before the reaction was initiated with the 
addition of 1 mM of NADPH. Importantly, CPR was added to the CYP-Nanodisc in the optimal 
3:1 CPR to CYP ratio. Previous reports demonstrated the incorporation of the same full-length 
CPR construct into Nanodiscs using the same conditions as verified by size-exclusion 
chromatography (17). Additionally, in a previous work we prepared discs containing both the full 
length and truncated forms of 2J2 using size exclusion chromatography and showed that the 
nanodiscs retain both the P450 and the reductase when incorporated into the membrane bilayer 
(20).  Incubations for subsequent qualitative LC-MS analysis contained saturating concentrations 
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of each substrate whereas samples for quantitative kinetic analysis contained either 1, 5, 10, 20, 
40 or 60 µM of each respective substrate.  Incubations were reacted for 30 minutes, unless 
otherwise stated in the figure legends.  Samples lacking NADPH were performed in parallel as a 
routine control.  For termination of the reaction, samples were quenched with glacial acetic acid 
to pH of 3-4 and extracted (three times) with an equal volume of ice cold ethyl acetate, vortexed 1 
minute and centrifuged at 1590 g for 3 min for phase separation (12).  The organic layer was 
removed and dried under a steady stream N2 and then reconstituted with 100 µL of methanol. AA, 
AEA and 2-AG incubations were qualitatively analyzed using LC-MS as described below.  For 
quantitative analysis, LC-MS/MS was used to directly quantify 14,15-, 11,12-, 8,9- and 5,6-EET 
turnover when AA was used as the substrates.  For quantitative analysis of EET-G, extracted 
samples were split into two pools. The first pool was quantified for EET content without further 
processing and the second pool was saponified to convert EET-G to the corresponding EET 
regioisomer and then analyzed for 14,15-, 11,12-, 8,9- and 5,6-EET compositions. The 
quantification of the 14,15-EET-EA metabolite was accomplished using LC-MS/MS as described 
below.        
  Preparation of bovine and porcine microsomes and incubations.  Fresh heart microsomes 
were prepared from the left myocardium of female porcine and male bovine hearts using 
differential centrifugation methods as described previously (22). Briefly, tissue from the left 
myocardium was dissected to remove the endo- and epicardium and minced. Tissue was weighed 
and diluted to 20% (w/v) using a buffer containing 250 mM sucrose, 10 mM Tris-Cl (pH 7.5), 1 
mM PMSF and a protease inhibitor cocktail for mammalian tissue extraction (Nacalai Tesque 
#25955-11). Next, tissue was homogenized on ice for 1 minute at maximum speed using a metal 
Bio-homogenizer (Biospec Inc., Bartlesville, OK). A low speed centrifugation step was employed 
to remove large tissue debris at 3000 g for 20 minutes at 4°C. The supernatant was then centrifuged 
at 10,000 g for 20 minute at 4°C using a Ti-45 rotor (Beckman) and then repeated once more. The 
resulting supernatant was centrifuged at 100,000 g for 90 min at 4°C to pellet the sarcoplasmic 
reticulum containing heart CYPs. The cell pellet was then re-suspended in 50mM Tris (pH 7.5), 
1mM DTT, 1mM EDTA and 20% glycerol with a Teflon homogenizer. The resulting microsomal 
solution was aliquoted and stored at -80°C until future use. Microsomal protein content was 
calculated using a BCA assay kit from Thermo Fisher Scientific (Product No. 23233). Incubations 
with both porcine and bovine microsomes were performed with a concentration of 1 mg/ml of 
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microsomes with saturating concentrations of AA, AEA and 2-AG and then processed as described 
with recombinant CYP2J2-ND incubations.  
  Immunoblotting of CYP2J2 located in cow and porcine heart microsomes. Heart microsomes 
were prepared as described above and used for CYP2J2 immunoblotting following a previously 
described protocol (23). In short, samples were boiled for 10 minutes 5x Laemmli buffer 
supplemented with 8 M urea and ran on a 12% SDS polyacrylamide gel. Proteins were transferred 
to the nitrocellulose membrane and blocked with 5% low-fat milk in Tris-buffered saline with 
tween 20 (TBST) for 1 hour before adding the primary polyclonal antibody raised against the 250-
275 segment of human CYP2J2 (antibodies-online.com, catalog No. ABIN1529400). The 
membrane was washed three times with TBST and the HRP conjugated donkey anti-rabbit 
antibody (Catalog No. ABIN101948) was used for detection. Blots were visualized using a HRP 
development solution (Thermo Sci. Catalog No. 34095) and a ChemiDoc XRS+ system (Biorad 
Inc., Hercules, CA). 
   Saponification of EET-G regioisomers to EETs and quantification. For the quantification of 
EET-G in solution, the extracted fatty acids were cleaved from the glycerol backbone using 
methanolic potassium hydroxide (KOH) hydrolysis as previously described (24). Extracted 
samples were hydrolyzed in 1 mL of methanol containing 0.4 N KOH and incubated at 50ºC for 
one hour.  Next 1.5 mL of Millipore water was added and glacial acetic acid was used to achieve 
pH 3-4. Samples were extracted with an equal volume of ice cold ethyl acetate (3x), vortexed 1 
minute and centrifuged at 1600 g for 3 min for phase separation (12).  The organic layer was 
removed and dried under a steady stream of N2 and then reconstituted with 100 µL of methanol. 
Thus, the saponified sample contained both free EETs originally present in solution and EETs 
derived from EET-G hydrolysis.  EET-G quantification at the time of reaction quenching was 
calculated using Equation 1. 
 
(Equation 1)  EET-G = EET (saponified) - Free EET 
 
Equation 1. EET-G to EET conversion. Extracted EET-G regioisomers were converted to their 
corresponding EETs using methanolic KOH (0.4 N) and quantified using LC-MS/MS as described 
below.  
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   LC-ESI-MS product analysis.  AA, AEA and 2-AG regioisomers were resolved using a C18 
column 2.1 x 150 mm, 3.5 µM (Waters, XTerra, P/N 186000408) and a Waters Alliance 2695 
HPLC coupled to an electrospray ionization (ESI) source. For analysis of AA and AEA 
metabolites, the mobile phases consisted of mobile phase A (Acetonitrile/H2O/Formic Acid, 
95:5:0.1) and mobile phase B (Acetonitrile/H2O/Formic Acid, 5:95:0.1) and were ran from 0-1 
min, 60% A; 1-41 min, 60-20% A; 41-42 min 0% A and then returned to initial conditions. The 
same solvent system was used in the analysis of 2-AG metabolites with a gradient of 0-1 min, 70% 
A; 1-51 min, 70-20% A; 51-52 min 0% A and then returned to initial conditions.  For ESI, a Q-
TOF Ultima time of flight mass spectrometer was used in positive ion mode for analysis of AEA, 
with a spray voltage of 4.5 V and capillary temperature of 200ºC.  Data were collected and 
processed using Mass Lynx software (version 4.1), initially scanning from 200 to 800 mass to 
charge ratio (m/z) and processed for the selected AEA-EET m/z of 364. The mass and elution time 
of the 14,15-EET-EA moiety was confirmed using the commercially available authentic standard.  
The detection of AA and 2-AG metabolites were detected with the same system in negative ion 
mode, with a cone voltage of 35 V and a 200ºC desolvation temperature, scanning from 200 to 800 
mass to charge ratio (m/z) and processed for the selected EET m/z of 319 and EET-G m/z of 393-
394.  The mass and elution times of the EET regio-isomers were confirmed with commercially 
available authentic standards. For 2-AG analysis, the mass and elution time of the commercially 
available 14,15-EET-G, EETs and AA lipids were confirmed with authentic standards purchased 
from Cayman Chemical. 
  Liquid chromatography- tandem mass spectrometry for quantitation of 14,15-, 11,12-, 8,9-
, 5,6-EETs, 14,15-EET-EA and 14,15-EET-G.  Quantification EET regioisomers derived from 
in vitro CYP2J2 incubations were analyzed with the 5500 QTRAP LC/MS/MS system (AB Sciex, 
Foster City, CA) with a 1200 series HPLC system (Agilent Technologies, Santa Clara, CA) 
including a degasser, an autosampler, and a binary pump.  The LC separation was performed on 
an Agilent Zorbax Eclipse XDB C18 column (4.6 x 150 mm, 5 µm) (Agilent Technologies, Santa 
Clara, CA) with mobile phase A (0.1% formic acid in water) and mobile phase B (0.1% formic 
acid in acetonitrile). The flow rate was 0.4 mL/min.  The linear gradient was as follows: 0-2 min, 
90% A; 8 min, 50% A; 13-25 min, 25% A; 30 min, 20% A; 35 min, 15% A; 36-42 min, 90% A.  
The autosampler was set at 5ºC.  The injection volume was 5 µL.  Mass spectra were acquired 
with negative electrospray ionization (ESI) and the ion spray voltage was -4500 V. The source 
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temperature was 450 ºC. The curtain gas, ion source gas 1, and ion source gas 2 were 32, 50, and 
65, respectively. Multiple reaction monitoring (MRM) was used to quantify EETs: 5(6)-EET m/z 
319.2  m/z 191.0; 8(9)-EET m/z 319.2  m/z 155.1; 11(12)-EET m/z 319.2  m/z 167.0; 
14(15)-EET m/z 319.2  m/z 219.1; internal standard 16(17)-EpDPE m/z 343.2  m/z 274.1.   
 Quantification of 14,15-EET-EA samples were analyzed using the with the 5500 QTRAP 
LC/MS/MS system with a LC separation method consisting of 0-1min, 50%A; 5-17min, 0%A; 
17.5-23min, 50%A.  The autosampler was set at 5ºC.  The injection volume was 2 µL.  Mass 
spectra were acquired with positive electrospray ionization (ESI) and the ion spray voltage was 
5500 V.  The source temperature was 450 ºC. The curtain gas, ion source gas 1, and ion source gas 
2 were 32, 50, and 65, respectively. Multiple reaction monitoring (MRM) was used to quantify 
14(15)-EET Ethanolamide (m/z 364.3  m/z 346.3) with spiked d4-Anandamide (m/z 352.3  
m/z 287.2) as the internal standard). 
  Direct quantification of the 14,15-EET-G regioisomer were analyzed using the 5500 QTRAP 
LC/MS/MS system with a linear gradient as follows: 0-2 min, 90% A; 8 min, 55% A; 13-25 min, 
40% A; 30 min, 30% A; 35 min, 25% A; 40 min, 2% A; 45-47min, 15%A; 48-56min, 0%A; 57-
62min, 90%A.  Mass spectra were acquired under positive (ion spray voltage at 5500 
V) electrospray ionization (ESI).  The source temperature was 450 ºC. 14,15-EET-G (m/z 395.3--
> m/z 377.3) was measured in positive ESI with arachidonoly-1-thio-glycerol (m/z 395.3--> m/z 
287.3) as an internal standard.  
 Quantification of CYP2J2-ND rate of 2-AG ester cleavage.  The rate of 2-AG ester cleavage 
was quantified using a reversed-phase liquid chromatography (HPLC) system consisting of an 
Alliance 2695 analytical separation module (Waters, Milford MA) coupled to a Waters 996 
photodiode array (PDA) and a C18 column, 1.3 Å, 2.1 mm × 50 mm, 3.5 µm pore size column 
(Waters, XTerra). The mobile system was composed of two solutions: solvent A 
(H2O/ACN/AcOH 95:5:0.1) and solvent B (H2O/ACN/AcOH 5:95:0.1).  The linear gradient was 
as follows: 0-1 min, 60% A; 30 min, 20% A; 31 min, 0% A; return to initial conditions.  Elution 
times of 12.6 min for 2-AG and 19.7 min for AA were verified with authentic standards. 
Quantification of free AA was calculated using AA absorbance at 204 nm.  For kinetic analysis, 
samples containing CYP2J2-ND (50 pmol; 0.2 µM), CPR (150 pmol; 0.6 µM), 0.1% BHT in 0.1M 
phosphate buffer (pH 7.4) were incubated at 37ºC for 5 minutes with 1, 5, 10, 20, 40 and 80 µM 
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of 2-AG before initiation of reaction with 1 mM NADPH at 37 ºC for 20 minutes. Controls lacking 
either NADPH or CYP2J2 were run simultaneously with 80 µM of 2-AG.   
  CYP2J2 MOE Homology Modeling.  A multiple sequence alignment was performed using the 
protein data bank to cross-reference the CYP2J2 sequence against 2A1, 2D6, 2E1, 2R1, 2A6, 2C8, 
2B4, 2C5, 2C9, 2A13.  For construction of the CYP2J2 homology model, crystal structure PDB 
coordinates were used for the isozymes’ with the closest homology to 2J2 and included CYP2B4 
(backbone-42% primary sequence homology), 2C8 (B-region-38% primary sequence homology), 
2R1 (FG region-40% primary sequence homology) and 2C9 (β4-region-26% primary sequence 
homology).  An open CYP2J2 conformation was initially used to dock AA, AEA, 2-AG following 
previously described procedures (25). Two apparent CYP2J2 active site cavities, exhibited 
adjacent/overlapping areas near the heme in agreement with the highest propensity of ligand 
binding number (PLB) and were both used for docking of each respective substrate. Next, we 
conducted an energy minimization step for each respective ligand conformation and the induced 
fitting resulted in the CYP2J2-substrate model used to examine heme and ligand distances as well 
as the predicted interacting active site residues.  Lastly, interaction energies were calculated for 
each substrate to examine the energetics and feasibility of substrate binding.  
   Spectral titrations of CYP2J2-ND. Spectral binding studies were performed by titrating AA 
(both arachidonic acid and sodium arachidonate), AEA, 2-AG, MS-PPOH and ebastine against 
CYP2J2-Nanodiscs (8 µM) in 100 mM phosphate buffer (pH 7.4).  Importantly, substrate stocks 
were prepared with DMSO (5 mM and 50 mM) after the addition of ethanol and acetonitrile were 
determined to cause type I binding. CYP2J2-ND were incrementally titrated with increasing 
concentrations of each putative substrate (either 5 mM or 50 mM stocks) at 22ºC and allowed to 
equilibrate for 5 minutes before measuring the spectra. The total dilution of the original CYP2J2 
concentration was ≤ 1.5%.  Absorbance spectra were collected from 800-200 nm using a Cary Bio 
300 UV-Vis spectrophotometer (Agilent Technologies, Santa Clara CA).  Raw absorbance spectra 
were processed to the corresponding subtraction spectra using a standard MATLAB subroutine 
(Mathworks Inc., MI).  The absolute absorbance difference of the subtraction spectra (peak and 
trough) were plotted against the corresponding substrate concentration in Origin Lab (Origin Lab 
Inc., Northhampton, MA) and fitted using a single binding isotherm (Eq. 2). 
(Equation 2) ΔA = Amax [S] / (Ks + [S]) 
94 
 
Where ∆A is the absorbance difference at each difference spectra peak and trough, Amax is the 
amplitude corresponding to maximal spin shift, Ks is the spectral dissociation constant, S is the 
substrate concentration. None of the substrates investigated exhibited any homotropic 
cooperativity and hence the titration data was fitted to a single binding isotherm.    
   Cyanide binding and equilibrium constant (Ks) determination for CYP2J2-ND.  The steady-
state cyanide spectral equilibrium constants were determined by titrating cyanide concentrations 
(800 mM and 4 M stocks) against ~3 μM of CYP2J2-ND in the absence and the presence of 40 
µM of AA, AEA, 2-AG and MS-PPOH until saturation was reached (15).  The CYP2J2 
concentration change due to cyanide addition was ≤ 3% and did not affect Soret peak height. The 
raw data collected was converted into the difference spectra using a MATLAB subroutine 
(Mathworks Inc., MI).  The ΔA  (ΔA 444-414nm) was plotted against the corresponding cyanide 
concentration  and fitted to a single binding isotherm equation using Origin Pro 8.6 (San Clemente, 
CA) with equation 1 where ΔA = ΔA 444-414nm. 
 Transient cyanide binding kinetics to CYP2J2 active site measured using stopped-flow 
spectroscopy. The cyanide binding kinetics to the CYP2J2 active site in the absence and presence 
of varying concentrations of AA, AEA, 2-AG and MS-PPOH was determined using stopped-flow 
spectroscopy.  Raw data was collected using an Applied Photophysics SX.18MV (Leatherhead, 
UK) spectrophotometer to monitor the rate of cyanide binding.  A dual syringe system was 
prepared, with syringe I containing CYP2J2-ND in the absence or presence of varying 
concentrations (10, 20 and 40 µM) of substrate and syringe 2 containing 80 mM cyanide in the 
absence or presence of varying concentrations (10, 20 and 40 µM) of substrate. The relatively high 
cyanide concentration was selected based on steady state cyanide binding measurements and was 
necessary to ensure pseudo first-order binding kinetics (26).  The parameters for rapid mixing and 
data collection were as follows: 1.5 msec of dead time, external triggering mechanism, photodiode 
array detection and collection obtained on a logarithmic scale over 20 seconds. The raw data was 
converted to the difference spectra by subtracting each successive scan from the time = 0 scan 
using a MATLAB subroutine (Mathworks Inc., MI) that produced the typical 446 and 415 nm 
cyanide binding peaks.  The difference of absorbance was plotted against time and analyzed with 
a double exponential equation using Origin Pro 8.6. 
(Equation 3) ∆A444–414nm = A0 + A1e xk1 + A2exk2 
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Where A1 and A2 are the amplitudes of the fast and slow phases of the reaction respectively and 
k1 and k2 are the rates of fast and slow phases of substrate binding to the protein, determined from 
fitting data obtained to equation 3. 
  Data Analysis. Data were analyzed and presented as means ± standard error.  For all experiments, 
data were collected in triplicate (n = 3) or greater. Stopped flow data were analyzed for statistical 
significance using a student’s t-test where p < 0.05, p < 0.01 and p < 0.001 were denoted by *, **, 
and ***, respectively 
5.4 RESULTS 
    CYP2J2 mediated metabolism of AA and AEA determined using LC-ESI-MS. We first 
investigated the metabolism of AA and AEA by CYP2J2. CYP2J2 was recombinantly expressed 
in E.coli, purified and assembled into nanodiscs as described in the materials and methods. Due to 
increased functional stability of the CYP2J2-CPR-nanodisc system, all the studies reported here 
were done with the proteins incorporated into nanodiscs.   To examine the metabolism of AA and 
AEA, a LC-ESI-MS method was developed to qualitatively assess the product formation. 
Importantly, the use of a slow linear gradient was necessary for separation of the regioisomers and 
structural identification by mass and elution time. Product analysis of CYP2J2-ND-CPR 
incubations with AA produced four regioisomers (m/z = 319.5) corresponding to the mass and 
elution times of 14,15-, 11,12-, 8,9- and 5,6-EET (Figure 5.2A). The additional peaks (m/z 319), 
19-HETE, was confirmed at earlier elution times (11 min). Similarly, analysis of CYP2J2 and 
AEA incubations produced the same olefin oxygenation pattern as AA, with a regioisomer 
corresponding to the elution times of 14,15-EET-EA as confirmed using the authentic standard 
(Figure 5.2B). The identity of the 11,12-, 8,9-, and 5,6-EET-EA were extrapolated based on 
literature describing the elution profile and peak mass confirmation. Similar to AA, the presence 
of two additional metabolites corresponding to 19- and 20-HETE-EAs were observed. These 
results show that both AA and AEA are substrates of CYP2J2 and form four epoxide products 
similar to previous reports with other P450s (Snider et al., 2010).  
  CYP2J2 mediated metabolism of 2-AG determined using LC-ESI-MS.  The in vitro 
incubations containing CYP2J2-ND-CPR and 2-AG produced the following products - two 
detectable 2-AG epoxide metabolites (m/z 393.3), arachidonic acid (m/z 303.3) and EETs (m/z 
319.5) as shown in Figure 5.3. Authentic standards were used to confirm the 14,15-EET-G, EETs 
(14,15-, 11,12-, 8,9-, 5,6-EET) and AA metabolites. While the 11,12-EET-G was not 
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commercially available, the results from EET-G saponification confirmed the production of the 
11,12-regioisomer.  
  In contrast to AA and AEA, only two olefin sites of 2-AG were epoxidized to form 2-AG-EETs 
(m/z 393.3). Thus, the functional data suggests that the interaction of 2-AG within the CYP2J2 
binding pocket is influenced by the presence of the bulky glycerol group of 2-AG (Figure 5.1). 
Previous incubations with other P450s have failed to produce the EET-G regioisomers (3). Here 
we report that CYP2J2 is identified as an isoform of P450 that produces epoxide 2-AG metabolites. 
As a control we analyzed CYP2C8 (supersomes) with 2-AG following the same methodology and 
failed to observe any detectable EET-G formation (Figure 5.8).  This suggests that CYP2J2 may 
be unique in the epoxidation of 2-AG as compared to other family 2 P450s.   
  Quantitative analysis of CYP2J2 mediated epoxidation of 2-AG and AEA using LC-ESI-
MS/MS. The detection and quantification of fatty acids and their metabolites have been most 
commonly examined using radio flow HPLC due to the high sensitivity and ease of use (27). 
Alternatively, detection by mass spectrometry after derivatization, coupled with gas 
chromatography or liquid chromatography has also been widely used for EET analysis (28).  Here 
we successfully used HPLC coupled to a triple quadrupole detector utilizing one of the most 
sensitive commercially available ion trap (QTRAP 5500) which enabled a highly sensitive, 
accurate and reproducible method for detection of all the EET regioisomers in multiple reaction 
monitoring (MRM) mode. The limit of quantitation (LOQ) with a 10:1 signal to noise ratio for 
5(6)-EET was 5.0 ng/mL, whereas 8,9-, 11,12-, 14,15-EET were calculated at 2.5 ng/mL.  Prior to 
each run a six point standard curve was generated for each set of samples using authentic standards. 
Extraction efficiency was calculated for each of the EET regioisomers using the acidification and 
the three step ethyl acetate extraction. 14,15-, 11,12-, and 8,9-, and 5,6-EETs were extracted from 
the reaction mixture with a 95% or greater efficiency. Reaction linearity was demonstrated for 
each of the substrates at 15, 30 and 60 minutes with R2 values of 0.98 or greater.  The advantages 
of a LC-MS/MS method are that it provides structural elucidation, quantification and efficiency 
with excellent sensitivity without the need of derivatization. This method should be widely 
applicable for complex biological samples with low levels of EETs. The identification of the 
metabolites of 2-AG and AEA were followed by quantification and measurement of the rate of 
formation using a LC-MS-MS method as described in the materials and method section (Figure 
5.4). 
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  The rates of formation of the two EET-G regioisomers were determined by saponification of the 
EET-G to the corresponding EET regioisomers. The final value of EETs arising from EET-G was 
obtained by subtracting the free EETs as determined in the materials and methods. The kinetics of 
EET-G formation were as follows: 14,15-EET-G Vmax = 265.4 ± 12.3 pmol/min/nmol and Km = 
32.6 ± 1.7 µM; 11,12-EET-G Vmax = 125.5 ± 5.2 pmol/min/nmol and Km = 13.6 ± 1.3 µM.  
  In a separate experiment, the rate of metabolism of arachidonic acid to form the four EET regio-
isomers was measured in the presence of saturating concentrations of AA. Catalytic rates were 
calculated at 103 ± 4.6, 61.5 ± 5.6, 18.4 ± 1.7 and 8.9 ± 0.1 pmol/min/nmol of CYP2J2 for  14,15-
, 11,12-, 8,9- and 5,6-EET, respectively.   
 Additionally, we examined the CYP2J2 mediated epoxidation of saturating amounts of AEA (60 
µM) towards the production of 14,15-EET-EA which was calculated to be 391 ± 12 
pmol/min/nmol of CYP2J2. Thus, the production of the 14,15-EET-EA appears to proceed at a 
significantly faster rate when compared to the production 14,15-EET from AA despite sharing a 
similar qualitative product profile and binding characteristics as discussed later.   
 CYP2J2 mediated 2-AG ester cleavage and production of free AA. The ESI-LC-MS product 
analysis of 2-AG incubations revealed significant amounts of free AA in solution (Figure 5.3). 
Control experiments showed that the conversion of 2-AG to AA required the presence of both 
NADPH and CPR for catalytic turnover indicating that the reaction proceeded through an oxidative 
mechanism (controls not shown). As seen in Figure 5.4D, analysis of 2-AG incubations followed 
Michaelis-Menten kinetics, indicating that the reaction was dependent on substrate binding. The 
Km of the ester cleavage reaction was calculated at 3.25 µM with a Vmax of 2.2 ± 0.2 
nmol/min/nmol of CYP2J2. Samples lacking NADPH and CYP2J2 were ran in parallel as controls.  
Arachidonic acid was not detected in the NADPH-free sample. Additionally, 2-AG was stable in 
buffer at 37ºC with negligible hydrolysis.  The ability of CYP to mediate ester cleavage reactions 
has long been reported and rates determined in this work show similar catalytic properties of other 
CYP isozymes (29, 30). However, this is the first account of the P450 mediated cleavage of a fatty 
acid ester of an endogenous substrate. The same reactions were run with CYP2C8 (supersomes) 
which also produced AA in a NADPH dependent reaction (Figure 5.8). However, CYP2C8 
epoxygenase did not demonstrate the ability to oxygenate the 2-AG olefin bonds.    
  Bovine and porcine heart microsomes metabolism of AA and 2-AG. To examine whether the 
novel endocannabinoid epoxygenation reactions would occur within a complex environment in the 
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presence of other proteins, we prepared heart microsomes from the tissue of bovine and porcine 
left ventricular myocardium. The rate of metabolism of AA, AEA and 2-AG are summarized in 
Table 5.2. We chose bovine and porcine species because they both contain CYP2J2 with high 
sequence homology to humans (Figure 5.10). CYP2J2 immunoblotting of the bovine and porcine 
microsomes were performed using a polyclonal rabbit IgG antibody for human CYP2J2. The 
microsomal preparations cross-reacted with the CYP2J2 antibody demonstrating the presence of 
CYP2J2 cross-reactivity in bovine and porcine hearts (Figure 5.11).  First, the functionality was 
assessed by measuring AA metabolism of bovine and porcine microsomes which produced 1.8 ± 
0.3 and 2.08 ± 0.02 pmol min-1 mg-1 microsomal protein of EETs (all regio-isomers), respectively.  
Next we quantified 2-AG metabolism by directly measuring the production of the 14,15-EET-G 
regioisomer by bovine and porcine microsomes that was calculated at 1.17 ± 0.57 and 1.1 ± 0.55 
pmol min-1 mg-1 microsomal protein, respectively. The 14,15-EET-EA isomer was produced with 
a higher turnover in both bovine and porcine microsomes with values of 1.96 ± 0.05 and 2.25 ± 
0.07 pmol min-1 mg-1 microsomal protein, respectively.       
  CYP2J2 mediated lipase activity. CYP2J2 mediated oxidative cleavage of 2-AG into 
arachidonic acid raised questions whether this enzyme could act as a lipase and use AA containing 
phospholipids as direct substrates. PIP2 (phosphatidylinositol 4,5-bisphospate) is present in the 
plasma membrane where it is cleaved by phospholipase C to produce AA for subsequent entry into 
the eicosanoid cascade (8). Thus, we incubated PIP2 with CYP2J2-ND-CPR-NADPH system 
utilizing PIP2 concentrations below its critical micelle formation (CMC). In these experiments we 
did not to observe formation of AA or diacylglycerol (31).  
 Spectral binding studies of CYP2J2 with AA, AEA and 2-AG. In an effort to understand the 
binding interactions of AA and its derivatives (AEA and 2-AG) with the active site of CYP2J2, 
we performed spectroscopic binding studies. First, the interactions of AA, AEA, 2-AG, ebastine 
and MS-PPOH with the CYP2J2-ND active site were investigated using UV-Vis spectral binding 
titrations (Figure 5.5). As controls, the spectral binding properties of the potent epoxygenase 
inhibitor N-methylsulfonyl-6-(2-propargyloxyphenyl) hexanamide (MS-PPOH) (32) and ebastine 
were investigated and both induced type-I shifts with apparent spectral binding constants (Ks) of 
10.8 ± 1.5 µM and 5.6 ± 0.7, respectively. 
  The fatty acids presented with smaller changes in spin-state and minor shifts in Soret band.  
Specifically, the Soret band at 417 nm red-shifted by 0.5 nm with a slight decrease in amplitude 
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for both AA and AEA. The difference spectra revealed prominent troughs for both ligands at 414 
nm and broad peaks at 434 and 435 nm for AA and AEA, respectively (Figure 5.5A). Both 
substrates were fitted to single binding isotherm with apparent Ks of 11.3 ± 1.3 µM for AA and 
13.1 ± 1.4 µM for AEA (Figure 5.5D). The similarities between AA and AEA spectral shifts and 
binding equilibrium suggest that the presence of the ethanolamide (AEA) motif does not 
significantly alter substrate distances and positioning in relation to the heme when compared with 
AA. Conversely, 2-AG spectral titrations resulted in a blue-shift while slightly decreasing the 
Soret.  The apparent Ks of binding for 2-AG was calculated at 18 ± 2.7 µM.  Taken together, these 
data demonstrate that the modification of the carboxylic acid of the arachidonic acid with the 
glycerol moiety affects binding in CYP2J2’s large yet narrow binding cavity (33). Note that the 
observed Soret shifts are not as prominent as xenobiotic P450 substrates, yet are consistent with 
the few published spectra of other fatty acids binding to membrane bound CYPs (34).  Moreover, 
the lack of significant Soret perturbations corresponds to the relatively low turnover rates of the 
AA metabolizing epoxygenases such as CYP2J2 (35). Additionally, these experiments were 
further validated using steady state cyanide binding experiments in the presence of AA, AEA and 
2-AG to probe the access and binding of cyanide to the heme (Figure 5.9).   
   Kinetics of cyanide binding to CYP2J2-ND in the presence of substrates. The cyanide 
binding kinetics of CYP2J2 was investigated in the absence or presence of hydrophobic substrates 
using stopped-flow spectroscopy. For each substrate tested, rapid mixing and formation of the 
heme-cyanide complex red-shifted the Soret (Figure 5.6A).  As shown in Figure 5.6B, the 
difference spectra Δ (A444 – 414 nm) were analyzed as a function of time and yielded an exponential 
biphasic curve that were comprised of a fast and slow phase (36). The “fast phase” corresponds to 
the rate of cyanide binding to the ferric heme active site.  Specifically, it can be used as a direct 
measure of substrate egress from the immediate vicinity of the heme active site to accommodate 
formation of the cyanide complex. In the fast phase the presence of increasing concentrations 
ebastine significantly decreased cyanide-binding rates in a concentration-dependent manner. 
Conversely, the fatty acid ligands only slightly decreased cyanide binding (Figure 5.6C). The ratio 
of the fast-and slow-phase amplitudes were compared to determine how ligand concentrations 
affect the presence of the ratios. As seen in Figure 5.6D-G, saturating concentrations of ebastine 
significantly increases the ratio of the slow-phase (17.4% to 66.4%) whereas the arachidonate 
containing ligands only slightly increased the slow-phase ~10%. To rule out non-specific fatty acid 
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binding we examined the rates of cyanide binding in the presence of saturating concentrations of 
palmitate. As shown in Figure 5.6H the presence of palmitate does not noticeably alter the ratio of 
the two phases. While not dramatic, the reported results provide important characterization of the 
nature of fatty acid binding. 
   CYP2J2 Homology Modeling with AA, AEA and 2-AG.  Molecular Operating Environment 
(MOE, Chemical Computing Group) software was used to identify substrate-binding 
characteristics within the active site of a CYP2J2 homology model.  A hybrid structure model was 
constructed from the crystal PDB coordinates of similar CYP isozymes (class dependent sequence 
alignment strategy) as described in the materials and methods section (37). This approach takes 
advantage of the conserved sequences that maintain the secondary and tertiary P450 folds to 
generate the core structures surrounding the buried catalytic sites.  Given the fatty acids relatively 
low turnover there are likely many ‘unproductive’ conformations within the active site.  As shown 
in Figure 5.7A, AA was docked in the most preferred configuration for epoxidation of the 14,15-
olefin when closest to the heme (5.1 Å), followed by the 11,12-, 8,9-, and 5,6-olefins with 
calculated heme distances of 8.6, 11.3 and 12.9 Å, respectively. As shown in Figure 5.7B, the 
distances of the AEA 14,15-, 11,12-, 8,9- and 5,6-olefins were calculated at 6, 8.5, 12.1 and 13.5 
Å, respectively. Interestingly, 2-AG (Figure 5.7C) yielded significantly different active site 
interactions albeit with similar heme distances of the 14,15-, 11,12-, 8,9- and 5,6-olefin estimated 
at 5.9, 7.6, 9 and 11.5 Å, respectively. The interaction potential energies predict feasibility of 
binding and were similar for each polyunsaturated fatty acid with calculations of -68.3 kcal/mol, -
69.4 kcal/mol, and -73.4 kcal/mol for AA, 2-AG and AEA, respectively.  Thus, the olefin distances 
of the MOE model were in agreement experimental differences observed in AA, AEA and 2-AG 
metabolism. Additionally, the model predicted significantly different binding characteristics based 
on the presence of the carboxylate/ethanolamide or glycerol moiety. For example, a patch of 
hydrophobic residues appeared to mediate AA and AEA positioning within the CYP2J2 active site 
with Pro 112, Ile 487 and Ile 376 common for both substrates. Interactions of polar residues were 
fewer with only Gln 228 interacting with the polar carboxylate/ethanolamide groups. Conversely,  
positioning of the 2-AG utilized both hydrophobic residues (Ile127, Val 380 and Ile 487) as well 
as interactions of the hydrophilic glycerol moiety with polar CYP2J2 residues (Asn 231, Ser 224, 
Gln 228 and Ser 64).  The relatively fewer polar interactions of AA and AEA might enable 
sampling of different conformations of these substrates in the active site leading to the epoxidation 
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of the 8,9- and 5,6-olefin groups.  Conversely, the glycerol group appears tethered and cannot 
sample orientations for epoxidation of the 8,9- and 5,6-olefins. In absence of a high resolution 
CYP2J2 crystal structure, this model provides a useful tool to predict the interactions of AA, AEA 
and 2-AG within the active that provide CYP2J2’s regioselectivity.  
5.5 DISCUSSION 
  Extrahepatic CYP2J2 epoxygenase metabolizes AA to form EETs that are essential for regulation 
of blood pressure and cardiovascular function (38). As previously mentioned, AA derived 
endocannabinoids play an important role in the cardiovascular system. Therefore we explored the 
metabolism of functionalized arachidonate containing lipids such as the endocannabionids with 
the  cytochrome P450 most highly expressed in the human heart. The two most well characterized, 
arachidonic acid derived endocannabinoids are AEA and 2-AG whose dysregulation have been 
implicated in a wide range of pathophysiological states (1, 39, 40). Herein, we demonstrate 
CYP2J2 mediated metabolism of AEA and 2-AG using recombinant human CYP2J2 and heart 
microsomes derived from bovine and porcine tissues. The results provided here show the 
endocannanbinoids 2-AG and AEA are both substrates of human CYP2J2 and that the predominant 
products, 14,15-EET-EA and 14,15-EET-G, are produced in heart microsomal systems of two 
different mammalian species, lending credibility to the proposed pathway in tissues.    
   The qualitative product analysis of CYP2J2-AEA incubations by LC-MS revealed four epoxide 
regio-isomers at the 5,6-, 8,9-, 11,12- and 14,15-olefin positions. The quantitative analysis of 
14,15-EET-EA exhibited 4-fold more product when compared to the rate of formation of 14,15-
EET regioisomer from AA.   Previously, the oxygenation of AEA into a single hydroxy-product, 
20-HETE ethanolamide, as well as four epoxide regio-isomers 5,6-, 8,9-, 11,12- and 14,15-EET-
EA were demonstrated by several hepatic P450s including CYP2D6, CYP3A4 and CYP4F2 (41). 
However, this is the first report of the AEA metabolism by a CYP epoxygenase that is highly 
expressed in the myocardium and endocardium.  Given the increasing reports of an 
endocannabinoid mediated regulation of blood pressure and the cardiovascular system, the role of 
the oxygenated AEA metabolites may provide an interesting avenue for future studies.  For 
instance, AEA is a partial agonist of both CB1 and CB2 receptors whereas the 5,6-EET-EA 
metabolite selectively binds CB2 with much greater affinity (42).  Additionally there is mounting 
evidence of CB2-cardioprotection versus CB1-cardiotoxicity and the ability to selectively target 
these pathways may provide a useful therapeutic target for the treatment of heart disease (40, 43).  
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Moreover, less is known about the physiological effects of the other EET-EA metabolites and 
whether they also exhibit differential receptor binding profiles and in vivo effects.   
   Previously, the epoxide metabolites of 2-AG, 14,15- and 11,12-EET-G were found 
endogenously in rat kidney and spleen tissues. These metabolites bound both CB1 and CB2 with 
greater affinity than 2-AG (3). Incubations with family 2 CYPs - CYP2C8, CYP2C11, and 
CYP2C3 failed to produce these metabolites (3). Therefore it was concluded that these epoxide 
metabolites do not arise from epoxidation of 2-AG through the CYP pathway. Our modeling 
studies show that CYP2J2 contains a relatively large active site that can accommodate 2-AG as 
compared to other family 2 CYPs. Moreover, we show it is possible to directly oxygenate 2-AG 
by CYP2J2 to produce relatively high levels of both 14,15- and 11,12-EET-G. Additionally our 
results show that CYP2J2 produces only two epoxide metabolites - 14,15-EET-G and 11,12-EET-
G similar to the 2-AG epoxide metabolites identified in vivo. Thus, these results provide an 
alternative pathway for the biosynthesis of 2-AG epoxides through the direct enzymatic 
oxygenation by CYP2J2. 
  Due to the demonstrated beneficial functions of the endocannabinoids, there are several drugs in 
the market that target the enzymes that attenuate the in vivo levels of these substrates (44). Previous 
inhibition of enzymes that inactivate AEA and 2-AG have shown that the inhibition is incomplete 
(13) indicating that there may be alternative pathways of attenuation of these endocannabinoids. 
We demonstrate here that 2-AG is converted to AA by CYP2J2 and CYP2C8 using an oxidative 
ester cleavage mechanism. Subsequent control experiments confirmed that the cleavage proceeded 
via an oxidative NADPH-dependent CYP2J2-CPR mechanism. To our knowledge, these results 
provide the first evidence of a P450 mediated endocannabinoid attenuation pathway for production 
of free arachidonic acid for subsequent metabolism in the classical eicosanoid pathways (COX, 
LOX and EPOX). Thus far, there have been no reports of an oxidative ester cleavage mechanism 
of endogenous 2-AG. However, other P450 isozymes have long been recognized as important 
sources of carbonyl products through non-hydrolytic ester cleavage reactions (29, 30).  
 The potential of CYP2J2 to produce its own substrate through the cleavage of arachidonic acid 
from PIP2 was also explored. Several different conditions were examined and it was concluded 
the PIP2 is not a CYP2J2 substrate. Considering the tissue distribution of cytochrome P450s, the 
role of a CYP mediated attenuation of 2-AG may constitute further examination in vivo.  
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  The binding interactions of arachidonic acid and its derivatives with the active site of CYP2J2 
revealed relatively low spin state changes. Thus, the uses of the nanoscale lipid bilayers of 
nanodiscs were essential for the characterization of AA, AEA and 2-AG binding in spectroscopic 
studies with minimal spectral scattering.  In general, there are very few examples of human CYP 
titrations in the literature, likely due to issues with solubility, scattering and low spin state changes. 
Interestingly, the few that have been published typically present with a similar spectra to what is 
presented in this work (34).  The ebastine, MS-PPOH and 2-AG Soret shifts present with classical 
type I binding modes (Figure 5.5).  The binding of AA and AEA was less clear and difficult to 
conclusively assign the classical type I and type II shifts due to the low signal to noise ratio. 
However, all the binding shifts were concentration dependent and reach saturation and are present 
with clear peaks/troughs lending credibility to the calculated binding constants.  While the spin-
state changes of the arachidonic acid and the derivatives are minor when compared with ebastine 
they do correspond to the relatively low catalytic turnover of these substrates. Importantly, the 
relatively slow turnover rates of CYP2J2 resemble the functions of the steroid synthesizing P450’s 
that regulate complex homeostatic processes rather than the very fast detoxification functions of 
liver CYPs.   
  The results for the CYP2J2-ND substrate-free and substrate-bound stopped-flow cyanide binding 
experiments are summarized in Figure 5.6 and Table 5.3.  For cyanide binding studies we 
employed ebastine and showed that the rates of the fast phase were significantly decreased with 
increasing ebastine concentrations similar to other P450-substrate systems (26).  Conversely, AA, 
AEA and 2-AG only showed modest inhibition of cyanide binding as shown in Figure 5.6C and 
indicated that they either more easily egress from the active site or are bound as to not block 
cyanide binding.  Similarly, the ratio of the fast- to slow-phase was significantly decreased in the 
presence of increasing concentrations of ebastine and only modestly decreased in the presence of 
increasing concentrations of AA, AEA and 2-AG (Figure 5.6E – G).  This effect was consistent 
and repeatable and not due to non-specific fatty acid binding as evidenced by the lack of change 
induced by palmitate (Figure 5.6H).   
   The enzymatic turnover of CYP2J2 is several orders of magnitude lower than xenobiotic 
metabolizing hepatic P450s and it might be tempting to disregard the potential biological 
significance of the CYP2J2 pathway based solely on these low enzymatic turnover rates. However, 
the extrahepatic epoxygenases, including CYP2J2, function to regulate complex homeostatic 
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functions within the body and exhibit significantly lower turnover of the endogenous fatty acids 
(35) in a highly regulated manner. Thus, the formation of these metabolites likely represents a far 
more elegant mechanism for control of the many delicate homeostatic processes within organs 
such as the heart and kidneys. Therefore, similar to the steroid synthesizing CYPs, the enzymatic 
expression levels rather than the catalytic turnover are likely the prominent mechanism for 
metabolic control in each respective organ. 
   In summary, we have demonstrated the ability of CYP2J2 to metabolize a diverse range of AA-
containing substrates into a number of unique metabolites that have previously been shown to 
contain important physiological effects in vivo.  Additionally, we provide important evidence that 
CYP2J2 can directly attenuate 2-AG levels through a NADPH-dependent oxidative cleavage 
mechanism, thereby producing free arachidonic acid for subsequent metabolism within the 
classical eicosanoid cascade. We further show that the formation of the metabolites of 2-AG and 
AEA are in agreement with the spectral binding studies and modeling. 
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5.7 FIGURES AND TABLES  
 
FIGURE 5.1. Chemical structures of substrates that bind to CYP2J2-nanodiscs. Endogenous 
CYP2J2 ligands include (A) arachidonic acid, (B) anandamide and (C) 2-arachidonoyl glycerol. 
(D) The xenobiotic, ebastine, is a cardiotoxic 2J2 substrate.  (E) MS-PPOH (N-(methylsulfonyl)-
2-(2-propynyloxy)-benzenehexanamide) is a non-specific CYP inhibitor. (F) Schematic of 
CYP2J2 and CPR incorporated into the membrane bilayers of nanodiscs. The membrane scaffold 
protein (MSP) is represented in cyan surrounding a bilayer of phospholipids colored white with 
gold phosphate head groups. CYP2J2 is red and its obligate redox partner cytochrome P450 
reductase is colored blue.   
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FIGURE 5.2. Metabolism of AA and AEA by human CYP2J2-ND-CPR identified 
qualitatively using LC-ESI-MS.  CYP2J2-ND incubations with substrates were analyzed as 
described in the materials and methods. The different regio-isomers of (A) AA (m/z = 319.5 of 
14,15-EET at 22.5 min) and (B) AEA (m/z = 363.4 of 14,15-EET-EA at 14 min) produced six 
different products including four epoxide regio-isomers at the 5,6-, 8,9-, 11,12- and 14,15-olefin 
positions and two HETEs. 
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FIGURE 5.3. Metabolism of 2-AG by CYP2J2-ND-CPR identified qualitatively using LC-
ESI-MS. Metabolism of 2-AG by incubations with CYP2J2-ND-CPR revealed the following 
metabolic profile as represented in the chromatogram that consists of an overlay of two EET-G 
regio-isomers, 14,15-EET-G and 11,12-EET-G (m/z 393), three detectable EET regio-isomers, 
14,15-EET, 11,12-EET and 8,9-EET (m/z = 319) and arachidonic acid (m/z = 303). 
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FIGURE 5.4. Kinetics of CYP2J2 mediated metabolism of 2-AG. (A) Schematic of the 
proposed routes of 2-AG metabolism by CYP2J2 that produces AA, EET-G and EET. The kinetic 
rates of the three products were quantified as described in the materials and methods. (B) Kinetics 
of the formation of the four regio-isomers, 14,15-, 11,12-, 8,9- and 5,6-EET were detected by LC-
MS-MS. These correspond to the free EETs in solution that were generated either from epoxidation 
of AA or oxidative ester cleavage of EET-G. (C) Kinetics of the formation of the two EET-G 
regioisomers, 14,15-EET-G and 11,12-EET-G analyzed as described in the materials and methods 
section. (D)  The kinetics of CYP2J2-ND mediated 2-AG ester cleavage and arachidonic acid 
production were determined by monitoring AA formation. The data were fitted to Michaelis-
Menten kinetics in Origin Pro 8.6 for calculation of Vmax and Km. The kinetic rates of the 
epoxidation reactions and side reactions are summarized in Table 5.1. 
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FIGURE 5.5. Equilibrium binding using absorption spectra for interactions of substrate 
with CYP2J2-Nanodiscs.  (A) AEA titration Ks was determined to be 13.1 ± 1.4 µM (inset: 
difference spectrum of AEA bound CYP2J2-Nanodiscs). (B) 2-AG titration Ks  was determined to 
be 18 ± 2.7 µM (inset: difference spectrum of 2-AG bound CYP2J2-Nanodiscs) (C) MS-PPOH 
titration Ks was determined to be 10.8 ± 1.5 µM (inset: difference spectrum of MS-PPOH bound 
CYP2J2-Nanodiscs showing a type I binding mode) (D) Summary of the λmax (nm) of peak/trough, 
Ks  and Δmax for binding of arachidonic acid, anandamide, 2-arachidonoyl glycerol, ebastine and 
MS-PPOH to CYP2J2-Nanodiscs.   
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FIGURE 5.6. Stopped-flow cyanide binding spectroscopy with CYP2J2-ND and AA, 2-AG, 
AEA and ebastine. (A) Stopped-flow spectroscopy was used to monitor kinetics of cyanide 
binding to CYP2J2-ND by recording the formation of the cyanide-heme complex at 444 nm as a 
function of time in the presence of saturating [CN-]. (B) The difference spectra (ΔAbs 444-414 
nm) was plotted against time and fitted to a double exponential equation for determination of the 
rate of the (C) fast-phase for each substrate concentration tested and determination of statistical 
significance relative to the substrate free condition when p < 0.05, p < 0.01 and p < 0.001 which 
are denoted by *, **, and ***, respectively. The ratio of the amplitudes of the fast-phase (black) 
to slow-phase (gray) were dramatically altered in the presence of (D) ebastine whereas the presence 
of the polyunsaturated fatty acids such as (E) AEA (F) 2-AG and (G) AA were modestly changed. 
(H) The saturated fatty acid palmitate did not alter cyanide binding characteristics.  
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FIGURE 5.7. Substrate bound CYP2J2 Homology model with arachidonic acid, anandamide 
and 2-arachidonoyl glycerol. Proposed docking of the polyunsaturated fatty acids into the active 
site of CYP2J2.  (Left)  the substrate (A) AA (B) AEA and (C) 2-AG are represented as stick 
figures (green) surrounded by space-filling dots. The CYP2J2 ribbon structure is colored blue and 
the heme-oxygen motif is in red. The interaction potential energies predict feasibility of binding 
and were similar for each polyunsaturated fatty acid with calculations of -69.4 kcal/mol, and -73.4 
kcal/mol for 2-AG and AEA, respectively. (Right)  predicted ligand-residue interactions within 
the CYP2J2 active site for (A) AA (B) AEA and (C) 2-AG. 
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Figure 5.8. Incubations of CYP2C8 supersomes with 2-AG. Incubations containing CYP2C8 
and 2-AG were performed as described in the materials and methods. Product analysis revealed 
the presence of arachidonic acid in the reaction but did not produce detectable levels of EET-G or 
EETs. 
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Figure 5.9. Steady-state cyanide binding to substrate-free and substrate bound CYP2J2-ND. 
(A) The UV-Vis spectra of an equilibrium binding titration of cyanide to CYP2J2-ND. The binding 
of cyanide red shifted the Soret band.  (B) The change in absorbance (ΔAbs) from 444 nm to 414 
nm was calculated for each titration and plotted against the corresponding cyanide concentration. 
Data were fit to the single binding isotherm by using Origin Pro 8.6. The cyanide Ks (µM) of 
substrate-free and 40 µM substrate bound were calculated for each substrate. The apparent binding 
constant (Ks) of the steady state cyanide binding to the active site of substrate free CYP2J2-ND 
was calculated at 3.1 ± 0.2 mM. The presence of 40 µM of either AA or AEA modestly increased 
the Ks of cyanide binding to 7.7 ± 1.1 mM and 5.2 ± 1.4 mM, respectively. The presence of 2-AG 
only slightly shifted the Ks of cyanide binding to 4.3 ± 0.2 mM. When the system was incubated 
with 40 µM of ebastine, the Ks of cyanide binding more than tripled with values of 13.3 ± 0.2 mM 
(Table 5.3). Notably, these results were inversely proportional to the equilibrium binding constants 
calculated from spectral binding assays. This suggests that a tighter substrate binding blocks 
cyanide access to the active site.  
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Figure 5.10. Multiple sequence alignment of human, bovine and porcine CYP2J2 sequences. 
Inter-species alignments of CYP2J2 from porcine, bovine and calculated an 80% homology for 
comparison of porcine to bovine, 77% homology for porcine to human and a 75% homology for 
bovine to human.  The single fully conserved residue for each of all of the species is denoted by 
(*). The majority of other residues polarity was maintained as represented by (:) for the 
conservation of strong groups and (.) for conservation of weak groups.   
 
 
Porcine_CYP2J2      MPLALGSLAEALWTALRPSTILLGAVAFLFFADFLKKRRPKNYPPGPPRLPFIGNLFHLD 
Bovine_CYP2J2       MLEALSSLATALWAALRPDTVLLGTLAFLLFVDFLKRRHPKNYPPGPPGLPFVGNLFQLD 
Human_CYP2J2        MLAAMGSLAAALWAVVHPRTLLLGTVAFLLAADFLKRRRPKNYPPGPWRLPFLGNFFLVD 
                    *  *:.*** ***:.::* *:***::***: .****:*:********  ***:**:* :* 
 
Porcine_CYP2J2      LDKGHLSLQRFVKKYGNVFSLDFGALSSVVITGLPFIKEAFVHQDKNFSNRPIVPIQQRV 
Bovine_CYP2J2       PEKVPLVLHQFVKKYGNVFSLDFGTVPSVLITGLPLIKEVLVHQGQIFSNRPIVPLQEHI 
Human_CYP2J2        FEQSHLEVQLFVKKYGNLFSLELGDISAVLITGLPLIKEALIHMDQNFGNRPVTPMREHI 
                     ::  * :: *******:***::* :.:*:*****:***.::* .: *.***:.*::::: 
 
Porcine_CYP2J2      FKDKGVVMSNGQVWKEQRRFALTTLRNFGLGKKSLEERIQEEAQYLIQAIGEENGQPFNP 
Bovine_CYP2J2       INNKGLIMSSGQLWKEQRRFALTTLRNFGLGKKSLEERIQEEASYLIQTIREENGQPFDP 
Human_CYP2J2        FKKNGLIMSSGQAWKEQRRFTLTALRNFGLGKKSLEERIQEEAQHLTEAIKEENGQPFDP 
                    ::.:*::**.** *******:**:*******************.:* ::* *******:* 
 
Porcine_CYP2J2      HFKINNAVSNIICSITFGERFDYQDNQFQELLKLLDEVMCLQTSVWCQIYNIIPWIMKFL 
Bovine_CYP2J2       HLTINNAVSNIICSITFGERFDYQDDQFQELLRMLDEILNLQTSMCCQLYNVFPRIMNFL 
Human_CYP2J2        HFKINNAVSNIICSITFGERFEYQDSWFQQLLKLLDEVTYLEASKTCQLYNVFPWIMKFL 
                    *:.******************:***. **:**::***:  *::*  **:**::* **:** 
 
Porcine_CYP2J2      PGPHQTLFSNWEKLKMFVAHVIENHRRDWNPAEARDFIEAYLQEIEKHKGDATSSFQEEN 
Bovine_CYP2J2       PGPHQALFSNMEKMKMFVARMIENHKRDWNPAEARDFIDAYLQEIEKHKGDATSSFQEEN 
Human_CYP2J2        PGPHQTLFSNWKKLKLFVSHMIDKHRKDWNPAETRDFIDAYLKEMSKHTGNPTSSFHEEN 
                    *****:**** :*:*:**:::*::*::******:****:***:*:.**.*:.****:*** 
 
Porcine_CYP2J2      LICSTLDLFVAGTETTSTTLRWGLLYMALYPEIQEKVQAEIDRVLGQLQQPSTAARESMP 
Bovine_CYP2J2       LIYNTLDLFLAGTETTSTSLRWGLLFMALNPEIQEKVQAEIDRVLGQSQQPSMAARESMP 
Human_CYP2J2        LICSTLDLFFAGTETTSTTLRWALLYMALYPEIQEKVQAEIDRVIGQGQQPSTAARESMP 
                    ** .*****.********:***.**:*** **************:** **** ******* 
 
 
Porcine_CYP2J2      YTNAVIHEVQRMGNIIPLNVPREVAEDTTLAGYHLPKGTMVIANLTALHSDPTEWATPDT 
Bovine_CYP2J2       YTNAVIHEVLRMGNIIPLNVPREVAVDTTLAGYHLPKGTMVMTNLTALHRDPTEWATPDT 
Human_CYP2J2        YTNAVIHEVQRMGNIIPLNVPREVTVDTTLAGYHLPKGTMILTNLTALHRDPTEWATPDT 
                    ********* **************: **************:::****** ********** 
 
Porcine_CYP2J2      FNPEHFLENGKFKKREAFLPFSVGKRACLGEQLARTELFVFFTSLLQKFSFRPPDNEKLS 
Bovine_CYP2J2       FNPEHFLENGQFKKRESFLPFSIGKRMCLGEQLARTELFIFFTSLLQKFTFRPPENEQLS 
Human_CYP2J2        FNPDHFLENGQFKKREAFMPFSIGKRACLGEQLARTELFIFFTSLMQKFTFRPPNNEKLS 
                    ***:******:*****:*:***:*** ************:*****:***:****:**:** 
 
Porcine_CYP2J2      LKFRMGLTLSPVTYRICAVPRA 
Bovine_CYP2J2       LKFRVSLTLAPVSHRLCAVPRG 
Human_CYP2J2        LKFRMGITISPVSHRLCAVPQV 
                    ****:.:*::**::*:****:  
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Figure 5.11. CYP2J2 immunoblotting in bovine and porcine microsomes using a polyclonal 
rabbit IgG antibody for human CYP2J2. The inter-species cross-reactivity with the anti-body 
raised against the human CYP2J2 was examined. From left to right, lane 1 contains 100 ug of pig 
heart microsomes, lane 2 contains 100 ug of cow heart microsomes and lane 3 contains 100 pmol 
of recombinant CYP2J2 used in these studies.  
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Table 5.1. The product formation kinetics for CYP2J2 nanodisc incubations with 2-
arachidonoyl glycerol (2-AG).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Km (µM) 
Vmax  
(pmol/min/nmol)   Vmax / Km 
    
14,15-EET-G 32.6 ± 1.7 265.4 ± 12.3 8.1 ± 0.3 
11,12-EET-G 13.6 ± 1.3 125.5 ± 5.2 9.2 ± 0.2 
 
14,15-EET 8.3 ± 2.0 53.3 ± 2.9 6.4 ± 1.25 
11,12-EET 6.7 ± 1.3 34.8 ± 1.5 5.1 ± 0.4 
8,9-EET 6.2 ± 1.8 8.9 ± 1.1 1.4 ± 0.3 
5,6-EET 12.7 ± 3.8 3.1 ± 0.3 0.2 ± .05  
 
.       
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Substrate 
Metabolite(s)  
Detected 
Bovine          
Microsomes       
pmol min-1 mg-1 
Porcine    
Microsomes      
pmol min-1 mg-1 
AA Total EET (all regio-isomers)  1.8 ± 0.3  2.08 ± 0.02  
 
2-AG 
 
14,15-EET-G         
 
1.1 ± 0.57  
 
1.18 ± 0.55  
 
AEA 14,15-EET-EA         
 
1.96 ± 0.05 
 
2.25 ± 0.07 
 
Table 5.2. Metabolism of AA, 2-AG and AEA by bovine and porcine heart microsomes.  
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 N.D. = not detected 
Table 5.3. Summary of cyanide binding in the presence of fatty acids and ebastine. Substrate 
concentrations were compared to the substrate free sample and significance was attained when p 
< 0.05, p < 0.01 and p < 0.001 and were denoted by *, **, and ***, respectively. 
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CHAPTER VI: CYP2J2 AND ENDOCANNABINOID PATHWAY 
CROSSTALK PRODUCES OMEGA-3 ENDOCANNABINOID EPOXIDES 
 
6.1 ABSTRACT   
  Numerous clinical studies suggest that diets rich in omega-3 (ω-3) fatty acids provide beneficial 
anti-inflammatory effects, in part, through their conversion to bioactive metabolites. In the 
following study, we report on a new class of ω-3 derived metabolites originating from the cross-
talk between endocannabinoid and cytochrome P450 (CYP) epoxygenase metabolic pathways. 
These metabolites share structural similarity to both their endocannabinoid and epoxide parent 
compounds, with potential to exert similar physiological effects. The direct biosynthesis of these 
metabolites was mediated by enzymes of the CYP epoxygenase pathway while their degradation 
was facilitated by soluble epoxide hydrolase (sEH) and fatty acid amide hydrolase (FAAH). The 
presence of these metabolites in rat brain prompted neuroinflammation studies using BV-2 
microglia cells, which showed that the predominant metabolites dose-dependently ameliorated 
pro-inflammatory IL-6 cytokines whilst increasing anti-inflammatory IL-10 cytokines, in part, 
through cannabinoid receptor-2 (CB2) receptor activation. Additional studies revealed that these 
metabolites exerted anti-angiogenic effects in human microvascular endothelial cells (HMVECs), 
vasodilatory properties in bovine coronary arteries and reciprocally regulated platelet aggregation 
in washed human platelets. Taken together, these bifunctional ligands exhibited enhanced 
endocannabinoid properties while retaining their epoxide-like bioactivity.  
 
 
 
 
 
 
 
 
4Submitted for publication as Daniel R. McDougle, Amr A. Abdeen, Josephine E. Watson, Reheman Adili, Megan 
Caputo, John Krapf, Rodney Johnson, Kristopher Kilian, Michael Holinstat and Aditi Das*. Anti-inflammatory 
Omega-3 Endocannabinoid Epoxides. 
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6.2 INTRODUCTION  
  Epidemiological evidence suggests that a diet rich in omega-3 fatty acids (-3 FAs) promotes 
beneficial cardiovascular (1) neurological (2), and anti-inflammatory (3) health effects. However, 
the biochemical mechanism(s) facilitating these effects has yet to be fully elucidated. There is 
mounting evidence to suggest that these actions are mediated through the oxidative and non-
oxidative metabolism of -3 FAs into bioactive metabolites.  
  One of the non-oxidative pathways involves the conversion of -3 FAs into endocannabinoids. 
Endocannabinoids elicit similar effects as Δ9-tetrahydrocannabinol (THC), the active ingredient 
of Cannabis sativa. They play important physiological roles that are primarily exerted through 
activation of the cannabinoid receptors – cannabinoid receptor 1 (CB1) and 2 (CB2) (4, 5). One of 
the well-studied endocannabinoids is an arachidonate (ω-6 FA) derivative known as anandamide 
(AEA) (Figure 6.1). AEA is involved in regulating physiological processes in both the central 
nervous system (CNS) and peripheral tissues (6-8). It was recently reported that the -3 FA, 
docosahexaenoic acid (DHA), can be converted to docosahexaenoic ethanolamide (DHEA) which 
acts as a weak cannabinoid receptor agonist (Figure 6.1) (7, 8). DHEA exhibits anti-cancer (7, 8), 
anti-inflammatory (9) and synaptogenic (10) properties and has been detected in both the brain 
and retina at concentrations comparable to those for AEA (11-13). Another -3 FA, 
eicosapentanoic acid (EPA), is similarly converted to eicosapentanoic ethanolamide (EPEA) 
(Figure 6.1) (14). Notably, dietary supplementation with EPA and DHA resulted in increased 
levels of EPEA and DHEA at the expense of AEA, thereby providing a mechanism for modulation 
of the ω-6 and ω-3 lipidome (15). Overall, the in vivo formation of -3 endocannabinoids – DHEA 
and EPEA motivates a careful characterization of their metabolism in order to better understand 
the complex interrelationships that exist among these lipid metabolism pathways. 
  Endocannabinoids are metabolized by eicosanoid synthesizing enzymes to generate complex 
lipid metabolites with multiple functional groups that tend to exhibit unique biological functions 
(16). There are three broad classes of eicosanoid synthesizing enzymes - the cyclooxygenases 
(COX), lipoxygenases (LOX) and cytochrome P450 epoxygenases (CYP). The CYP epoxygenase 
branch typically generate epoxide lipid metabolites that are anti-inflammatory, anti-nociceptive, 
and anti-hypertensive (17). Previously, we detailed how a specific epoxygenase, CYP2J2, 
converted AEA into AEA epoxides (EET-EAs) (18) (Figure 6.1). Notably, Hollenberg and 
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coworkers demonstrated that the 5,6-EET-EA metabolite selectively binds cannabinoid receptor 2 
(CB2) with 1000-fold greater affinity than cannabinoid receptor 1 (CB1) (19). Recently it was 
shown that DHEA can be converted by enzymes of the LOX pathway to form novel oxygenated 
metabolites with CB2-preferring agonist activity (20). However, there have yet to be any studies 
examining EPEA or DHEA metabolism by the CYP epoxygenases.  
In general, CYP epoxygenases functionalize polyunsaturated FAs olefins with molecular oxygen 
to form an epoxide motif that imparts bioactivity. A physiologically important pathway includes 
the epoxygenation of arachidonic acid (AA), DHA, and EPA into epoxyeicosatrienoic acids 
(EETs), epoxydocosapentaenoic acids (EDPs), and epoxyeicosatetraenoic acids (EEQs), 
respectively (21, 22). Thus we hypothesized that some of the CYP epoxygenases could directly 
utilize DHEA and EPEA as substrates to form novel bioactive oxygenated metabolites with 
potential to modulate the inflammatory response. Moreover, this unexplored pathway would 
provide new insights towards understanding the beneficial health benefits of -3 FAs.   
The present report tests the hypothesis that CYP epoxygenases metabolize DHEA and EPEA to 
form novel -3 endocannabinoids epoxides - EDP-EA and EEQ-EA (Figure 6.1). These 
metabolites are produced as a result of the cross-talk between enzymes in the CYP epoxygenase 
and endocannabinoid metabolic pathways. Herein, we employed a newly developed mass 
spectrometry method to determine the levels of the -3 endocannabinoid epoxides endogenously 
present in various rat tissues. Furthermore we demonstrate that they are naturally produced in 
lipopolysaccharide (LPS) stimulated BV2 microglial cells (resident macrophages in brain). One of 
the primary epoxygenases of the brain and heart, CYP2J2, was expressed, purified and 
incorporated into nanodisc bilayers for metabolism studies. This CYP epoxygenase found to 
directly convert DHEA and EPEA substrates to a diverse range of epoxides. We also explored 
common degradation pathways of these endocannabinoid epoxides by soluble epoxide hydrolase 
(sEH) and fatty acid amide hydrolase (FAAH).  
Besides unraveling the pathway for the formation and degradation of EEQ-EA and EDP-EA, we 
also report the potential biological functions of the -3 endocannabinoid epoxides. These 
metabolites have two functional motifs – “N-acyl ethanolamide of endocannabinoids” and 
“epoxide” that typically function through divergent signaling pathways with many similar 
functional outcomes. Anti-inflammatory effects are common to both motifs and given the presence 
125 
 
of these metabolites in the brain we explored their potential role in a model of neuro-inflammation 
using BV2 microglial cells. Additionally, as these epoxides were widely distributed in the 
periphery and because -3 FA epoxides are known to be vasoactive, we also studied the “epoxide-
like” property of these molecules by measuring vasodilation in bovine coronary artery, 
angiogenesis in human microvascular endothelial cells (HMVECs) and platelet aggregation in 
washed human platelets.   
Taken together, this is the first report of a new class of -3 endocannabinoid epoxides – EDP-EA 
and EEQ-EA in the brain and periphery that are produced through direct epoxygenation by CYP 
epoxygenases that exert both ‘endocannabinoid-like” and “epoxide-like” biological activities. 
Overall, the complete understanding of the biosynthetic pathways and evaluation of some key 
biological activities will provide new insights into disease pathologies linked to the dietary 
consumption of -3 and -6 fatty acids.   
6.3 MATERIALS AND METHODS 
  Tissue Cell Culture Materials. Dr. Robert H. McCusker Jr. (University of Illinois at Urbana-
Champaign) generously provided the BV-2 cell line originally created by Blasi et. al.(23). Primary 
human microvascular endothelial cells (HMVEC) were purchased from cell systems (Certificate 
#CSC 2M1).  Complete serum containing medium kit was purchased from cell systems (Cat. #4Z0-
500). Fetal bovine serum (cat. #16140-071) and DMEM (cat. 10-013-CV) were obtained from 
Gibco. Pertussis toxin (cat. #181) was purchased from List Bio Labs. AM630 (cat. #10006974), 
rimonabant (cat. #9000484), GW9962 (cat. #70785), LY294002 (cat. #70920), HA-100 (cat. 
#14955), AMG9810 (cat. #14715), ruthenium red (cat. #14339), wortmannin (cat. #10010591) 
were procured from Cayman Chemical.  
  Animal Materials. Fresh bovine hearts were obtained on ice from the local slaughterhouse at 
time of slaughter. Fresh whole female porcine brains and hearts were obtained from the UIUC 
meat sciences laboratory.  At the time of sacrifice, male Sprague-Dawley (250-300 gm) rat 
carcasses were obtained from the Division of Animal Resource facility (University of Illinois at 
Urbana-Champaign) and immediately dissected for brain, heart, kidneys, spleen and livers organs. 
  Other Chemical and Reagents Materials. Technical grade meta-chloroperoxybenzoic acid (Cat 
#273031) and dichloromethane was obtained from Sigma-Aldrich. Eicosapentaenoic acid (EPA) 
and docosahexaenoic acid (DHA) used for synthesis were purchased from Nu-Chek Prep Inc 
(Elysian, MN). 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) HCl was purchased from 
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Thermo Scientific (catalog #22980). N-hydroxysuccinimide (NHS) was purchase from Acros 
Organics (catalog #157270250). NADPH was obtained from P212121 (Ann Arbor, MI). POPC 
[1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphocholine],1-palmitoyl-2-oleoyl-sn-
glycero-3-phosphocholine], POPS [1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phospho-l 
serine] were purchased from Avanti Polar Lipids (Alabaster, AL). 19,20-EDP, 16,17-EDP, 17,18-
EEQ, 14,15-EEQ, 11,12-EEQ, 8,9-EEQ, 5,6-EEQ and 14,15-EET were obtained from Cayman 
Chemical (Ann Arbor, MI). The antioxidant butylated hydroxytoluene (BHT) and was obtained 
from Sigma-Aldrich (St. Louis, MO). PAR4-AP (AYPGKF) was purchased from GL Biochem 
(Shanghai, China). Thrombin was purchased from Enzyme Research Laboratories (South Bend, 
IN), Collagen, ristocetin was purchased from Chorono LOG. ADP was purchased from Sigma. All 
other materials and reagents used were purchased from Sigma-Aldrich and Fisher Scientific. 
  Chemical synthesis of EEQ-EA and EDP-EA regioisomers. EEQ-EA and EDP-EA chemical 
synthesis was performed using a two-step synthesis. For non-specific epoxygenation reaction, 10 
mg of either EPA or DHA was dissolved in 2 mL of dichloromethane (DCM) with 2 molar 
equivalents of mCPBA and reacted for 1 hour. The reaction was stopped with an equal volume of 
10% aqueous NaHCO3 for removal of mCPBA from the organic layer and the aqueous layer was 
re-extracted with equal volumes of DCM (3x) and dried under vacuum. Purification was achieved 
using normal phase high-performance liquid chromatography (NP-HPLC) using a Zorbax-NH2 5 
µm 9.4 x 250 mm semi-preparative column (Agilent, PN880952-208) with an isocratic gradient 
(hexane/methanol/acetic acid; 90:10:0.1) coupled to a high-performance liquid chromatography 
(HPLC) system (Figure 6.13A-B). In the instances of co-eluting regioisomers of DHA epoxides 
(19,20-EDP and 13,14-EDP) and EPA epoxides (17,18-EEQ and 11,12-EEQ), the mixtures were 
further purified on the same system using a reversed phase high-performance liquid 
chromatography (RP-HPLC), Sun Fire Prep C18 5 µm 19 x 50 mm (Waters, PN 186002566) and 
a mobile system composed of solvent A (H20/acetonitrile/acetic acid 95:5:0.1) and solvent B 
(H20/acetonitrile/acetic acid 5:95:0.1) and a linear gradient from 50% A to 0% A in 50 minutes 
(Figure 6.13C-D). The synthesis of 17,18-EEQ, 14,15-EEQ, 11,12-EEQ, 8,9-EEQ, 5,6-EEQ, 
19,20-EDP and 16,17-EDP was confirmed by comparing retention times relative to authentic 
standards purchased from Cayman Chemical and high resolution mass spectrometry.  
  In the second step, the coupling of each respective EEQ or EDP regioisomer to ethanolamine was 
achieved by dissolving the epoxide/EDC/NHS/ethanolamine in acetonitrile in 1:10:10:10 ratio and 
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rocking at room temperature for 16 hours. Lastly, the resulting EEQ-EA and EDP-EA regioisomers 
were purified by RP-HPLC using a Sun Fire Prep C18 5 µm 19 x 50 mm column (Waters, PN 
186002566). Purity and retention times were assessed using bioanalytical RP-HPLC and 
successful synthesis was confirmed by high resolution mass spectroscopy and proton nuclear 
magnetic resonance (Figure 6.14).  
Synthesis of 17,18-DiHETE-EA and 19,20-DiHDPA-EA authentic standards. The EPA and 
DHA terminal epoxides, 17,18-EEQ and 19,20-EDP, were synthesized and purified as described 
above. The conversion of 17,18-EEQ and 19,20-EDP (100 ug) to the corresponding diol was 
accomplished by first solubilizing the standard in 100 uL acetonitrile and adding 1 mL of glacial 
acetic acid and water (1:1). The hydration of the epoxide to the diol moiety was accomplished by 
purging the reaction with N2 and incubating the reaction at 45°C for 12 hours. The resulting diols 
were extracted with ethyl acetate and purified by RP-HPLC. The ethanolamide coupling was 
performed with the same conditions as the epoxides as listed above. Successful synthesis of the 
standards was confirmed by high resolution mass spectrometry and RP-HPLC elution times. 
  Expression and purification of cytochrome P450 reductase. Cytochrome P450 reductase 
(CPR) from Ratticus norvegicus was expressed and purified as previously described (24).  
  Liquid chromatography mass spectrometry analysis. Samples were analyzed with the 5500 
QTRAP LC/MS/MS system (AB Sciex, Foster City, CA) in Metabolomics Lab of Roy J. Carver 
Biotechnology Center, University of Illinois at Urbana-Champaign.  Software Analyst 1.6.2 was 
used for data acquisition and analysis.  The 1200 series HPLC system (Agilent Technologies, 
Santa Clara, CA) includes a degasser, an autosampler, and a binary pump.  The LC separation was 
performed on an Agilent Eclipse XDB-C18 (4.6 x 150mm, 5μm) with mobile phase A (0.1% 
formic acid in water) and mobile phase B (0.1% formic acid in acetontrile). The flow rate was 0.4 
mL/min. The linear gradient was as follows: 0-2min, 90%A; 8min, 55%A; 13-25min, 40%A; 
30min, 30%A; 35min, 25%A; 40-47min, 20%A; 47.5-54min, 90%A. The autosampler was set at 
5°C. The injection volume was 10 μL. Positive mass spectra were acquired with the ion spray 
voltage of 5500 V under electrospray ionization (ESI). The source temperature was 450°C. The 
curtain gas, ion source gas 1, and ion source gas 2 were 32 psi, 60 psi, and 60 psi, 
respectively.  Multiple reaction monitoring (MRM) was used for quantitation: 19,20-EDP-EA and 
7,8-EDP-EA m/z 388.1  m/z 62.1; 16,17-EDP-EA, 13,14-EDP-EA, and 10,11-EDP-EA m/z 
388.1  m/z 370.1; 17/18-EEQ-EA, 14/15-EEQ-EA, and 11/12-EEQ-EA m/z 362.1  m/z 344.1; 
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8/9-EEQ-EA m/z 362.1  m/z 62.0; 5/6-EEQ-EA m/z 362.1  m/z 91.0; EPEA 346.3  m/z 
62.1; DHEA 372.4  m/z 62.1; Anandamide m/z 348.3  m/z 62.1.  Internal standards were 
monitored at: m/z 350.3  m/z 66.1 for EPEA-d4, m/z 376.4  m/z 66.1 for DHEA-d4; m/z 
352.3  m/z 66.1 for anadamide-d4, m/z 372.1  m/z 354.1 for 14/15-EET-EA-d8.   
  LC-MS/MS method for quantitation of 17,18-DiHETE-EA and 19,20-DiHDPA-EA. 
Samples were analyzed with the 5500 QTRAP LC/MS/MS system (AB Sciex, Foster City, CA) in 
Metabolomics Lab of Roy J. Carver Biotechnology Center, University of Illinois at Urbana-
Champaign.  Software Analyst 1.6.2 was used for data acquisition and analysis.  The 1200 series 
HPLC system (Agilent Technologies, Santa Clara, CA) includes a degasser, an autosampler, and 
a binary pump.  The LC separation was performed on an Agilent Eclipse XDB-C18 (4.6 x 150mm, 
5μm) with mobile phase A (0.1% formic acid in water) and mobile phase B (0.1% formic acid in 
acetontrile). The flow rate was 0.4 mL/min. The linear gradient was as follows: 0-2min, 90%A; 
8min, 60%A; 15-22min, 40%A; 23-29min, 90%A. The autosampler was set at 10°C. The injection 
volume was 1 μL. Positive mass spectra were acquired with the ion spray voltage of 5000 V 
under electrospray ionization (ESI). The source temperature was 450 °C. The curtain gas, ion 
source gas 1, and ion source gas 2 were 32 psi, 60 psi, and 55 psi, respectively.  Multiple reaction 
monitoring (MRM) was used for quantitation: 19,20-DHDPA-EA m/z 406.3m/z 370.3; 17,18-
DHETE-EA m/z 380.3m/z 344.3.  Internal standard 14,15-DHET-EA was monitored at m/z 
382.3 m/z 346.3.     
  Extraction of AEA, EPEA, DHEA, EEQ-EA and EDP-EAs from rat tissue. The tissue 
extractions of AEA, DHEA, EPEA, EEQ-EAs and EDP-EAs were performed similarly as 
previously reported for the quantitative analysis of the EDCs (25, 26). Following Sprague-Dawley 
euthanasia, whole organs were immediately dissected, pooled (n = 3/pool), weighed and 
mechanically homogenized on ice with a Bio-homogenizer (Biospec, Bartlesville, OK) in a 1:1 
ratio with PBS supplemented with AUDA (30 µm) and PMSF (1 mM) until a homogenous slurry 
was formed. The equivalent of 1 gram of each tissue was homogenized in 40 mL of ethyl 
acetate/hexane (9:1) with a Bio-homogenizer (Biospec, Bartlesville, OK) at room temperature and 
then sonicated for 1 min. The resulting solution was washed with a 30% volume of water and 
centrifuged for layer separation. The organic layer was removed and the aqueous layer was 
extracted twice with an equal volume of ethyl acetate/hexane (9:1). The pooled organic supernatant 
was removed using a Buchi 120 rotary evaporator (New Castle, DE), reconstituted in 1 mL of 
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chloroform and the metabolites of interest were isolated by solid-phase extraction (SPE) using a 1 
mL silica gel column (Sigma # 214477). The reconstituted samples were added to the pre-
conditioned silica column, washed 3 column volumes of chloroform and then eluted with 4 column 
volumes of methanol/chloroform (1:9). The eluent was dried and samples were reconstituted in 
ethanol for analysis via LC-MS-MS.  
To validate the method, the metabolite extraction linearity was examined for each class of lipids 
from homogenized rat brain tissue.  The metabolites 17,18-EEQ-EA, 19,20-EDP-EA, DHEA, 
EPEA and AEA were spiked at 20, 60 and 300 ng into homogenized rat brain tissue and extracted 
as described above. The average percent recovery was calculated by subtracting a non-spiked 
sample of each metabolite for comparison to authentic standards at low, middle and high levels on 
the standard curve. Extraction linearity for 20, 60 and 300 ng of all metabolites (17,18-EEQ-EA, 
19,20-EDP-EA, DHEA, EPEA and AEA) were similar among lipids with average percent 
recoveries of 89.1 ± 3.1, 84.8 ± 2.8, and 71.5 ± 4.5 %, respectively.   
  Whole-cell metabolism assays. BV-2 microglial cells were seeded in 6-well dishes (5 x 
105/well) and grown to 90% confluence in DMEM (Gibco, USA), 10% fetal bovine serum (Gibco, 
USA), penicillin (100 U/mL) and streptomycin (0.1 mg/mL) at 37°C and 5% CO2. At the time of 
the experiment the supernatant was replaced with serum free media and cells were activated with 
100 ng/mL of LPS for 12 hrs. In one set of experiments the supernatant and cells were collected 
at 1, 2, 4, 8, and 12 hours post-LPS stimulation and examined for the natural production of target 
lipid mediators. Alternatively, after the 12 hour LPS activation, cells were incubated with either 
EPEA (20 µM) or DHEA (20 µM) in serum free media for 30 minutes. The general P450 inhibitor, 
ketoconazole (0.5 µM) was added in some experiments for CYP inhibition of the CYP3A, CYP2C 
and CYP2J families. Controls lacking LPS stimulation were run in parallel with the experiment. 
After the appropriate time-period, cells were scraped and the supernatant was collected and 
subjected to three rapid freeze-thaw cycles using liquid N2 and a warm water bath (37°C) for cell 
lysis. The supernatant and cells were extracted three-times with 4 volumes of ethyl acetate/hexane 
(9:1).   
  Incubations of EPEA and DHEA with brain microsomes. The preparation of microsomes 
derived from mouse tissues was achieved using previously described differential centrifugation 
methods(18). Tissues were dissected from Sprague-Dawley rats, weighed, homogenized and 
diluted to 20% (w/v) using a buffer containing 250 mM sucrose, 10 mM Tris-Cl (pH 7.5), 1 mM 
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PMSF and a protease inhibitor cocktail for mammalian tissue extraction (Nacalai Tesque #25955-
11). A series of low (3000g) and medium speed (10,000g) centrifugation speeds were employed 
to remove cellular debris, nuclear and mitochondrial fractions. The resulting supernatant is 
centrifuged at 100,000 g for 90 min at 4°C to pellet the endoplasmic reticulum containing CYPs. 
The cell pellet was re-suspended in 50mM Tris (pH 7.5), 1mM DTT, 1mM EDTA and 20% 
glycerol with a Teflon homogenizer. Microsomal protein content was measured using a BCA assay 
kit (Thermo Fisher Scientific, Product No. 23233). Incubations with microsomes were performed 
at a concentration of 1 mg/ml of microsomes with high concentrations of DHEA and EPEA and 
then extracted using three volumes of ethyl acetate/hexane (9:1) three times. The organic layer was 
dried under vacuum and reconstituted in ice cold ethanol for LC-MS/MS analysis.  
  CYP2J2-ND kinetic metabolism of EPEA and DHEA. Human CYP2J2 was heterologously 
expressed and incorporated into the lipid bilayers of nanodiscs as previously described (24). 
Incubation mixtures contained CYP2J2-ND (0.2 µM), CPR (0.6 µM), BHT (0.1%) and 
incremental increases of either EPEA or DHEA (500 µl total volume) in 100 mM phosphate buffer 
(pH 7.4). Samples were equilibrated at 37°C for 5 minutes before the reaction was initiated with 
the addition of 0.5 mM NADPH. Reactions were stopped after 15 minutes, extracted three times 
with 1 mL of ethyl acetate and the organic layer was dried and reconstituted in ice cold ethanol for 
LC-MS/MS analysis.  
  Kinetic analysis of 17,18-EEQ-EA and 19,20-EDP-EA hydrolysis by soluble epoxide 
hydrolase. LC-MS/MS was performed to quantitate the conversion of the terminal epoxide to their 
vicinal diols using LC-MS/MS. Enzymatic linearity over a 10 min period was confirmed. Enzyme 
kinetics were estimated using incremental increases of substrate for the generation of kinetic 
curves that were fit to the Michaelis-Menten equation for calculation of Vmax and Km. Incubations 
were performed with recombinant sEH ([E] final = 6 nM) in NaPO4 (100 mM, pH 7.4), bovine serum 
albumin (0.1 mg/ml) and substrate (17,18-EEQ-EA or 19,20-EDP-EA) at 37°C. After 5 minutes 
the reaction was stopped with methanol supplemented with AUDA (0.5 µM) and the solution was 
centrifuged to pellet protein (10,000 g x 10 min). The supernatant was collected and analyzed via 
LC-MS/MS.   
  PRESTO-Tango β-arrestin recruitment assay. Functional CB1 and CB2 assays were 
performed by the NIMH PDSP as previously described (27). In short, each metabolite was 
screened in triplicate at 10 µM in transiently transfected CB1/CB2 HEK293 cells for their ability 
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to functionally activate each respective receptor. Results reflect the percent receptor activation 
relative to CP55940 EC90. 
  Microglial neuroinflammation studies. BV2 microglial cells were plated in 24-well dishes (2 
x 105/well) and grown to 80-90% confluence in DMEM (Gibco, USA), 10% fetal bovine serum 
(Gibco, USA) penicillin (100 U/mL) and streptomycin (0.1 mg/mL) at 37°C and 5% CO2. At the 
time of the experiment, media was replaced with serum-free media and the cells were pre-treated 
with 19,20-EDP-EA for 4 hours prior to stimulation with 25 ng/mL LPS (Sigma-Aldrich, USA). 
Media was collected at 24 hours and the production of nitric oxide (NO) was determined by 
evaluating the media nitrite (NO2
-) content using the Griess method. Collected media (80 µL) was 
mixed with Griess reagent A (Cayman Chem, #780018) and Griess reagent B (Cayman Chem, 
#780020) and the absorbance at 490 nm was used to quantify NO2
- production using a standard 
curve. Media supernatant was also examined for the production of IL-6 (Cayman, #583371) and 
IL-10 (affymetrix eBioscience, #88-7105-22) cytokines. Compound cytotoxicity was assessed by 
measuring lactate dehydrogenase (LDH) release in the media using a commercially available kit 
(Cayman Chem, #601170).  
  Platelet aggregation studies. University of Michigan Review Board approved studies and 
written informed consent was obtained from all participants prior to blood collection. Human 
whole blood was drawn from the antecubital vein of healthy donors. Platelet- rich-plasma (PRP) 
was obtained from whole blood by centrifugation at 200g for 10 minutes. Platelets were pelleted 
from PRP in the presence of ACD (2.5%) and apyrase (0.02 U/mL) by centrifugation at 2000g for 
10 minutes then resuspended in Tyrodes buffer (12 mM NaHCO3, 127 mM NaCl, 5 mM KCl, 0.5 
mM NaH2PO4, 1 mM MgCl2, 5 mM glucose, 10 mM HEPES) to a final concentration of 3.0 x 10
8 
platelets/mL. Change in light transmission was recorded by eight channel platelet aggregometer 
(Chronolog) under stirring at 1200 rpm at 37°C. 
Washed human platelets were incubated with 12.5 µM, 25 µM, and 50 µM 17,18-EEQ-EA for 5 
min and platelet aggregation was induced by 5 µM AA, Thrombin (1 nM), PAR4-AP (50µM), 
collagen (2mg/mL) U46619 (1 µM). DMSO and 14,15 EET were used as controls. No platelet 
agonists were added for the tests of 19, 20-EDP-EA in washed platelets. Experiments with platelet 
rich plasma (PRP) were adjusted to 3.0 x 108 platelets/mL using PPP from same donor. PRP was 
incubated with 12.5 µM, 25 µM, and 50 µM 17,18-EEQ EA for 5 min and platelet aggregation 
was induced by ADP (1 µM ), collagen (2 µg/mL) or ristocetin (1 mg/mL). 
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  Bovine coronary artery vasodilation assay. Fresh bovine hearts were procured on ice from the 
local butcher. The left anterior coronary artery was dissected from the adjacent connective tissue 
and cut into 2 mm ring sections. The artery lumen was then mounted on two parallel pins attached 
to a piezoelectric transducer for isometric tension measurements using a Myograph Tissue Bath 
System (DMT, Ann Arbor, MI) as previously described(28). Basal tension (100% relaxation) was 
set at 30 mN and tissues were equilibrated in Krebs Buffer (130 mM NaCl, 4.7 mM KCl, 1.18 mM 
KH2PO4, 1.17 mM MgSO4, 14.9 mM NaHCO3, 5.5 mM dextrose, 0.026 mM EDTA, 1.6 mM 
CaCl2) for 1 hr. Maximal contractions were determined by washing with Krebs buffer 
supplemented with 60 mM KCl for 3 min, and then washed with Krebs Buffer to return to basal 
tension. This step was repeated until consistent contractile measurements were achieved. The 
thromboxane receptor agonist U46619 (20-40 nM) was used to constrict the rings to approximately 
40-80% of maximal contraction (0% relaxation). Cumulative additions of either EEQ, EDP, EEQ-
EA and EDP-EA (1 nM, 10 nM, 100 nM, 1 µM, 10 µM) were added to each chamber and the 
resulting % relaxation was plotted against the corresponding substrate dose. 
  Inhibition of human microvascular cell tube formation. The EEQ, EEQ-EA, EDP, and EDP-
EA inhibition of vascular endothelial cell growth factor (VEGF) promoted tube formation was 
assessed in human microvascular endothelial cells (HMVEC, Cell Systems) as previously 
described(29).  Briefly, 35 µl of matrigel are plated on the bottom of a 48 well plate and allowed 
to gel for 30 minutes at 37ºC. ~15,000 HMVECs are then seeded per well in EBM-2 media (Lonza) 
Supplemented with VEGF at 50% of the concentration used in EGM-2. After adding the 
compounds at the desired concentration, tube formation by HMVECs was quantified after 8 hours. 
Cells were imaged using a Cannon Rebel DSLR camera and tube area was quantified using ImageJ. 
  LC-ESI-MS for global analysis of CYP2J2-ND incubations with EPEA and DHEA. The 
reactions containing CYP2J2, CPR and NADPH with either EPEA or DHEA were resolved using 
a XTerra C18 column 2.1 × 150 mm, 3.5 µM (Waters), and a Waters Alliance 2695 reversed-phase 
high performance liquid chromatography (HPLC) coupled to an electrospray ionization (ESI) 
source. The different regioisomers were separated with mobile phase A (acetonitrile/H2O/formic 
acid, 95:5:0.1) and mobile phase B (acetonitrile/H2O/formic acid, 5:95:0.1) over a linear gradient 
as follows: 0–1 minute, 40% B; 41 minutes, 80% A; 42 minutes, 100% B; and then returned to 
initial conditions. For ESI, a Q-TOF Ultima time-of-flight mass spectrometer was used in positive 
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ion mode, with a spray voltage of 4.5 V and capillary temperature of 200°C. The mass and elution 
times of the metabolites were confirmed using authentic standards synthesized in-house.  
  17,18-EEQ-EA and 19,20-EDP-EA hydrolysis by rat forebrain membranes containing 
FAAH. The preparation of rat forebrain membranes were achieved using dounce homogenization 
in buffer (50 mM Tris pH 7.4, 1 mM EDTA and 3 mM MgCl2) and membrane pelleting as 
previously described (30). Incubations contained 100 µg forebrain protein in a 0.5 mL reaction 
containing 50 mM Tris (pH 7.4), 1 mM EDTA, 3 mM MgCl2, and 17,18-EEQ-EA or 19,20-EDP-
EA at 50 µM. Linearity of the reactions were confirmed at 5, 20 and 40 minutes. Reactions were 
quenched with methanol containing 1 mM PMSF and centrifuged to pellet protein (10,000 g x 10 
min). The supernatant was collected and analyzed via LC-MS/MS as outlined below.    
  LC-MS/MS method for quantitation of 17,18-EEQ and 19,20-EDP. Analyses were performed 
using the 5500 QTRAP LC/MS/MS system (AB Sciex, Foster City, CA) in Metabolomics Lab of 
Roy J. Carver Biotechnology Center, University of Illinois at Urbana-Champaign.  The 1200 series 
HPLC system (Agilent Technologies, Santa Clara, CA) includes a degasser, an autosampler, and 
a binary pump, and this system was used to separate the metabolites. LC separation was performed 
on an Agilent Eclipse XDB-C18 (4.6 x 150mm, 5μm) with mobile phase A (0.1% formic acid in 
water) and mobile phase B (0.1% formic acid in acetonitrile) at a flow rate was 0.4 mL/min. The 
linear gradient was as follows: 0-2min, 90%A; 8min, 55%A; 13-25min, 40%A; 30min, 30%A; 
35min, 25%A; 40min, 20%A; 45-47min, 15%A; 48-54min, 90%A. The autosampler was set at 
5°C. The injection volume was 10 μL. Negative mass spectra were acquired with the ion spray 
voltage of -4500 V under electrospray ionization (ESI). The source temperature was 450 °C. The 
curtain gas, ion source gas 1, and ion source gas 2 were 32 psi, 50 psi, and 55 psi, 
respectively.  Multiple reaction monitoring (MRM) was used for quantitation: 17,18-EEQ m/z 
317.0  m/z 299.0 and 19,20-EDP m/z 343.0  m/z 299.0 using 14,15-EET as the internal 
standard.  
  Primary microglia neuroinflammation studies. Primary microglia cultures were isolated from 
freshly euthanized piglets following previously described methods (31). Isolated microglia cells 
were plated at 2 x 106 in 24-well plates and allowed to adhere for 3 hrs before a 1 hour compound  
pre-incubation step followed by stimulation with LPS (10 ng/mL) for 12 hours in presence or 
absence of compound. Supernatant was analyzed for IL-6 content using a porcine specific ELISA 
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(R&D Systems Inc., Minneapolis, USA cat #P6000B). The final vehicle (DMSO) concentration 
was 0.04% (n = 3 or greater).  
  Statistics. Results are presented as average ± standard error unless noted otherwise. Kinetic 
parameters were determined by nonlinear regression of the Michaelis-Menten equation using 
Origin Pro 8.6. Data were analyzed for statistical significance using a two-sided student’s t-test 
where *P < 0.05, **P < 0.01, and ***P < 0.001. 
6.4 RESULTS 
  The -3 endocannabinoid epoxides are endogenous lipids in the brain and peripheral tissues. 
Previously, a wide range of N-acyl amide lipids have been successfully quantified using HPLC 
coupled with fluorescence detection (32), GC-MS (33), LC-MS (34), and Ag+ coordination LC-
MS/MS in selected reaction monitoring (SRM) mode (35). As shown in Figure 6.2A, a new LC-
MS/MS in multiple reaction monitoring mode (MRM) was developed to structurally identify and 
quantitate EDP-EA regioisomers (19,20-, 16,17-, 13,14-, 10,11-, and 7,8-), EEQ-EA regioisomers 
(17,18-, 14,15-, 11,12-, 8,9-, and 5,6-), EPEA, DHEA, and AEA. The authentic standards of EEQ-
EA and EDP-EA regioisomers were prepared in a two-step synthesis and purified using HPLC as 
reported in the methods section.  
  The target endocannabinoid metabolites were extracted from the tissues using a two-step 
extraction method followed by LC-MS/MS (25). To estimate the basal levels of the endogenous 
EEQ-EA and EDP-EA regioisomers, three sets of pooled (n = 3) Sprague-Dawley rat brain, spleen, 
heart, liver, and kidneys were extracted and analyzed. As shown in Figure 6.2B, both classes of 
EEQ-EA and EDP-EA metabolites were measured in rat brain, with the two terminal epoxides, 
17,18-EEQ-EA and 19,20-EDP-EA being the predominant metabolites. A similar trend was also 
observed in peripheral organs with both classes of metabolites being found in all the tissues (Figure 
6.2C; Table 6.1). Specifically, the values of 17,18-EEQ-EA were relatively consistent among 
tissues from brain, spleen, heart, liver, and kidney with levels varying from 60-90 pmol gram-1, 
whereas the values of 19,20-EDP-EA were more variable with brain, spleen, heart, liver, and 
kidney levels measured at 70-400 pmol gram-1 (Figure 6.2C and Table 6.1).  
  Notably, similar levels of DHEA were extracted from tissues, which were generally comparable 
to the levels of 19,20-EDP-EA and AEA. Conversely, relatively low levels of EPEA parent 
compound were detected, with levels significantly lower than the corresponding 17,18-EEQ-EA. 
Importantly, the relatively higher levels of DHEA and lower EPEA levels are consistent with what 
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is reported in the literature lending credibility to the quantitative values (9). Some of the 
metabolites were also detected at lower levels in porcine brains and pooled human plasma (Table 
6.1). The detection of the -3 endocannabinoid epoxides warranted further investigation with 
regards to their production in live cells.  
  EEQ-EA and EDP-EA are naturally produced by LPS stimulated BV-2 microglial cells. 
Microglial cells are metabolically active brain macrophages that continuously survey the brain 
parenchyma and maintain homeostasis.  If microglia encounter harmful endogenous ligands and 
microbes, they display pro-inflammatory activity followed by anti-inflammatory activity to 
promote defense and healing, respectively. Previously, it was demonstrated that activation of BV-
2 microglia resulted in upregulation of AEA metabolizing CYPs which produced EET-EA 
regioisomers when supplemented with AEA (19). Given the endogenous presence of EPEA and 
DHEA in the brain (Figure 6.2B), we explored metabolite production by quiescent and activated 
BV-2 microglial cells in a post-LPS stimulated time-course. As shown in Table 6.2, both EEQ-EA 
and EDP-EA metabolites are naturally produced at 1 hour after LPS stimulation and persist 
throughout a 12 hour period. Similar results were observed for EPEA and AEA at 4 hours, with 
levels more than an order of magnitude greater than the epoxides at 12 hours. While DHEA levels 
time-dependently increased from 1-4 hours, they diminished at 12 hours.  
  To test whether activated BV-2 microglial cells could directly convert the EPEA and DHEA 
parent compounds into EEQ-EA and EDP-EA metabolites, we used cell media supplemented with 
either EPEA or DHEA for 30 min and analyzed for metabolite production. As shown in Figures 
6.2D and 6.2E, EPEA and DHEA were rapidly converted to all EEQ-EA and EDP-EA 
regioisomers, respectively. Total levels of EEQ-EAs were approximately one order of magnitude 
greater than EDP-EAs. Importantly, the production of both the EEQ-EA and EDP-EA metabolites 
was reduced when cells were pre-incubated with the CYP inhibitor ketoconazole (0.5 µM), thus 
showing that the -3 endocannabinoid epoxides are produced enzymatically via involvement of 
CYP epoxygenase enzymes.  
  Epoxygenation of EPEA and DHEA by rat brain microsomes. To evaluate the ability of the rat 
brain CYPs to directly epoxygenate EPEA and DHEA, we performed metabolism studies where 
we incubated rat brain microsomes with substrate in the presence of the CYP redox partner, 
cytochrome P450 reductase (CPR), and NADPH. As shown in Figure 6.3A, when EPEA was 
utilized as substrate, the microsomal CYP epoxygenases produced all EEQ-EA regioisomers, with 
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catalytic preference for the terminal olefin (17,18-EEQ-EA) which accounted for 46% of the total 
epoxide product. Similarly, when DHEA was used in the reactions, epoxygenases produced all the 
EDP-EA regioisomers, with preference for the terminal olefin (19,20-EDP-EA), which accounted 
for 48% of total epoxide formed (Figure 6.3B). In an effort to understand the substrate specificity 
and regioselectivity when both substrates are present, we performed rat brain microsomal 
incubations in the presence of equimolar amounts of EPEA and DHEA (Figure 6.3C). Notably, 
there was some evidence of competition between EPEA and DHEA as the total EEQ-EA and EDP-
EA products were reduced in this reaction. Similar results were obtained when pig brain 
microsomes were used to study metabolism of DHEA and EPEA (Figure 6.6). Taken together, this 
suggests that similar CYP epoxygenases are implicated in the metabolism of both DHEA and 
EPEA and there is competition for the substrates among the various CYP isoforms in rat brain 
microsomes. Microsomes contain various CYP epoxygenase enzymes; therefore it is important to 
identify which isoform is responsible for the formation of these metabolites in human.  
  Recombinant human CYP2J2 incorporated into nanodiscs directly epoxygenates EPEA and 
DHEA to form EEQ-EA and EDP-EA metabolites. In humans, the epoxygenase pathway is 
predominantly mediated by CYP2C8, CYP2C9, and CYP2J2. Notably, these isozymes were 
previously shown to convert both EPA and DHA into EEQ and EDP monoepoxides, respectively 
(36). Previously we showed that the -6 endocannabinoids, AEA and 2-arachidonoylglycerol, are 
converted into their corresponding epoxides by CYP2J2 epoxygenase, the most highly expressed 
CYP epoxygenase in brain and cardiovascular system (18, 37).  
  CYP2J2 was recombinantly expressed and incorporated with its redox partner into nanodiscs 
(18). CYP2J2-CPR-nanodisc incubations with EPEA or DHEA linearly produced EEQ-EA and 
EDP-EA regioisomers for 30 minutes (data not shown). Kinetic curves of metabolism were 
generated for both EPEA and DHEA and were fit to Michaelis-Menten kinetics. As shown in 
Figure 6.3D, CYP2J2-ND metabolism of EPEA into EEQ-EA regioisomers followed Michaelis-
Menten kinetics with Vmax, Km and Vmax/Km values listed in the top right table.  Notably, 
CYP2J2 demonstrated a preference for the EPEA (80 µM) terminal olefin with the average 
regioselectivity of the different regioisomers reported in figure 6.3D; top middle. CYP2J2-ND 
metabolism of DHEA produced EDP-EA regioisomers following Michaelis-Menten kinetics with 
Vmax, Km and Vmax/Km listed in the adjacent table (Figure 6.3D; bottom right). The CYP2J2 
enzyme demonstrated a dramatic preference for the DHEA (80 µM) terminal olefin with the 
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average regioselectivity the regioisomers reported in Figure 6.3D; bottom middle. Therefore we 
demonstrate that CYP2J2 can metabolize EPEA and DHEA with substantially higher efficiency 
than the reported rates for EPA or DHA (36). As the terminal epoxides 17,18-EEQ-EA and 19,20-
EDP-EA were predominantly produced by the CYP enzymes, further characterization and 
biological activity was measured using these epoxides.  
  Hydrolysis of 17,18-EEQ-EA and 19,20-EDP-EA by soluble epoxide hydrolase and fatty acid amide 
hydrolase (FAAH). The EEQ-EA and EDP-EA metabolites are unique in that they contain both 
epoxide and ethanolamide motifs (Figure 6.1). Therefore we next evaluated if these metabolites 
are targets for both soluble epoxide hydrolase (sEH) and fatty acid amide hydrolase (FAAH). 
Bioactive fatty acid epoxides are short-lived lipid mediators due to their rapid inactivation by 
soluble epoxide hydrolase (sEH) in vivo. Previous studies have shown that EEQ and EDP are 
hydrolyzed to their less active di-hydroxy metabolites by sEH (38). To determine if sEH 
hydrolyzes 17,18-EEQ-EA and 19,20-EDP-EA into their corresponding vicinal diols 17,18-
DiHETE-EA and 19,20-DiHDPA-EA (Figure 6.3E), we developed a new LC-MS/MS method for 
quantitation of  the diols. Incubations containing 17,18-EEQ-EA or 19,20-EDP-EA with sEH were 
performed. Enzyme kinetics were estimated and fitted to the Michaelis-Menten equation. As 
shown in Figure 6.3F, 17,18-EEQ-EA was rapidly hydrolyzed with Vmax/Km value of 77.7 ± 1.9 
nmol min-1 mg-1 of sEH (Figure 6.3F). Interestingly, the metabolism of 19,20-EDP-EA was 
substantially slower with Vmax/Km value of 12.3 ± 0.2 nmol min
-1 mg-1 of sEH (Figure 6.3G).  
  In separate studies, 17,18-EEQ-EA hydrolysis to 17,18-EEQ by rat forebrains containing FAAH 
was measured approximately three-fold faster than 19,20-EDP-EA conversion to 19,20-EDP 
(Figure 6.8). Taken together, we show that both 17,18-EEQ-EA and 19,20-EDP-EA are efficiently 
hydrolyzed by human sEH and FAAH with preference for 17,18-EEQ-EA metabolite.  
  Anti-inflammatory signaling actions of 17,18-EEQ-EA and 19,20-EDP-EA. One of the striking 
hallmarks of ongoing inflammation in neurodegenerative diseases is chronic microglial activation 
(macrophages in the CNS) (39). There is a wide interest in unearthing lipid metabolites that can 
reduce microglial activation and thereby combat neuroinflammation. Several studies indicate that 
the endocannabinoids reduce microglial-promoted neuroinflammation through activation of the 
CB2 receptor. Consequently, there is a strong interest in search for the discovery of 
endocannabinoid derivatives that are CB2 selective agonists as means to mitigate inflammatory 
pathologies (40-42). The 17,18-EEQ-EA and 19,20-EDP-EA metabolites have “N-acyl 
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ethanolamide endocannabinoid” functional motif and are also produced endogenously by activated 
BV-2 microglia cells (Figure 6.2D-E; Table 6.2). Hence we examined the anti-inflammatory 
effects of these molecules using LPS stimulated microglial cells.  
  As shown in Figure 6.4A, 17,18-EEQ-EA dose-dependently decreased LPS-induced production 
of IL-6 and nitrite, whilst decreasing LPS-induced cytotoxicity in BV-2 cells, further 
demonstrating nullification of the pro-inflammatory effects (43). We also observed significant 
production of the anti-inflammatory cytokine IL-10 (Figure 6.4A). More potent dose-dependent 
inhibition was measured when 19,20-EDP-EA was employed, as evidenced by significant 
inhibition of IL-6 and nitrite production at concentrations equal or greater than 2.5 µM (Figure 
6.4B). Moreover, the LPS-induced cytotoxicity was significantly decreased at doses equal or 
greater than 5 µM. Similar to 17,18-EEQ-EA, the 19,20-EDP-EA metabolite also promoted the 
production of IL-10 in the presence of LPS.  
  It is known that both fatty acid epoxides and endocannabinoids function through multiple 
receptors (6, 44). Therefore, we performed mechanistic studies with selected inhibitors to delineate 
the mechanism of the anti-inflammatory action (Figure 6.4C-D and Figure 6.9). Using CB2 
selective antagonist (AM630) or PPAR-γ selective antagonist (GW9662), we consistently 
observed a partial reversal of the anti-inflammatory effects of both metabolites indicating that CB2 
and PPARγ are involved in mediating the anti-inflammatory action of 17,18-EEQ-EA (Figure 
6.4C) and 19,20-EDP-EA (Figure 6.4D). Lastly, the anti-inflammatory effects of the compounds 
was confirmed at 5 µM using freshly isolated piglet microglia cells stimulated with LPS which 
diminished IL-6 production thereby confirming their activity in primary cells (Figure 6.10). As 
previously noted, the anti-inflammatory response of both 17,18-EEQ-EA and 19,20-EDP-EA were 
more pronounced in the BV-2 cell line,. 
  Determination of the activation of cannabinoid receptor-2 by 17,18-EEQ-EA and 19,20-EDP-
EA using β-arrestin-recruitment PRESTO-Tango assay. Previously it was shown that CYP-
mediated epoxidation of both AEA and 2-AG resulted in increased CB2 binding and activation 
(35, 45). Additionally, as shown in Figure 6.4C-D, it was determined that the anti-inflammatory 
action of endocannabinoid epoxides is partly mediated by CB2. In literature, EPEA and DHEA 
are reported as weak agonists of the cannabinoid receptors (9). To explore if oxygenation of EPEA 
or DHEA by CYPs alters the activity at these receptors, functional assays were performed utilizing 
139 
 
a β-arrestin-recruitment PRESTO-Tango assay for comparison to full CB1 and CB2 agonists as 
previously described (27).  
  As shown in Figure 6.4E, the DHEA parent compound was a weak agonist of CB2 with little 
activation of CB1, as determined previously. However, the DHEA monoepoxides, 19,20-EDP-EA 
and 16,17-EDP-EA, were more potent functional activators of both cannabinoid receptors with 
greater preference for the CB2 receptor. Similarly, the EPEA parent compound was a weak agonist 
of CB1 with negligible activation of CB2 but the conversion to the EPEA monoepoxides, 17,18-
EEQ-EA and 14,15-EEQ-EA, also demonstrated significant CB2 activation of CB2 relative to 
EPEA. Thus, the CYP-mediated epoxygenation of EPEA and DHEA resulted in formation of their 
corresponding epoxides that are CB2 preferring partial agonists. Qualitatively, these findings 
generally support the hypothesis that the CYP mediated epoxygenation of -6 and -3 
endocannabinoids produces CB2 preferring metabolites and are consistent with what is reported 
in the literature for both AEA and 2-AG (19, 35). As the PUFA epoxides are also documented 
hemodynamic regulators, efforts were undertaken to determine a potential role for the omega-3 
endocannabinoid epoxides in regulating aspects of the clotting cascade. 
  The endocannabinoid epoxides 17,18-EEQ-EA and 19,20-EDP-EA are regulators of platelet 
function. The CYP-mediated epoxygenation of AA produces EETs that are endothelial derived 
hyperpolarizing factors (EDHF) that inhibit platelet aggregation and adhesion to endothelial cells 
(46). Correspondingly, 17,18-EEQ and 19,20-EDP metabolites also inhibit platelet aggregation 
with comparable IC50 values relative to 14,15-EET (47). Thus, the EEQ-EA and EDP-EA 
metabolites were hypothesized to modulate platelet function. Using washed human platelets we 
show that 17,18-EEQ-EA inhibited AA-induced platelet aggregation in a dose-dependent manner 
(48) (Figure 6.5A). These inhibitory effects were not observed in thrombin, PAR4-AP, collagen 
and U46619 induced platelet aggregation (Figure 6.11). Additionally, no significant inhibition of 
platelet aggregation in platelet rich plasma was observed when ADP, collagen, or ristocetin was 
used to induce aggregation (Figure 6.12). Thus, the anti-platelet aggregatory properties of 17,18-
EEQ-EA appear to specifically inhibit the AA-induced platelet aggregation.  
  Conversely, 19,20-EDP-EA did not inhibit AA-induced platelet aggregation. Rather a dose-
dependent increase of aggregation under stirring conditions, in the absence of any agonist, was 
consistently observed (Figure 6.5B). As the 19,20-EDP metabolite mediates anti-platelet 
aggregatory properties, there was a deviation in the behavior of 19,20-EDP-EA, suggesting that 
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the addition of the ethanolamide motif to 19,20-EDP is responsible for the observed pro-
aggregatory effects.  
  17,18-EEQ-EA and 19,20-EDP-EA mediate coronary artery vasodilation. CYP epoxygenases 
convert -3 fatty acids EPA and DHA into their corresponding epoxides EEQ and EDP that are 
vasodilatory in nature (49). These epoxide metabolites are thought to be largely responsible for 
the observed anti-hypertensive effects of -3 fatty acids (50). Therefore, we compared the 
vasodilatory effects of 17,18-EEQ-EA and 19,20-EDP-EA relative to the 17, 18- EEQ and 19, 20- 
EDP parent compounds by monitoring their ability to relax bovine coronary arteries pre-
constricted with U-44619 using isometric tension measurements. As shown in Figures 6.5C and 
6.5D, both 17,18-EEQ-EA and 19,20-EDP-EA dose-dependently relaxed constricted bovine 
coronary arteries. However, the ED50 values were approximately two-fold greater than 17,18-EEQ 
and 19,20-EDP. Thus, the endocannabinoid epoxides were vasodilatory in nature, albeit with 
reduced potency relative to their epoxide parent compounds.  
  17,18-EEQ-EA and 19,20-EDP-EA inhibit angiogenesis in human dermal microvascular 
endothelial cells (HMVEC). Angiogenesis plays many roles in both normal homeostatic functions 
as well as many pathological disease states. Accumulating evidence suggests that consumption of 
-3 fatty acids inhibit angiogenesis in cancer (49). Similarly, endocannabinoids are recognized for 
their ability to inhibit cancer, in part through their anti-angiogenic properties (51, 52). To 
determine if the EEQ-EAs and EDP-EAs demonstrate a greater, similar, or diminished ability to 
inhibit angiogenesis, a matrigel tubulogenesis assay was performed utilizing HMVEC and pro-
angiogenic VEGF, as previously described (29). As represented in Figure 6.5E, 17,18-EEQ-EA at 
1 and 3 µM dose-dependently inhibited VEGF-mediated tubulogenesis with a decrease of 
tubulogenesis surface area of 18% and 46%, respectively. Parallel studies were used for 17,18-
EEQ, which produced similar, albeit slightly less potent results with 1 and 3 µM average decreases 
of 9% and 28%, respectively. Identical conditions were used to screen 19,20-EDP-EA at 1 and 3 
µM with tubulogenesis surface area decreased by 31% and 75%, respectively. Following a similar 
albeit less potent trend, 19,20-EDP at 1 and 3 µM decreased tubulogenesis by 25% and 61%, 
respectively. Previously, the anti-angiogenic actions of the EDP metabolites were shown to be 
mediated through potent inhibition of VEGF-stimulated cell migration through a yet to be 
identified ω-3 epoxyeicosanoid pathway (53).   
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6.5 DISCUSSION  
  In this work, we demonstrate that the -3 endocannabinoids, EPEA and DHEA, are oxygenated 
by enzymes of the CYP epoxygenase pathway to generate a novel class of bioactive lipids that we 
termed as -3 endocannabinoid epoxides - EEQ-EAs and EDP-EAs. These molecules share 
structural similarity to both their endocannabinoid and epoxide parent compounds, with potential 
to exert physiological effects that are mediated through the cross talk of the endocannabinoid and 
epoxide signaling pathways. To gain improved understanding of the formation, degradation and 
biological function of these metabolites, we performed several studies.  
  First, a targeted lipidomics LC-MS/MS method was developed which revealed a wide distribution 
of EEQ-EAs and EDP-EAs in both the brain and peripheral organs. Notably, the detection of 
relatively high endogenous levels of the terminal epoxides, 17,18-EEQ-EA and 19,20-EDP-EA 
regioisomers, in the rat brain and peripheral tissues are close to the levels of AEA and DHEA.  
This suggested that they are produced enzymatically and implicated the involvement of the CYP 
epoxygenases in their biosynthesis comes as the terminal -3 double bond is the preferred site of 
the CYP mediated catalysis of -3 FAs (22).  
  As the microglial cytochrome P450 (CYP) epoxygenase pathway is upregulated under 
inflammatory conditions (54), there is a strong possibility of CYP mediated metabolism of these 
endocannabinoids. We demonstrated that BV-2 microglia CYPs are involved in EPEA/DHEA 
metabolism as the epoxygenation of both substrates was significantly diminished by pre-
incubating microglia cells with ketoconazole (0.5 µM). Ketoconazole is involved in CYP 
inhibition of the CYP2, CYP3 and CYP4 families (Figure 6.2D-E).  
  The discovery of the metabolites in the different tissues prompted us to investigate the specific 
CYP enzymes that synthesize these metabolites. We performed in vitro incubations of DHEA and 
EPEA with the rat brain microsomes and quantified the epoxide products by LC-MS/MS. While 
the metabolism of DHEA and EPEA by microsomes informs us about metabolism in milieu of 
other proteins, it is important to identify specific CYPs that give rise to these epoxides in humans. 
In humans, the main epoxygenases are CYP2C8, CYP2C9 and CYP2J2. Consequently, we did 
further metabolism studies with CYP2J2 (the major epoxygenase in the brain and heart of human) 
and brain microsomes to directly epoxygenate EPEA and DHEA (Figure 6.3A-D). As shown in 
Figure 6.3A and 6.3B, rat brain microsomes epoxygenated both EPEA and DHEA with similar 
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preference for both ligands. When equimolar amounts of EPEA and DHEA were added to the 
incubation, we observed a comparable decrease of EEQ-EA and EDP-EA total products relative 
to incubations when only one ligand was employed (Figure 6.3C). This implied that DHEA and 
EPEA are in competition for some of the same CYPs with neither substrate showing clear 
preference for these enzymes. Because the rat CYP epoxygenases are enzymatically different from 
human CYP epoxygenases, we also performed incubations with porcine brain microsomes which 
contain a CYP2J isozyme with similar homology as human CYP2J2 (18). Importantly, the pig 
brain microsomes exhibited similar trends as the rat brain microsomes that supported the 
hypothesis that some of the same CYPs oxygenate both EPEA and DHEA (Figure 6.6). We further 
demonstrated using recombinant human CYP2J2 incorporated into nanodiscs, which revealed an 
epoxygenation of both substrates at comparable rates, albeit with a different regioselectivity 
(Figure 6.3D).  
  As discussed above, we confirmed the direct epoxygenation of EPEA/DHEA by recombinant 
protein, brain microsomes, and microglial cells. Thus, when adequate EPEA/DHEA and specific 
CYP epoxygenases are present, these metabolites will be spontaneously generated in vivo. 
However, there is the possibility of an indirect biosynthetic route that involves the CYP-mediated 
epoxygenation of -3 FAs into EEQ or EDP, followed by their re-esterification and storage into 
the plasma membrane. These epoxides are then cleaved by phospholipases and converted to EEQ-
EA or EDP-EA metabolites, presumably through the same biosynthetic pathway as EPEA or 
DHEA.  
  The EEQ-EA and EDP-EA metabolites are unique in that they contain both epoxide and 
ethanolamide motifs that are specific functional targets for both soluble epoxide hydrolase (sEH) 
and fatty acid amide hydrolase (FAAH). Therefore in order to estimate if the in vivo half-life of 
the metabolites might differ among classes we examined the degradation of 17,18-EEQ-EA and 
19,20-EDP-EA metabolism by soluble epoxide hydrolase (sEH) and fatty acid amide hydrolase 
(FAAH). In mammals, these serine hydrolases are found in the brain as well as the peripheral 
organs where they rapidly inactivate bioactive lipids via hydrolysis (55, 56). Previous reports 
demonstrated that both EEQ and EDP regioisomers are efficiently hydrolyzed by sEH to their 
corresponding diols and are preferred substrates relative to the ω-6 EETs (38). Herein, we show 
the sEH conversion of 17,18-EEQ-EA into 17,18-DiHETE-EA is more than 7-fold more efficient 
than the 19,20-EDP-EA hydrolysis to 19,20-EDP (Figure 6.3F-G). Additionally, the 17,18-EEQ-
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EA hydrolysis to 17,18-EEQ by rat forebrains containing FAAH was measured approximately 
three-fold faster than 19,20-EDP-EA conversion to 19,20-EDP (Figure 6.8). Thus, the relatively 
faster turnover of EEQ-EA was of interest since its endogenous levels were comparable to EDP-
EA, which might suggest that EEQ-EA is being produced at a faster rate. Consistent with this idea, 
it is known that EPA and DHA are absorbed at similar rates in the brain, but EPA levels are ~300 
fold lower than DHA due to rapid oxygenation through different pathways (57). Thus, it is logical 
to surmise that EEQ-EA levels might be increased at the expense of EPA through metabolism in 
CYP epoxygenase and EDC pathways in the brain.  
  The similar endogenous brain levels of these metabolites prompted examination of both their 
bioactive signaling properties in the context of the CNS. Both the epoxide and ethanolamide 
functional motifs separately exert anti-inflammatory effects in a wide range of tissues including 
the brain (41, 58). As discussed above, the production of EEQ-EA and EDP-EA regioisomers by 
LPS-stimulated BV-2 cells suggested a role for these metabolites in microglia inflammation (Table 
6.2). As shown in Figure 6.4A-B, both 17,18-EEQ-EA and 19,20-EDP-EA dose-dependently 
inhibited the production of two prototypic pro-inflammatory biomarkers, IL-6 and NO, whilst 
increasing the production of the anti-inflammatory cytokine, IL-10. Additionally, the reduction of 
lactate dehydrogenase (LDH) release associated with LPS stimulation provided further 
confirmation of the nullification of toll-like receptor-4 signaling. The decrease of IL-6 and increase 
of IL-10 cytokines raises questions whether these metabolites can influence microglia states from 
the pro-inflammatory M1 phenotype to the repair M2 phenotype that produces anti-inflammatory 
cytokines. This notion is consistent with recent reports that detail a role for CB2 ligands and 
epoxide lipids (EETs) in the promotion of the M2 macrophage phenotype (59, 60). Notably, the 
anti-inflammatory effects were blocked, in part, with AM630 (CB2 inhibitor), GW99662 (PPARγ 
inhibitor) (Figure 6.4C-D) and pertussis toxin (PTX) (Figure 6.9C-D). Importantly, PTX acts to 
ribosylate the ɑi subunit thereby attenuating CB1/CB2 intracellular signaling through its typical 
pathway.  However, the inhibitors/toxins that were tested only partially blocked the anti-
inflammatory effects of the endocannabinoid epoxides suggesting alternative pathways.  
  To validate the CB2 mediated anti-inflammatory pathway we employed a β-arrestin recruitment 
assay for both CB1 and CB2 receptors (Figure 6.4E). The functional assay demonstrated that the 
epoxygenation of the EPEA and DHEA converted weak CB1/CB2 agonists to partial CB2 
agonists. Interestingly, the 19, 20-, and 16,17-EDP-EA were shown to be the most potent and 
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preferential CB2 agonists with the CB2:CB1 activation ratio of three- and four-fold, respectively. 
These findings were consistent with previous studies that demonstrated that the CYP-mediated 
epoxygenation of the -6 endocannabinoids, AEA and 2-AG, produced novel endocannabinoid 
epoxides with increased potency and preferential targeting of CB2 (19, 35). Collectively these 
separate studies establish that the CYP mediated epoxidation of endocannabinoids such as AEA, 
2-AG, DHEA and EPEA enhances the activation of the CB2 receptor and possibly provides a CYP 
mediated mechanism to regulate inflammatory pathologies by producing anti-inflammatory 
metabolites.  
  EETs play an important role in neuroglio-vascular coupling and there is potential interaction 
between EETs and neuroactive endocannabinoid signaling pathways (58). Relative to EETs the 
effects of EEQs and EDPs share many of the same physiological effects, such as vasodilation and 
inhibition of platelet aggregation, while exerting opposite effects in the inhibition of angiogenesis. 
We therefore focused on the potential biological actions of 17,18-EEQ-EA and 19,20-EDP-EA in 
the blood and vasculature.  
  The inhibition of platelet aggregation by 17,18-EEQ-EA (Figure 6.5A) is consistent with what is 
known about the 17,18-EEQ parent compound and other related epoxides. Specifically, the CYP 
metabolism of AA, EPA, and DHA produces bioactive epoxides such as 14,15-EET that are 
recognized for their ability to inhibit platelet aggregation and reduce thrombocyte adhesion (61). 
Conversely, early reports demonstrated that 2-AG and AEA induce platelet aggregation only after 
hydrolysis by fatty acid amide hydrolase (FAAH) through a pro-clotting arachidonic acid mediated 
mechanism (62, 63). Surprisingly, 19,20-EDP-EA failed to inhibit platelet aggregation and rather 
promoted platelet clotting under stirring conditions (Figure 6.5B). When it is considered that 
19,20-EDP, 19,20-DHETE, and DHA are anti-aggregatory mediators, our finding reveal a 
potentially important structure activity relationship among these lipids. Moreover, this affords the 
first evidence of a pro-platelet aggregatory mechanism of an -3 derived metabolite which should 
be taken into consideration when weighing the potential benefits of DHA supplementation. 
Moreover, when targeting these pathways it is critical to understand how each metabolite will 
affect the wide range of physiological functions in order to maintain lipid concentrations within a 
therapeutic window.  
  Considering that lipid mediators such as thromboxane promote platelet aggregation while 
simultaneously constricting vessels, we examined the effects of the EEQ-EAs and EDP-EAs on 
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vascular tone. The pro-vasodilatory effects of 17,18-EEQ and 19,20-EDP parent compounds are 
well documented and are thought to be associated with the anti-hypertensive effects associated 
with -3 supplementation (22, 64). The administration of both 17,18-EEQ-EA and 19,20-EDP-
EA provided less potent dose-dependent relaxation of pre-constricted bovine arteries, which 
suggested a mechanistic function similar to that of the parent epoxide mediators (Figure 6.5C-D).  
  The anti-angiogenic effects of the EDPs are opposite to the pro-angiogenic effects of the EETs 
and identifying the roles of eicosanoids in these functions constitutes an active area of research 
(49). As shown in Figure 6.5E, the anti-angiogenic effects of 17,18-EEQ-EA and 19,20-EDP-EA 
were more potent when compared to their epoxide parent compounds in VEGF promoted 
angiogenesis of HMVEC cells. This additive effect is possibly mediated through the 
endocannabinoid moiety that also provides anti-cancer activity (7, 8).    
  Overall, we report on a new class of metabolites that are naturally produced from endogenous -
3 endocannabinoids via cross talk of the enzymes in the endocannabinoid and cytochrome P450 
pathways. These dual functional lipid-signaling molecules show diverse bioactivity with respect 
to their inflammatory action, vasodilation, platelet aggregation and angiogenesis. Taken together, 
these separate studies establish that the CYP mediated epoxidation of -3 endocannabinoids 
DHEA and EPEA leads to the formation of CB2-preferring agonist activity when compared to the 
parent compounds.  
  When considered in the larger context of ω-3 FA dietary supplementation and the current 
development of sEH and FAAH inhibitors as therapeutics, it is critically important to first 
understand what lipids comprise the lipidome and what their biological actions are in order to fully 
understand the mechanisms of these drugs and avoid any untoward effects. In summary, this is the 
first step to evaluate CYP epoxygenase derived ω-3 endocannabinoid epoxides that in the future 
by virtue of their biological properties will serve as potential therapeutic targets for diseases such 
as neuroinflammation and cerebrovascular disorders. 
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6.7  FIGURES AND TABLES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1. Overview of the CYP epoxygenase mediated metabolism of endocannabinoids. 
Both -6 and -3 dietary fatty acids are stored in plasma membrane and can be converted to -6 
and -3 endocannabinoids - AEA, DHEA and EPEA. AEA is a substrate for enzymes of the 
cytochrome P450 (CYP) epoxygenase pathway that produces EET-EA metabolites (14,15-EET-
EA regioisomer shown). Another possible pathway includes the metabolism of EPEA and DHEA 
by CYP epoxygenases to form EEQ-EA and EDP-EA regioisomers, respectively. The terminal 
endocannabinoid epoxide regioisomer is shown and other possible epoxides at each double bond 
are denoted by the numbering system.  
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Figure 6.2. Endogenous levels of EEQ-EA and EDP-EA regioisomers in rat tissues and their 
production in BV-2 microglia. (A) Authentic standards were used for the development of a LC-
MS/MS method in the separation and quantitation of EEQ-EA, EDP-EA, AEA, EPEA, and DHEA 
lipid mediators using MS/MS fragments and retention times unique to each lipid class. (B) Lipid 
metabolites were extracted and analyzed from pooled Sprague-Dawley rat (n = 3) brain and (C) 
peripheral organs as described in the materials and methods. (D) & (E) LPS-activated BV-2 
microglia cells  directly convert EPEA to EEQ-EA regioisomers and DHEA into EDP-EA 
regioisomers was examined in the absence and presence of the CYP inhibitor ketoconazole (0.5 
µM). 
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Figure 6.3. Direct enzymatic production of EEQ-EA and EDP-EA regioisomers and 
hydrolysis by soluble epoxide hydrolase. Brain microsomes were incubated with substrate in the 
presence of CPR and NADPH to measure the capacity of endoplasmic reticulum epoxygenases to 
directly epoxygenate either (A) EPEA (40 µM), (B) DHEA (40 µM) or (C) EPEA (40 µM) + 
DHEA (40 µM). (D) CYP2J2-CPR was incorporated into nanodiscs. The membrane scaffold 
protein (cyan) surrounds a lipid bilayer (aqua marine with gold phospholipid head groups) in which 
both CYP2J2 (dark blue) and CPR (grey) are incorporated. The regioselectivity and kinetics of 
EPEA and DHEA metabolism by human CYP2J2-CPR-Nanodiscs was performed leading to the 
epoxidation of EPEA to EEQ-EA or DHEA to EDP-EA. The production of the total product and 
each specific EEQ-EA and EDP-EA regioisomers were fit to Michaelis-Menten kinetics with the 
calculated Km, Vmax and Vmax/Km values listed in the adjacent table. (E) Incubations containing 
sEH ([E] final = 6 nM) in sodium phosphate (100 mM, pH 7.4), bovine serum albumin (0.1 mg/ml) 
and (F) 17,18-EEQ-EA or (G) 19,20-EDP-EA were performed at 37°C to measure conversion of 
epoxides to the corresponding vicinal diols using LC-MS/MS. Enzyme kinetics were estimated 
using incremental increases of substrate for the generation of kinetic curves that were fitted to the 
Michaelis-Menten equation for calculation of Vmax and Km. Incubations were performed in 
triplicate or greater and kinetic parameters were calculated using Origin Pro. 
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Figure 6.4.  17,18-EEQ-EA, 19,20-EDP-EA effects on LPS stimulated BV2 microglial cells 
and signaling properties. BV2 microglial cells were pretreated with a dose response of either (A) 
17,18-EEQ-EA or (B) 19,20-EDP-EA for 4 hours followed by LPS (25 ng/mL) stimulation. 
Culture medium was collected after 24 hours and analyzed for pro-inflammatory cytokines (Nitric 
oxide, IL-6) and anti-inflammatory cytokines (IL-10). Production of lactate dehydrogenase (LDH) 
was measured to assess cell toxicity relative to LPS in stimulated BV-2 microglia (n = 6). (C) The 
potential targets of 17,18-EEQ-EA and 19,20-EDP-EA were studied using AM630 (CB2 specific 
inhibitor) and GW9662 (PPARγ specific inhibitor) to gauge reversal of the anti-inflammatory 
effects by monitoring nitrite production (n = 6) (D) 17,18-EEQ-EA and 19,20-EDP-EA binding 
mediated activation of CB1 and CB2 receptors was measured using β-arrestin recruitment 
luciferase reporter assay in transiently transfected HEK293 cells. Values represent the percent 
activation of each ligand (10 µM) relative to a full CB1 and CB2 agonist (CP55940) at its EC90 
(n = 3).  
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Figure 6.5. Biological effects of 17,18-EEQ-EA and 19,20-EDP-EA on platelet aggregation, 
vasculature tension and angiogensis. The physiological functions of 17,18-EEQ-EA and 19.20-
EDP-EA regioisomers were examined in biological assays to characterize their effects on platelet 
aggregation, vasodilation and angiogenesis. In whole human blood, (A) 17,18 EEQ EA dose-
dependently inhibited AA-induced platelet aggregation (n = 4) whereas (B) 19, 20 EDP EA -
induced platelet aggregation under stirring conditions in the absence of a platelet agonist (n = 7). 
Dose-dependent relaxation of bovine coronary arteries pre-constricted with U-46619 (40 nM) was 
measured for (C) 17,18-EEQ-EA and 17,18-EEQ (D) 19,20-EDP for and 19,20-EDP for the 
calculation of the ED50.  (E) 17,18-EEQ-EA and 19,20-EDP-EA were assessed for their ability to 
inhibit VEG-F promoted angiogenesis in HMVEC plated on Matrigel (n =7). Compounds were 
studied in parallel to each of their epoxide and ethanolamide parent compounds. All values are 
means ± SE.  
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Figure 6.6. Incubations of EPEA and DHEA with pig brain microsomes. Microsomes were 
prepared from pooled (n=2) homogenized whole porcine brain to measure the capacity of 
endoplasmic reticulum epoxygenases to directly epoxygenate (A) EPEA (40 µM), (B) DHEA (40 
µM) and (C) Equimolar mixture of EPEA (40 µM) and DHEA (40 µM). 
  
 
 
 
 
 
 
153 
 
 
 
Figure 6.7. LC-ESI-MS global analysis of the CYP2J2-ND mediated metabolism of EPEA 
and DHEA. LC-ESI-MS was employed to qualitatively characterize CYP2J2 nanodisc 
metabolism of EPEA and DHEA.  (A) Schematic of the CYP2J2-ND reactions. In the diagram the 
membrane scaffold protein (cyan) surrounds a lipid bilayer (light grey) in which both CYP2J2 
(red) and CPR (grey) are incorporated. The addition NADPH provides the electron source that 
drives the P450 cycle resulting in the olefin epoxidation of EPEA to EEQ-EA. The CYP2J2-ND 
metabolism of (B) EPEA produced the four detectable epoxide products 17,18-, 14,15-, 11,12-, 
and 8,9-EEQ-EA whereas (C) DHEA produced the three detectable epoxide products 19,20-, 
16,17-, and 13,14-EDP-EA.  
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Figure 6.8. Time-dependent hydrolysis of 17,18-EEQ-EA and 19,20-EDP-EA hydrolysis by 
rat forebrain membranes. Rat forebrain membranes containing fatty acid amide hydrolysis 
(FAAH) were isolated and protein content was determined using a BCA assay as described in the 
supplemental methods. Incubations were performed with 100 µg of forebrain protein, 50 µM of 
substrate (17,18-EEQ-EA or 19,20-EDP-EA) in the presence of 50 mM Tris (pH 7.4), 1 mM 
EDTA, 3 mM MgCl2 at 37°C as previously described. Samples were quenched with methanol 
containing 1 mM PMSF at 5, 20 and 40 minutes and analyzed via LC-MS/MS.     
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Figure 6.9. Effects of inhibitors on 17,18-EEQ-EA and 19,20-EDP-EA mediated anti-
inflammatory effects in BV-2 microglia cells. A panel of inhibitors were screened for their ability 
to reverse (A) 17,18-EEQ-EA and (B) 19,20-EDP-EA mediated anti-inflammatory effects in BV-
2 microglia cells. Inhibitor concentrations were chosen based on reported EC50 values and lack of 
inhibitor effect in the assay. (C-D) BV-2 cells were pre-incubated with vehicle or pertussis toxin 
(100 ng/mL) in serum free-media for 18 hours prior to LPS stimulation in the absence or presence 
of (C) 17,18-EEQ-EA and (D) 19,20-EDP-EA.  
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Figure 6.10. In vitro primary piglet microglial neuroinflammation model. Isolated piglet 
microglia cells were pre-treated with either 17,18-EEQ-EA (5 µM) or 19,20-EDP-EA (5 µM) for 1 
hour before stimulation with LPS (10 ng/mL). After 12 hours the supernatant was collected and 
IL-6 content was measured via ELISA. The final vehicle (DMSO) concentration was 0.04% and each 
group represents an n = 3 or greater.  
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Figure 6.11. Effects of 17,18-EEQ-EA on thrombin, PAR4-AP, collagen or U44619-induced 
aggregation in washed human platelets. Washed human platelets were activated with either (A) 
1 nM thrombin (B) 50 µM PAR-AP (C) 2 µg/mL collagen in the presence of 12.5, 25 and 50 µM 
17,18-EEQ-EA (n = 3) which had no significant effect on platelet aggregation as determined by 
light transmission (%).  (D) Similarly, washed human platelets activated with 1 µM U46619  (n = 
1) did not exhibit any change in the presence of either 50 µM 17,18-EEQ-EA or 19,20-EDP-EA 
as estimated by light transmission (%).  
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Figure 6.12. 17,18-EEQ-EA and 19,20-EDP-EA effects on ADP, collagen or ristocetin-
induced platelet aggregation in platelet rich plasma. The effects of 17,18-EEQ-EA, 19,20-EDP-
EA at 50 µM relative to vehicle (DMSO) in were investigated in platelet rich plasma clotting via 
(A) ADP (1 µM), (B) collagen (2 µg/mL) and (C) ristocetin (1 mg/mL).  
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Figure 6.13. Purification of EDP and EEQ regio-isomers from crude reaction mixture by 
normal- and reversed-phase HPLC. Synthesis reactions detailing the non-specific olefin 
epoxidation of EPA or DHA are detailed in the materials and methods. A combination of both 
normal phase-high performance liquid chromatographay (NP-HPLC) and reversed phase-high 
performance chromatography (RP-HPLC) were necessary for isolation epoxides. NP-HPLC was 
employed for separation of (A) EEQ and (B) EDP regioisomers from the crude reaction mixture. 
RP-HPLC was employed due to the alternative elution profile of (C) EEQ and (D) EDP 
regioisomers which elutes with the terminal epoxide first (17,18-EEQ or 19,20-EDP-EA) followed 
by the sequential elution of the other metabolites. The isolation of specific EEQ (17,18-, 14,15-, 
11,12-, 8,9-, and 5-6-EEQ) and EDP (19,20-, 16,17-, 13,14-, 10,11-, and 7,8-EDP)  regioisomers 
were confirmed using high resolution mass spectrometry and commercially available authentic 
standards for use in analytical RP-HPLC.   
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Figure 6.14. Spectral Data of purified 17,18-EEQ-EA and 19,20-EDP-EA. (A) 1H NMR (400 
MHz, CDCl3) δ6.03 (s, 1H), 5.55 to 5.33 (m, 10H), 3.72 (t, 2H, J = 4Hz), 3.42 (quartet, 2H, J= 4 
Hz), 3.03 to 2.79 (m, 6H), 2.43 (dt, 1H, J = 2Hz), 2.25 to 2.05 (m, 4H), 1.73 (apparent quintet, 2H, 
J = 8Hz), 1.67 to 1.48 (m, 6H), 1.05 (t, 3H, J = 8Hz). HRMS (m/z) calc. mass = 362.2695; HRMS 
measured mass = 362.2693; atomic form = C22H36NO3; UV-Vis λmax = 191 nm; Purity > 98% (B) 
1H NMR (400 MHz, CDCl3) δ6.03 (s, 1H), 5.55 to 5.33 (m, 8H), 3.72 (t, 2H, J = 4Hz), 3.42 
(quartet, 2H, J= 4 Hz), 3.00 to 2.79 (m, 8H), 2.43 (apparent quintet, 1H, J = 2Hz), 2.25 to 2.05 (m, 
4H), 1.73 (apparent quintet, 2H, J = 8Hz), 1.67 to 1.48 (m, 6H), 1.05 (t, 3H, 8Hz). HRMS calc. 
mass = 388.2828 ; HRMS (m/z) measured mass = 388.2852; atomic form = C24H38NO3; UV-Vis 
λmax = 191 nm; Purity > 98%. 
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Table 6.1. Summary of the average levels of detected EEQ-EA, EDP-EA, EPEA, DHEA and 
AEA levels in rat brain, rat heart, rat kidney, rat spleen, rat liver, porcine brain and human 
plasma. Sprague-Dawley rat tissues, pig brain and human pooled plasma were analyzed for EEQ-
EA, EDP-EA, EPEA, DHEA and AEA metabolites as described in the materials and methods 
(main text). 
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Table 6.2. Time course of EEQ-EA, EDP-EA, EPEA, DHEA and AEA production by LPS 
stimulated BV-2 cells. 6-well plates were seeded with 500,000 BV-2 cells and grown to 80-90% 
confluence. Microglia were stimulated with LPS (100 ng/mL) and placed back in the incubator 
(37°C and 5% CO2) for each specified period of time. At each time point, cells were scraped in 
the supernatant, lysed and extracted three times with ethyl acetate/hexane (9:1). The organic layer 
was dried down and re-suspended in ethanol for targeted lipidomic analysis using LC-MS/MS as 
described in the main text.  
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A.1 ABSTRACT 
  Semiconductor nanoplatelets are planar nanocrystals that have recently attracted considerable 
attention due to their quantum well-like physics, atomically precise thickness, and unique 
photophysical properties such as narrow-band fluorescence emission. These attributes are of 
potential interest for applications in biomolecular and cellular imaging, but it has been 
challenging to colloidally stabilize these nanocrystals in biological media due to their large 
dimensions and tendency to aggregate. Here we introduce a new colloidal material that is a 
hybrid between a nanoplatelet and an organic nanodisc composed of phospholipids and 
lipoproteins. We find that phospholipids adsorb to flat surfaces on the nanoplatelet and 
lipoproteins bind to sharp edges to enable efficient encapsulation of single nanoplatelets with 
long-term stability in biological buffers and high salt solutions. The lipoprotein–nanoplatelets are 
highly fluorescent with brightness comparable to wavelength-matched quantum dots at the 
ensemble level and at the single-molecule level. They also exhibit a unique feature of rapid and 
efficient internalization into living cells, after which they retain their fluorescence. These unique 
properties suggest that lipoprotein–nanoplatelets are particularly well suited for applications in 
live-cell single-molecule imaging and multiplexed cellular labeling. 
 
Reprinted, with permission, from Lim SJ, McDougle DR, Zahid MU, Ma L, Das A*, Smith AM. Lipoprotein 
Nanoplatelets: Brightly Fluorescent, Zwitterionic Probes with Rapid Cellular Uptake. JACS. 
2016 13;138(1):64-7. PMID: 26687504 
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A.2 MATERIALS & METHODS 
  Materials for Nanoplatelet Synthesis. Cadmium oxide (CdO, 99.99+%), cadmium acetate 
hydrate (Cd(Ac)2·H2O, 99.99+%), selenium powder (Se, ~100 mesh, 99.99%), ammonium sulfide 
((NH4)2S, 40–48 wt.% in H2O), tetramethylammonium hydroxide solution (TMAH, 25 wt.% in 
methanol), 3-mercaptopropionic acid (MPA, >99%), tributylphosphine (TBP, 97%), sodium 
chloride (NaCl), bromocresol green (ACS Reagent, dye content 95%), and dimethyl sulfoxide 
(DMSO, >99.9%, anhydrous) were purchased from Sigma-Aldrich. 1-octadecene (ODE, 90% 
tech.), oleic acid (OAc, 90% tech.), and oleylamine (OLA, 80–90% C18-content) were purchased 
from Acros Organics. Tris base (99%) and hydrochloric acid (37% in water) were purchased from 
Fisher Scientific. N-methylformamide (NMF, >99%) was obtained from Tokyo Chemical 
Industry. Other solvents including chloroform, hexane, methanol, ethanol, ethyl acetate, acetone, 
phosphate buffered sailine (PBS) were purchased from various suppliers including Acros 
Organics, Fisher Scientific, Macron Fine Chemicals. 
  Materials for Polymeric ligand synthesis. Tris(carboxyethyl)phosphine (TCEP, 98%), 
polyacrylic acid (PAA, MW 1.8 kDa), dimethylethylenediamine (DMDA, 99%), N,N-
diisopropylethylamine (DIPEA, 99.5%), N,N,N′,N′-tetramethyl-o-(1H-benzotriazol-1-yl)uronium 
hexafluorophosphate (HBTU, 98%), 1-hydroxybenzotriazole hydrate (HOBt, 97%), 1,3-
propanesultone (98%), trifluoroacetic acid (TFA, 99%), phenol (99%), triisopropylsilane (TIPS, 
98%) were purchased from Sigma-Aldrich. Dimethylformamide (DMF, 99.8% anhydrous) was 
purchased from Alfa Aesar. All chemicals were used as received. S-trityl-protected cysteamine 
was prepared according to the literature.(1) 40% octylamine-modified polyacrylic acid (amphipol, 
MW ~2.9 kDa) was synthesized using methods described in the literature.2 
  Materials for lipoprotein coatings, labeling, and surface modification. The phospholipids 1,2-
dimyristoyl-sn-glycero-3-phosphocholine (DMPC) and 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine (POPC) were purchased from Avanti Polar Lipids. Decyl maltoside (C10M) and 
ultrapure sodium cholate (≥ 97%) was purchased from Affymetrix.  
Membrane scaffold protein (MSP1E3D1) was expressed and purified as previously described (3).3 
Texas Red® 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine, triethylammonium salt 
(Texas Red® DHPE) and Alexa Fluor® 680 NHS ester, bis(triethylammonium salt) (Alexa Fluor® 
680 NHS) were obtained from ThermoFisher Scientific. Mono-Sulfo-NHS-Nanogold® (d ~1.4 
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nm) was purchased from Nanoprobes. α-Methoxy-ω-NHS ester (PEG-NHS, 2 kDa) was purchased 
from Rapp Polymere.  
  Materials for negative staining TEM. Sodium phosphotungstate hydrate (PTA, >99.9%) was 
purchased from Sigma-Aldrich.  Polymer 1. PAA (116.67 mg, 1.62 mmol COOH), HBTU (910.17 
mg, 2.4 mmol), HOBt (356.98 mg , 2.31 mmol) were dissolved in DMF (5 mL). DIPEA (846 µL, 
4.8 mmol) was added to activate the carboxylic acid and 10 minutes later S-trityl-protected 
cysteamine  (181.8 mg, 0.57 mmol) and DMDA (120 µL, 1.1 mmol) were added. The mixture was 
stirred overnight at room temperature. The product was precipitated with the addition of 10 mM 
NaOH solution (250 mL) and collected by centrifugation. The product was redissolved in acetone, 
mixed with anhydrous Na2SO4, filtered, and dried under vacuum. Finally, the viscous oil was 
washed with ether to remove any residual solvent to yield the product 1 as a yellow powder. Yield: 
40%. 1H NMR (d6-DMSO, δ, ppm, 500 MHz): 7.1-7.4 (Ar-H, br), 3.25-3.6 (br), 2.84 (-S-CH2, 
br), 2.75 and 2.4 (-CH2-N<, m), 2.0-2.4 (CH3, br). 
  Polymer 2. 1 (100 mg, 0.7 mmol) was treated with 1,3-propanesultone (129 mg, 1.05 mmol) in 
dry propylene carbonate (1.5 mL) under continuous stirring for 24 hours at room temperature, 
followed by 24 hours at 80°C. The product 2 was precipitated from the reaction mixture with ether 
(40 mL) to obtain a white powder. The product was then rinsed with ether and dried under vacuum. 
Yield: 70%. 1H NMR (D2O, δ, ppm, 500 MHz): 6.5-7.51 (Ar-H, br), 3.25-3.75 (br), 3.0-3.2 (br), 
2.4-3.0 (br), 1.8-2.3 (br). 
  Poly(thiol and sulfobetaine) (PTSB). 2 (10 mg, 11 µmol SH) and TCEP (3.2 mg, 11 µmol) was 
treated with TFA/phenol/TIPS (38:2:1 v/v/v, 1 mL) under N2 for 5 hours. The solid PTSB product 
was precipitated with ether (10 mL) and collected by centrifugation at 7,000 g/5 min. 
Nanoplatelet (NPL) synthesis 
  Core CdSe NPL. CdSe NPLs were synthesized and purified using literature methods with slight 
modifications.4 In a typical synthesis, CdO (0.6 mmol), OAc (1.2 mmol), and ODE (15 mL) were 
mixed in a 50-mL round bottom flask (r.b.f.) and heated to ~200°C under Ar until the mixture 
became clear and colorless due to the formation of cadmium oleate. The solution was cooled to 
140°C and Se powder (0.6 mmol) was added. Then the temperature was quickly raised to 240°C 
at a rate of ~20°C/min. At 190°C, Cd(Ac)2 (0.6 mmol) was swiftly added into the mixture to initiate 
NPL growth. After reaching 240°C, the mixture was heated for an additional 10 min and the 
reaction was quenched by removing the heating mantle. When cooled to ~130°C, OAc (1 mL) was 
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added to stabilize the NPL dispersion. The reaction yielded a mixture of NPLs with the first exciton 
abs at 510 nm as well as quantum dots (QDs). For purification, the reaction mixture was diluted 
with hexane (~15 mL), divided into two 50-mL centrifuge tubes, and sonicated for ~5 min before 
adding ethanol (~30 mL) containing TBP (1 mL) into each tube and centrifuged at 7,000g for 5 
min to precipitated all nanocrystals (NPLs and QDs). Precipitates were redispersed in hexane (20 
mL per tube) with sonication, then only NPLs were precipitated by adding ethanol (5 mL per tube) 
and centrifuging. Finally, pure NPLs were redispersed in hexane and stored as a stock solution.  
  Core/shell CdSe/CdS NPLs. CdS shells were grown layer-by-layer on purified CdSe NPLs by 
following the colloidal atomic layer deposition protocol developed by Ithurria and Talapin4c with 
slight modifications. In a typical reaction, a biphasic mixture of CdSe NPLs in hexane (top phase; 
band edge absorbance ~4, 2 mL) and NMF (bottom phase; 2 mL) was prepared in a glass vial with 
magnetic stir bar. While gently stirring the mixture, a drop of (NH4)2S solution (20 μL) was added 
into the top phase. This induced a sudden color change from yellow to dark orange followed by 
the flocculation of NPLs due to the deposition of sulfide layer on the NPL surface. The aggregates 
were eventually homogeneously dispersed into the bottom NMF phase. After complete phase 
transfer in 1–2 min, the top phase was discarded and the bottom phase was washed with hexane 
twice. The NPLs were isolated from excess sulfide ions by precipitation with ethyl acetate and 
centrifugation at 7,000g for 5 min. Sulfide-coated NPLs were redispersed in pure NMF (2 mL) 
and a solution of Cd(Ac)2 in NMF (0.1 M, 50 μL) was added, which induced a color change to 
dark red due to the growth of a monolayer (ML) of CdS shell on the NPL surface. After a few 
minutes, NPLs were isolated from the excess Cd ions by precipitation with ethyl acetate. These 
NPLs were redispersed in NMF and an additional monolayer of CdS shell was grown through 
another cycle of (NH4)2S addition – precipitation – redispersion in NMF – Cd(Ac)2 addition – 
precipitation – redispersion in NMF. The final core/shell NPLs were transferred back to organic 
phase by adding OAc (~100 μL) and OLA (~100 μL) in a biphasic mixture of NPL solution in 
NMF (bottom phase) and hexane (top phase; 2 mL) while gently stirring the mixture for ~10 min. 
After complete phase transfer, the bottom phase was discarded and the NPLs were purified by 
precipitation with excess methanol. Finally, pure core/shell NPLs were dispersed in CHCl3 and 
stored in the dark until use. 
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Lipoprotein–nanoplatelet (L–NPL) preparation and purification 
  L–NPL assembly. In a typical synthesis, a CdSe/CdS core/shell NPL stock in CHCl3 (~100 nM, 
@350nm ~5×10
7 cm−1M−1, 1 mL) was sonicated for 10 min and phospholipids (DMPC or POPC) 
dispersed in CHCl3 were added in a 10,000:1 lipid:NPL molar ratio. The mixture was sonicated 
for 10 min and CHCl3 was evaporated under a steady stream of N2. The dry product was stored 
under vacuum to ensure complete CHCl3 removal. The NPL–phospholipid mixture was 
reconstituted in PBS or Tris (0.1M, pH 7.4) containing detergents (sodium cholate or C10M) (10 
mM, 1 mL) and sonicated for 10 min before rocking at 22°C for 30 min. Next, MSP (MSP1E3D1) 
was added in a 100:1 MSP:NPL molar ratio and the mixture was rocked at 22°C for 6–8 hours to 
form a macromolecular assembly between the NPL, phospholipids, and MSPs, yielding L–NPL 
hybrids as well as a large excess of empty nanodiscs. The as-prepared L–NPL hybrid solution was 
filtered through a syringe filter (0.2 µm pores) to remove any aggregates, then the clear dispersion 
was dialyzed in the same buffer (PBS or Tris) for 1 day using a 50 kDa molecular weight cutoff 
(MWCO) dialysis tube (Spectrum Laboratories, Inc.) to remove excess lipids and detergents and 
concentrated using a 50 kDa MWCO centrifugal filter (Amicon® Ultra, EMD Millipore). Excess 
nanodiscs remaining after dialysis were removed using density gradient centrifugation. 
  NaCl density gradient centrifugation. A saturated NaCl solution (~6.5 M, d = 1.20 g/mL, 10 
mL) was prepared by dissolving NaCl in distilled water at room temperature. A series of lower 
density solutions (d = 1.17, 1.14, 1.10, 1.07, and 1.03 g/mL) were prepared by diluting the saturated 
NaCl stock. In a 14-mL ultracentrifugation tube (Ultra-ClearTM, Beckman Instruments, Inc.), a 
NaCl density gradient medium was prepared by carefully stacking NaCl layers with successively 
decreasing densities (~1 mL per layer, see Figure A.6). This discontinuous density gradient 
medium was then centrifuged at 26,000 g for 20 min to form a continuous density gradient 
medium. Then, 0.1-0.2 mL of concentrated L–NPL stock was loaded on top of the density gradient 
medium and centrifuged at 26,000 g for 2 hours. The denser L–NPLs migrated into the medium 
whereas the lighter nanodiscs remained at the top of the medium. After ultracentrifugation, the 
location of L–NPLs was identified by the absorption color (brown) and the fluorescence under UV 
light (red). The portion of medium containing L–NPLs was recovered and dialyzed (50 kDa 
membrane, in PBS or Tris) to remove excess NaCl. 
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Dye-labeled lipoprotein and nanodisc synthesis  
  Dye-labeled MSP. For quantification of MSP number per L-NPL, Alexa Fluor® 680-labeled 
MSP was prepared using amine-reactive Alexa Fluor® 680 NHS. A solution of the dye in 
anhydrous DMSO was added dropwise to a stirring solution of MSPE3D1 (50 uM) in 0.1 M 
sodium carbonate buffer (pH 8.3). The dye:MSP1E3D1 molar ratio was 10:1. The reaction was 
stirred at room temperature for 4 hours and the protein product was purified using a G-25 column 
(GE Healthcare). The number of dyes per MSP was measured spectroscopically by absorbance of 
MSP at 280 nm (ε = 29,400 cm−1 M−1) and absorbance of the dye at 683 nm (ε = 184,000 cm−1 
M−1). See Figure A.8a for the results.  
  Dye-labeled nanodisc. Dye-labeled nanodiscs containing were prepared by incorporating a dye-
labeled lipid during synthesis using previously described methodology.5 Briefly, Texas Red® 1,2-
Dihexadecanoyl-sn-Glycero-3-Phosphoethanolamine (DHPE) and DMPC were suspended in a 
solution of cholate (50 mM) in potassium phosphate buffer (KPi, pH 7.4) at a 3:97 molar ratio and 
sonicated for 5 min. Next,  phospholipids were added to MSP1E3D1 at a 130:1 lipid:MSP molar 
ratio and equilibrated for 30 min. Assembly of the Texas Red® DHPE-containing nanodiscs was 
initiated upon addition of Amberlite Biobeads for detergent removal and the mixture was gently 
rocked overnight at 22°C. Biobeads were removed and the homogenous labeled nanodiscs were 
purified using size exclusion chromatography with a Superdex 200 10/300 column (GE 
Healthcare) coupled to an HPLC (Waters Alliance 2695), running 100 mM KPi (pH 7.4) buffer at 
a 0.5 mL/min flow. Collected fractions of fluorescent nanodiscs were pooled and concentrated 
using Amicon Ultra (10,000 MWCO) centrifugal filters (Millipore).  
L–NPL labeling and PEGylation 
  L–NPLs with dye-labeled MSPs. L–NPLs were prepared and purified by following the steps 
described above using dye-labeled MSPs instead of normal (unlabeled) MSPs. The average 
number of MSPs per L–NPLs was determined based on the relative absorbance contributions from 
the dye and NPL. See Figure A.8b for the results. 
  Nanogold-labeled L–NPL. A purified L–NPL solution in PBS (~1.45 nM, 1 mL) was mixed with 
freshly prepared solution of Mono-Sulfo-NHS-Nanogold® in PBS at a 500:1 nanogold:L–NPL 
ratio. The mixture was incubated for 1 hour at room temperature, then excess nanogold was 
removed by multiple cycles of centrifugal filtration using a 100kDa MWCO filter (Amicon® Ultra, 
EMD Millipore). As a negative control, purified L–NPLs were mixed with non-functional 
174 
 
nanogold prepared by quenching Mono-Sulfo-NHS-Nanogold® with Tris (105 molar excess) for 
12 hours. 
  L–NPL PEGylation. A purified L–NPL dispersion in PBS (~1 nM, 0.5 mL) was mixed with 
PEG-NHS in DMSO (~0.625 mM, 50 μL) and incubated at room temperature for 2 hours. Excess 
PEG and DMSO were removed by multiple cycles of centrifugal filtration using a 50 kDa MWCO 
filter. 
Polymer-coated NPLs and QDs 
  Amphipol-coated core/shell CdSe/CdS NPLs. A CHCl3 solution of amphipol (~150 mg/mL, 0.2 
mL) was added dropwise to a NPL dispersion in CHCl3 (~1 µM, 2 mL) with vigorous stirring. The 
amphipol:NPL ratio was ~5,000:1. While stirring, the solvent was slowly evaporated in a vacuum 
desiccator. The dried film was redispersed in NaOH solution (0.1 M, 2 mL) with stirring and 
sonication. Any aggregates were removed using a 0.2 µm syringe filter. 
  Zwitterionic PTSB-coated QDs. Purified red-emitting QDs ( em 600 nm) in hexane were phase 
transferred into NMF by adding TMAH (100 equivalents of QD surface atoms). PTSB dissolved 
in NMF (0.5 mL) was mixed with the OH−-coated QDs in NMF (1 µM, 0.4 mL) (5:1 thiol to QD 
surface atom) and purged with N2 for 2 min. The mixture was stirred at 110°C for 4 hours and then 
diluted with 50 mM sodium borate buffer (pH 8.5, 4 mL). QDs were purified using centrifugal 
filtration (Amicon Ultra 50 kDa MWCO) in 50 mM sodium borate buffer (pH 8.5). The dilution – 
filtration cycle was performed five times. 
  Single-molecule imaging, diffusion, and cell interaction studies. For single-molecule 
brightness and blinking analysis, a dilute suspension of L–NPLs or QDs in PBS (~4 pM for L–
NPLs and ~100 pM for QDs, 100 μL) were spin-coated on a glass coverslip (2,500 rpm, 30 s) and 
a solution of dye-labeled nanodisc (1 nM, 100 μL) was drop-and-dried on a coverslip to achieve 
similar particle density. Then fluorescence was immediately measured under ambient conditions 
using a Zeiss epifluorescence/total internal reflectance fluorescence (TIRF) microscope. To 
determine brightness values from single-particle fluorescence videos, the method of Arnspang et 
al. was used (6).6Briefly, the center positions (x,y) of emitting spots were determined using the 
detection/estimation/deflation algorithm of Serge et al.7 and the intensities of 3x3 points centered 
on these spots were measured. Intensity histograms were then plotted for each emitter, which were 
fit to a sum of a symmetric Gaussian function (the background signal) and an asymmetric Gaussian 
function (the emitter signal) using the least squares method. These two Gaussian centroid positions 
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were compiled into histograms for each particle sample and plotted in Figure A.10. Because the 
emission wavelengths of the NPLs and QDs were similar, no scaling factor was needed to account 
for the wavelength dependent sensitivity of the detector. 
  For single-molecule diffusion studies, 0.5 nM L–NPLs were dispersed in a 50% (w/w) mixture 
of glycerol and aqueous sodium borate buffer (50 mM, pH 8.5). 100 μL of this solution was then 
transferred to a #1.5 coverglass and imaged using highly inclined and laminated optical sheet 
(HILO) microscopy. Emitter position centroids were determined using the methods of Serge et al.7 
to calculate mean squared displacements per time increment. The first 3-5 points from MSD plots 
were fitted to a line with slope equal to 2D, where D is the diffusion coefficient.  
For cell interaction studies, A431 cells (ATCC) were seeded at a density of 30,000–35,000 
cells/cm2 in CellView glass dishes (Greiner Bio-One) 24 hours before incubation with 
nanoparticles (1 nM) in phenol red-free serum-free DMEM (Cell Media Facility, UIUC).  
Incubation was allowed to proceed for 5 min, 15 min, 1 hour, or 24 hours at 37°C.  After the 
respective incubation times, the cells were rinsed with PBS three times in order to remove free 
nanoparticles. The cells were then stained sequentially with 3,3’-dioctadecyloxacarbocyanine 
perchlorate (DiO) (Santa Cruz Biotechnology) to label the membrane (10 min at 37°C) and 
Hoechst 33258 (Life Technologies) to label the nuclei (15 min at 4°C). After staining, the cells 
were fixed using paraformaldehyde (electron Microscopy Sciences) freshly diluted to 4% in PBS 
for 10 min at room temperature.  
  To study the effect of L–NPL surface PEGylation on cellular uptake, A431 cells (ATCC) were 
seeded at a density of 30,00–35,000 cells/cm2 in CellView glass dishes (Greiner Bio-One, 
Kremsmünster, Austria) 24 hours before addition of nanoparticles (0.076 nM) in phenol red-free 
serum-free DMEM (Cell Media Facility, UIUC). Incubation was allowed to proceed for 24 h at 
37°C. The cells were then rinsed with PBS three times in order to remove the free nanoparticles, 
and then stained and fixed using the same procedures described above.  
  Optical spectroscopy and fluorescence quantum yield (QY) measurements. Absorption spectra 
were obtained with an Agilent Cary 5000 UV–Vis–NIR spectrometer and fluorescence spectra 
were acquired using a Horiba NanoLog spectrofluorometer. For fluorescence QY measurements, 
the solution was diluted to give NPL absorption of ~0.1 at 490 nm. QY was calculated relative to 
a reference dye (fluorescein in 1mM NaOH, QY=92%). 
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  Transmission electron microscopy (TEM). TEM images were obtained using a JEOL 2010 LaB6 
high-resolution microscope in the Frederick Seitz Materials Research Laboratory Central Research 
Facilities at University of Illinois. For NPLs in organic solvents, samples were prepared by placing 
a drop of dilute NPL solution in hexane on a ultrathin carbon film TEM grid (Ted Pella; Product 
# 01824) and then wicking the solution off with a tissue. For L–NPLs, a drop of sample solution 
in buffer was added to the grid and allowed to incubate for 5 min before wicking off the liquid 
with a tissue. Then a drop of 1% PTA solution in DI water (pH 7) was loaded and wicked off after 
30–40s. 
  Elemental analysis and NPL extinction coefficient calculation. Elemental analysis was 
performed using a PerkinElmer Optima 2000DV ICP–optical emission spectrometer. Detailed 
protocols for sample preparation and NPL extinction coefficient calculation can be found in our 
previous work (8).8 
  1H NMR. 1H NMR spectra were recorded using a Varian U500 MHz or VXR-500 MHz 
spectrometer. 
  Zeta potential. For zeta potential measurement, a sample dispersion (L–NPLs, nanodiscs, or 
QDs) in high-salt buffer (e.g. PBS) was dialyzed against phosphate buffer (10 mM, pH 7.4) for 1 
day. Zeta potential was measured using a Malvern Zetasizer. 
  Ultracentrifugation. For density gradient centrifugation of L–NPL samples, ultracentrifugation 
was performed using a Beckman Coulter OptimaTM L-90K Ultracentrifuge equipped with a SW 
40 Ti swinging bucket rotor. 
  Fluorescence microscopy. For single molecule imaging and diffusion studies, samples were 
imaged via wide-field illumination on a Zeiss Axio Observer.Z1 inverted microscope with a 100x 
1.45 NA alpha Plan-Fluar oil immersion microscope objective with excitation from a 
488nm/100mW OPSL laser set in epifluorescence excitation mode. Excitation light was filtered 
using a 482/18 laser-line bandpass filter (Semrock Inc., Rochester, NY), and emission light was 
filtered with a 624/40 bandpass filter (Semrock Inc.). Images were acquired using a Photometrics 
eXcelon Evolve 512 EMCCD using Zeiss Zen software. Single molecule imaging was performed 
with epi-illumination of the sample and diffusion studies were performed using a HILO angle. 
Single-molecule brightness movies were collected at a rate of ~16 frames/s, while diffusion 
coefficient measurement movies were collected at a rate of ~7.6 frames/s. 
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  For cell interaction studies, fixed cell samples were imaged using a Zeiss LSM 700 confocal 
microscope with a 63x/1.40NA oil immersion objective at the Core Facilities at the Carl R. Woese 
Institute for Genomic Biology. The L–NPLs, QDs, and fluorescent nanodiscs were excited using 
a 555-nm laser line, DiO was excited using a 488-nm laser line, and Hoechst was excited with a 
405-nm laser line. Z-stacks of all three channels were acquired with slice spacing of ~0.74 µm 
spanning the entire height of the cell or cell cluster. 
A.3 INTRODUCTION, RESULTS AND DISCUSSION  
  Semiconductor nanocrystals have recently been the subject of extensive multidisciplinary studies 
due to their unique physical, optical, and electronic properties (2-4). Their primary emergent 
property is bright, stable fluorescence emission that is tunable across a broad range of wavelengths. 
This characteristic has enabled diverse applications as imaging agents and molecular probes in 
cells and tissues (2) as well as light-emitting components of diodes and display devices (3, 4). 
These particles have become especially useful in single-molecule imaging applications where their 
unique combination of high photon emission rate and compact size has facilitated the discovery of 
a host of new biomolecular phenomena (5, 6). 
  The prototypical materials used in these applications are either quasi-spherical quantum dots 
(QDs) or elongated nanorods (NRs) (7-10). But recently a new class of semiconductor nanocrystal 
has emerged called nanoplatelets (NPLs) with a variety of unusual structural and optical properties 
(8, 11, 12). NPLs are thin crystalline sheets with atomically flat surfaces, tunable from 1.2 to 2.8 
nm in thickness (11, 13, 14) and roughly 5 to 700 nm in lateral dimensions (15) and thus are 
colloidal analogues of quantum wells. Their fluorescence emission bandwidth is exceptionally 
narrow (8–20 nm full-width at half maximum, FWHM) compared to QDs (typically 25–35 nm 
FWHM) and organic fluorophores (typically 35–45 nm FWHM). Their light collecting efficiency 
can be very large; a single CdSe NPL with 1.5 nm thickness and 30 nm lateral dimensions has a 
molar extinction coefficient near 5 × 107 M−1 cm−1, roughly 1,000-times that of green fluorescent 
protein. In addition, unlike QDs, NPLs have high surface-area-to-volume ratios, which may 
facilitate efficient transfer of energy and charge and efficient modulation of their optical properties 
by changes in their local environment. Together, these properties could allow multiplexed imaging 
with reduced spectral crosstalk as well as enhanced sensitivity for analyte detection. Recently 
CdSe-based NPLs have been coated with CdS shells resulting in greatly enhanced fluorescence 
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quantum yield, (16-18) which is a critical step forward in the production of bright NPLs suitable 
for imaging in oxidizing environments. 
  However it is an outstanding current challenge to stabilize NPLs in aqueous solutions compatible 
with cells and tissues. Like QDs and NRs, these materials are synthesized in organic solvents at 
high temperature, and the resulting colloids are coated with aliphatic ligands (e.g. oleic acid) that 
render them insoluble in polar solvents. We found that conventional phase transfer techniques used 
for core/shell CdSe/CdS QDs, such as ligand exchange with hydrophilic thiolates, can damage the 
NPL structure and/or quench fluorescence entirely (see Figure A.4).  
  Here we demonstrate the production of a new class of water-stable NPLs encapsulated in 
lipoproteins. These lipoprotein–nanoplatelets (L–NPLs) derive from lipoprotein nanodiscs. 
Nanodiscs are nanoscale analogues of plasma membranes consisting of a phospholipid bilayer 
stabilized by helical, amphipathic membrane scaffold proteins (MSPs) that encircle the nanodisc 
like a belt (19-22). Nanodiscs are used to solubilize integral and transmembrane proteins in 
aqueous solution and encapsulate hydrophobic drugs (21, 23, 24), suggesting that they may be able 
to encapsulate and stabilize NPLs in aqueous solution. Lipid-encapsulation is a versatile strategy 
to transform hydrophobic colloidal nanoparticles into biocompatible nanostructures (25, 26). 
However it is critical to geometrically match the nanoparticle morphology with the native self-
assembled lipid structure to generate stable and individually coated nanoparticles. For example, 
spherical nanoparticles such as QDs and gold colloids are successfully encapsulated by 
amphiphilic polymers (27, 28), polyethylene glycol (PEG)-containing phospholipids (25, 26) and 
globular lipoproteins (29, 30) that individually self-assemble into spherical colloids in water. This 
is due to a high volume ratio of the polar head domain to the nonpolar tail domain, or a large 
packing parameter, which matches the high surface curvature of the encapsulated isotropic 
particles (31). We found that PEG-phospholipids can encapsulate flat NPLs, but their fluorescence 
entirely quenched, likely due to sparse lipid packing on the flat surfaces (see Figure A.4). Instead, 
lipids with small packing parameters are geometrically ideal for flat NPLs, however they have a 
tendency to form large liposomes entrapping multiple nanoparticles (32, 33). We therefore 
hypothesized that nanodisc components, which include phospholipids with packing parameters 
that yield flat structures and MSPs that stabilize the truncated edges with high curvature, are ideal 
for encapsulation of flat NPLs. 
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  L–NPLs were synthesized in a three step process schematically depicted in Figure A.1a, 
comprising (1) colloidal synthesis of CdSe core NPLs, (2) growth of a CdS shell, and (3) 
encapsulation of CdSe/CdS core/shell NPLs with nanodisc components (see Methods). CdSe was 
used for the core due to robust syntheses that allow independent tuning of lateral dimensions and 
thickness, as well as narrow-band fluorescence emission in the visible spectrum (11, 13). Figure 
A.1b shows an example of uniform rectangular-shaped CdSe NPLs with 41 nm × 11 nm lateral 
dimensions and 1.8 nm thickness, as measured by transmission electron microscopy (TEM). These 
thin nanocrystals are flexible and form stacks of twisted NPLs (see inset). Layer-by-layer shell 
growth techniques were recently introduced for deposition of CdS, which has a wider bandgap 
(2.5 eV) than the core CdSe material (1.76 eV) (16-18). The shell boosts quantum yield and allows 
better preservation of fluorescence in aqueous media (see below). Figure A.1c shows that after 2 
monolayers (ML) of growth, the lateral dimensions were similar (42 nm × 12 nm), but the thickness 
increased to 3.0 nm. Twisted and stacked NPLs were no longer observed (see inset) indicating that 
shell growth increased structural rigidity. Finally, these core/shell NPLs were encapsulated in 
lipoprotein nanodisc components through an evaporation–encapsulation process described below 
(20). Counter-stained TEM images in Figure A.1d show individual core/shell NPLs uniformly 
surrounded by a 3–4 nm organic coating, a thickness consistent with an inner layer of oleate ligands 
bound to the NPL surface and an outer layer of phospholipids and MSPs.  
  Efficient encapsulation of NPLs required three components: phospholipids, detergents, and MSPs 
(see Figure A.5). To generate L–NPLs, NPLs were dispersed in chloroform and self-assembled 
with excess phospholipids through slow solvent evaporation followed by dispersion in phosphate 
buffered saline (PBS) containing a mixture of detergents (sodium cholate or n-decyl-β-maltoside) 
and amphipathic MSPs (e.g. MSP1E3D1). Zwitterionic phospholipids were used to optimize 
biocompatibility and dispersion stability, and were chosen to have a packing parameter near 1 for 
dense assembly on the flat NPL surfaces; we used 1,2-dimyristoyl-sn-glycero-3-phosphocholine 
(DMPC) or 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC). Eliminating any one of 
the three components significantly reduced the phase transfer efficiency and stability of NPLs in 
aqueous solution.   Phospholipids alone natively self-assemble into larger liposomal structures (34, 
35), yielding a low percentage of NPLs transferred into aqueous buffer (most products were 
insoluble aggregates). Detergents dissociate liposomal structures into smaller metastable micelles 
(34); this increased the phase transfer efficiency of NPLs but aggregation was still substantial. 
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However the addition of MSPs caused NPLs to readily disperse in water without substantial 
aggregates. These L-NPLs were stable for more than one month after extensive dialysis and density 
gradient centrifugation in high salt (even in > 4 M NaCl solution) to remove empty nanodiscs and 
expel detergents (Figure A.6). MSPs also eliminated fluorescence quenching from detergents that 
strip off oleate ligands from the NPL (Figure A.7).  
  We characterized L-NPLs using multiple analytical methods and determined that the structure is 
consistent with the schematic in Figure A.1a, in which lipids cover flat NPL surfaces and MSP 
proteins adsorb to sharp edges. For L–NPLs made from NPLs with average dimensions of 37 nm 
× 10 nm × 3 nm, it was determined that there was an average of 1,193 DMPC lipids per NPL based 
on elemental analysis of cadmium (which is only in the CdSe/CdS NPL core) and phosphorous 
(only in the phospholipid). Assuming that DMPC adopts a similar area as in nanodiscs (0.69 nm2 
DMPC-1) (20), this quantity is consistent with a monolayer coating of the flat top and bottom of 
the NPL (740 nm2 surface area, or 1,070 lipids) and some of the sides (282 nm2 surface area, or 
409 lipids). The slight deficiency is likely covered by MSP proteins. We calculated an average of 
7.7 MSPs per L–NPL by spectral analysis of L–NPLs prepared with dye-labeled MSP (see Figure 
A.8). MSPs likely localize to edges to interact with lipid tail sides where they reside analogously 
in nanodiscs. This is consistent geometrically, as MSP1E3D1 extends to a length of 38 nm in a 
nanodisc (circumference of a nanodisc with 13 nm diameter) (20), so theoretically at least 5.0 
MSPs are needed to cover both top and bottom edges of the NPL (total perimeter length of 188 
nm), only slightly less than the measured value of 7.7. Deviations may arise from protein 
conformation differences on the circular nanodisc versus the rectangular NPL. This model was 
further justified by an imaging study to localize MSPs using TEM. We conjugated gold colloids 
activated with N-hydroxylsuccinimide (NHS) to L-NPLs. Because only the MSP protein contains 
primary amines with which NHS will conjugate, gold should only localize to the protein. TEM 
showed that NHS-gold was almost exclusively localized around the L–NPL perimeter, as opposed 
to the particle center (see Figure A.1d inset and Figure A.9). 
  The optical properties of CdSe core and CdSe/CdS core/shell NPLs before and after coating with 
lipoprotein/MSP are shown in Figure A.2. The crystalline CdS shell was necessary for maintaining 
fluorescence in water, as core-only NPLs completely quenched after lipoprotein/MSP 
encapsulation, despite a quantum yield (QY) of 2.3% in organic solvents. With CdS shell growth, 
QY increased significantly in organic solvents, and could reach 80% with thick shells (7–8 ML) 
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(18). Unlike core-only NPLs, the fluorescence of core/shell NPLs was preserved after 
encapsulation, but the QY partially decreased in a manner dependent on the CdS shell thickness. 
For a 2-ML shell (the structure used in cells below) a 4.3% QY in hexane resulted in a 1.6% QY 
in water (Figure A.2b, top). Thinner shells yielded more substantial QY loss while thicker shells 
provided greater QY retention. While a shell is necessary to maintain fluorescence, increasing 
thickness diminishes the unique optical attributes of NPLs as well as their potential for 
environmental sensitivity and flexibility. For example, CdSe-only NPLs have exceptionally 
narrow emission bands (FWHM = 9 nm for λem = 515 nm), but they monotonically broaden with 
shell growth, likely due to increasing structural heterogeneity or/and increased electron–phonon 
coupling (18). We find that at intermediate shell thickness (2–3 ML), bands are still much more 
narrow (FWHM = 21 nm at λem = 626 nm) than those of spectrally-matched QDs (FWHM = 25–
35 nm at λem = 600–650 nm), so we focused on this structural set for further investigations.  
  To investigate the potential of L–NPLs as fluorescent imaging probes, we measured their optical 
and diffusive behavior at the single-particle level using fluorescence microscopy. L–NPLs and 
QDs with similar emission wavelengths were spin-coated from dilute aqueous solutions on a glass 
coverslip. Individual emitters were readily distinguished by fluorescence intermittency (blinking) 
and homogeneous intensity levels in the blinking “on” state. L–NPLs exhibited longer “off”-times 
and shorter “on”-times (see Figure A.10). The “on”-time brightness values were measured for at 
least 250 single particles using the method of Lagerholm (see Methods) (36). Average relative 
single-particle brightness values were similar for L–NPLs (Brel,sp  = 2.06 ± 0.98) and QDs (Brel,sp  = 
1.94 ± 0.90), with L–NPLs being slightly brighter (by 6%). At the ensemble level, absolute 
brightness values were calculated from the relation Brel = 𝑄𝑌 ∙ 𝜀, where ε is the extinction 
coefficient calculated from the particle core volume from TEM and the CdSe concentration derived 
from elemental analysis (37). Ensemble brightness values were similar for L–NPLs (Brel,en  = 4.0 
× 105 cm−1 M−1) and QDs (Brel,en  = 4.7 × 10
5 cm−1 M−1), with L–NPLs being slightly dimmer (by 
14%). The small mismatch between ensemble and single-particle brightness values may originate 
from errors in extinction coefficient calculations due to anisotropic NPL structure, the possible 
presence of “dark” L–NPLs not counted in single-particle analyses, or preferential alignment on 
the substrate. These results confirmed that L–NPLs are bright single-molecule emitters, 
comparable to QDs, but with substantially narrower bandwidths.  
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The diffusion of L–NPLs was probed through single-particle fluorescence imaging in dilute 
solutions. By fitting mean squared displacements of 429 single particle trajectories to a model of 
Brownian motion, the mean center-of-mass diffusion coefficient was calculated to be 1.55 ± 0.71 
μm2 s−1 in 50% (w/w) glycerol–sodium borate buffer (Figure A.10). By the Stokes-Einstein 
equation, the diameter of an equivalent sphere is 46.1 nm, which is close to many QDs in common 
use and thus appropriate for cellular and molecular imaging applications (38).  
  Finally, we investigated the interactions of L–NPLs with living A431 human epidermoid 
carcinoma cells to evaluate their potential for use as single-molecule imaging probes and cellular 
labels (see Figure A.3). We compared L–NPLs directly with two chemically analogous 
nanoparticles: nanodiscs composed of the same lipid and lipoprotein components labeled with a 
fluorescent dye (Texas Red) and zwitterionic QDs. All three had similar red emission wavelengths. 
After casting on glass coverslips, all three were readily visible at the single-particle level under 
identical excitation conditions (Figure A.3a). Zeta potential measurements in phosphate buffered 
solution indicated that all nanoparticles were anionic; the L–NPLs and nanodiscs were similar (–
25 to –30 mV) but the zwitterionic QDs, which had no protein component, had a lower charge (–
11 mV) (Figure A.3b). When added to cells at equal particle concentrations (1 nM), cells exposed 
to L–NPLs showed a much higher level of intracellular red fluorescence (Figure A.3c–e) compared 
to control cells and cells exposed to nanodiscs or QDs (Figure A.3f–h). We tracked this process 
over time via confocal microscopy and stained cells with a nuclear dye (blue) and a plasma 
membrane dye (green). We observed that internalization is rapid, with L–NPLs colocalizing with 
the membrane within 5 minutes of exposure, and becoming internalized within 15 minutes. After 
24 hours, uptake was substantial, consisting of bright punctate cytosolic spots of L-NPLs likely in 
endosomal vesicles. It is surprising that among three chemically similar panicles, only L–NPL 
structures exhibited substantial uptake. Zwitterionic components were shared by all particles, so 
they likely did not contribute. The MSP protein was also not likely the contributor, since MSP-
containing nanodiscs did not exhibit substantial uptake. A change in protein conformation is also 
not likely the source, as the result was similar when MSP was PEGylated to block protein-mediated 
association with cells (see Figure A.11). We believe that strong uptake arises from the very high 
surface area and low curvature of L-NPLs, for which multiple weak adsorption events can become 
substantial in strength through multivalency effects. Overall these observations suggest that L–
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NPLs are a promising class of fluorophore for intracellular imaging and for efficient fluorescence 
tagging of cells. 
  In conclusion, we engineered a new composite nanocrystal comprising a quantum well-like 
nanoplatelet encapsulated within phospholipid and lipoprotein components of a nanodisc, yielding 
colloidally stable fluorophores with bright emission at the ensemble and single particle level. 
Employing geometrically compatible materials is critical, and extensive studies in nanodisc 
engineering (19-24) set the stage for diverse chemistries and biological functionality of L–NPLs. 
The unique shapes and optical properties of these materials are intriguing in the context of single-
molecule imaging, optical cellular tagging, and even drug delivery, as high aspect ratio particles 
have been observed to have enhanced permeation through crowded tissues and unique delivery 
capabilities in living animals (39, 40). To our knowledge, these studies are the first example of a 
colloidal fluorescent quantum well employed in biological systems. The unique finding of rapid 
cellular entry suggests that these materials may be immediately useful for cellular labeling 
applications to allow highly multiplexed spectral encoding of cellular identity. Furthermore this 
new material composite opens the door to reveal how 2-dimensional materials interact with 
biological systems at the single-particle level. 
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A.5 FIGURES  
 
 
Figure A.1. Synthesis and structure of lipoprotein–nanoplatelets. (a) Schematic illustration of 
synthesis steps. TEM images depict (b) CdSe core NPLs (unstained), (c) CdSe/CdS core/shell 
NPLs (unstained), and (d) L–NPL hybrids (counter-stained). Insets show side-views of the 
structures. Top inset in (d) shows L–NPLs after MSP conjugation to gold colloids. Scale bars = 50 
nm in wide-field images and 20 nm in insets. 
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Figure A.2. Optical properties of CdSe and CdSe/CdS L–NPLs. (a) Visible absorption (black) and 
fluorescence (red) spectra of CdSe core (bottom) and CdSe/CdS core/shell (top) NPLs in hexane 
(dotted lines) and corresponding L–NPL structures in PBS (solid lines). (b) Photographs of sample 
solutions under room light (left) or 366-nm lamp excitation (right).  
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Figure A.3. (a) Single-particle fluorescence images of L-NPLs, dye-labeled nanodiscs, and QDs 
cast from aqueous solution. (b) Zeta potential measurements of the three samples. (c-h) 
Fluorescence confocal microscopy images of A431 cells as 3D z-stack projections of three color 
channels. Blue = nuclear dye, Green = membrane dye, Red = L-NPL, nanodisc, or QD. Duration 
of exposure to each nanoparticle is given for each image. Uptake was only significant for L-NPLs. 
All scale bars = 10 μm. 
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Figure A.4. Photos of CdSe/CdS core/shell NPL dispersions (a) under room light and (b) under 
366-nm UV excitation. As-synthesized organic-dispersed NPLs show strong fluorescence in 
hexane (top phase) whereas MPA-capped aqueous NPLs show no fluorescence in water (bottom 
phase). 
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Figure A.5. Effects of lipid composition on the encapsulation efficiency of NPLs. Photographs 
depict vials containing NPLs dispersed in PBS (left) and corresponding reaction tubes containing 
insoluble NPL aggregates (right). NPLs were mixed with (a) DMPC, (b) DMPC with cholate, or 
(c) DMPC, cholate, and MSP. The primary structures of the corresponding self-assembled lipids 
without NPLs are depicted below, showing liposomes, micellar mixtures, and lipoprotein 
nanodiscs. 
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Figure A.6. L–NPL purification by NaCl density gradient centrifugation. (a,b) Photos of 
ultracentrifugation tubes containing NaCl density gradient media with (a) impure L–NPLs in Tris 
buffer and (b) impure Alexa Fluor® 680-labeled L–NPLs in PBS loaded at the top. Photos on the 
left show the density gradient media before ultracentrifugation. The numbers indicate densities of 
different NaCl layers and the horizontal dotted lines show their initial boundaries. Photos on the 
right show the same tubes after ultracentrifugation at 26,000 g for 2 hours. L–NPLs migrated 
downward into heavier NaCl media and can be located both by pale brown region under room light 
(left) and red fluorescence under UV light (right). (c,d) Negative-stained TEM images of aliquots 
obtained at the top and at the middle regions in the density gradient media (indicated by the braces) 
after ultracentrifugal purification of (c) L–NPLs and (d) Alexa Fluor® 680-labeled L–NPLs. TEM 
images of the top phase show numerous small white spots on the stained background verifying the 
presence of empty nanodiscs. TEM images of the middle phase show L–NPLs placed on solid dark 
backgrounds without any small white spots indicating the successful separation of L–NPLs from 
empty nanodiscs. 
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Figure A.7. Photographs of CdSe/CdS core/shell L–NPL solutions in PBS under room light (top) 
and under 366-nm UV excitation (bottom). NPLs encapsulated with POPC alone showed strong 
fluorescence in water (S1), but these POPC-encapsulated NPLs lost their fluorescence when 
cholate was added (S2). Adding MSPs eliminated cholate-enduced fluorescence quenching (S3) 
due to the formation of L–NPLs. 
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Figure A.8. Quantification of MSPs in L–NPLs. (a) Absorption spectrum of Alexa Fluor® 680-
labeled MSPs, indicating an average number of 0.75 dye per MSP. (b) Absorption spectrum of 
purified L–NPLs prepared with Alexa Fluor® 680-labeled MSPs. Inset shows the least squares 
fitted curve (red dashed line) comprising a linear combination of the absorption spectra of Alexa 
Fluor® 680-labeled MSPs and L–NPLs prepared with unlabeled MSPs (red dotted lines). The 
results show an average number of 7.7 MSPs per L–NPL. 
 
 
 
 
 
 
 
 192 
 
 
Figure A.9. Close-up images of L–NPLs conjugated to gold colloids through NHS-reactions with 
primary amines on the MSP lipoprotein. White arrows locate gold colloids. 
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Figure A.10. (a) Representative single-particle blinking traces of L–NPLs (top) and QDs (bottom). 
(b) Relative single-particle brightness values (Brel) of L–NPLs (top) and QDs (bottom). (c) Single-
particle diffusion coefficient histogram of L–NPLs in a glycerol-water solution.  
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Figure A.11. Confocal microscope images with z-stacks of A431 cells after 24-hour incubation 
(a) without L–NPLs, (b) with L–NPLs, and (c) with PEGylated L–NPLs, showing no major impact 
of PEGylation on cellular uptake. 
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APPENDIX B: METHODS FOR INCORPORATION OF 
CYCLOOXYGENASE-2 IN THE MEMBRANE BILAYERS OF 
NANODISCS 
 
B.1 ABSTRACT 
Cyclooxygenases (COX-1 and COX-2) oxygenate arachidonic acid (AA) to generate 
prostaglandins. The enzymes associate with one leaflet of the membrane bilayer. We utilized 
nanodisc technology to investigate the function of human (hu) COX-2 and murine (mu) COX-2 in 
a lipid bilayer environment. huCOX-2 and muCOX-2 were incorporated into nanodiscs composed 
of POPC, POPS, DOPC, or DOPS phospholipids. Size-exclusion chromatography and negative 
stain electron microscopy confirm that a single COX-2 homodimer is incorporated into the 
nanodisc scaffold. Nanodisc-reconstituted COX-2 exhibited similar kinetic profiles for the 
oxygenation of AA, eicosapentaenoic acid, and 1-arachidonoyl glycerol compared to those derived 
using detergent solubilized enzyme. Moreover, changing the phospholipid composition of the 
nanodisc did not alter the ability of COX-2 to oxygenate AA or to be inhibited by various 
nonselective NSAIDs or celecoxib. The cyclooxygenase activity of nanodisc-reconstituted COX-
2 was reduced by aspirin acetylation and potentiated by the nonsubstrate fatty acid palmitic acid 
to the same extent as detergent solubilized enzyme, independent of phospholipid composition. The 
stabilization and maintenance of activity afforded by the incorporation of the enzyme into 
nanodiscs generates a native-like lipid bilayer environment to pursue studies of COX utilizing 
solution-based techniques that are otherwise not tractable in the presence of detergents. 
 
 
 
 
 
 
Reprinted, with permission, from Orlando BJ, McDougle DR, Lucido MJ, Eng ET, Graham LA, Schnedier C, Stokes 
DL, Das A, Malkowski MG. Cyclooxygenase-2 catalysis and inhibition in lipid bilayer nanodiscs. Arch Biochem 
Biophys. 2014 15;546:33-40. PMID: 24503478 
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B.2 METHODS 
Incorporation of COX-2 into nanodiscs. COX-2 was reconstituted into nanodiscs comprised of 
POPC, POPS, DOPC, or DOPS phospholipids. Briefly, stock phospholipids were dissolved in 
chloroform, their concentrations were determined by total phosphate analysis using the 
manufacturer’s protocol, followed by resuspension in 50 mM TRIS, pH 7.4, 150 mM NaCl, and 
sodium cholate for use in nanodisc assembly. The sodium cholate concentration was at a 
concentration twice that of the phospholipid. The resulting mixtures were chilled on ice prior to 
the addition of MSP1E3D1(+) and detergent solubilized COX-2 to achieve a final 
phospholipid:MSP1E3D1(+):COX-2M ratio of 1950:15:1. The volume of the incorporation 
mixture was designed such that the final concentration of sodium cholate was at least 20 mM and 
twice the concentration of the phospholipid. The mixtures utilizing POPC, DOPC, and DOPS were 
incubated at 4 °C for 1 h, followed by the addition of 0.8 g of BioBeads per mL of reconstitution 
mixture. For POPS, the mixture was incubated at room temperature for 1 h, followed by BioBeads 
addition. Incorporation mixtures were incubated with BioBeads overnight to initiate detergent 
removal and concomitant nanodisc assembly. The BioBeads were subsequently removed and the 
resulting sample was dialyzed for 4 h at 4 °C against 1L 50 mM TRIS, pH 7.4, 150 mM NaCl. For 
purification of nanodisc-reconstituted COX-2, the dialyzed sample was loaded onto a column 
(2.5 cm × 10 cm) containing 10 mL of Anti-FLAG M2 affinity resin, washed with 10 column 
volumes of 50 mM TRIS, pH 7.4, 150 mM NaCl, and eluted with wash buffer containing 
100 μg/mL FLAG peptide. The elution fractions from the FLAG affinity column were pooled and 
loaded onto a 1 mL HiTrap Chelating HP column. The column was washed with 10 column 
volumes of 50 mM TRIS, pH 7.4, 150 mM NaCl, followed by 10 column volumes of 50 mM TRIS, 
pH 7.4, 150 mM NaCl, 35 mM imidazole. Nanodisc-reconstituted COX-2 was eluted from the 
column with 50 mM TRIS, pH 7.4, 150 mM NaCl, 350 mM imidazole. Fractions were pooled and 
dialyzed overnight at 4 °C against 25 mM TRIS, pH 7.4, 150 mM NaCl. For size-exclusion 
chromatographic analysis, dual affinity purified muCOX-2 reconstituted into POPC nanodiscs was 
loaded onto a Superdex 200 10/300 GL column equilibrated in 50 mM TRIS, pH 7.4, 100 mM 
NaCl. 
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B.3 FIGURES 
 
 
 
Figure B.1. Biophysical characterization of POPC:muCOX-2. (A) SDS-PAGE gel depicting 
the results from the dual affinity purification of nanodisc-reconstituted COX-2. Lane 1, molecular 
weight marker; lane 2, detergent solubilized COX-2 control; lane 3 MSP1E3D1(+) control; lane 
4, crude nanodisc incorporation mixture following detergent removal with BioBeads; lane 5, 
FLAG column flow through; lanes 6–9, FLAG affinity column wash fractions; lane 10, purified 
nanodisc-reconstituted COX-2 eluted from IMAC affinity column. (B) SEC Analysis of 
incorporation: muCOX-2 reconstituted into POPC nanodiscs (solid line); empty POPC nanodiscs 
(dotted line). 
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Figure B.2. Negative Stain EM Analysis of POPC:muCOX-2.  (A) Representative negative-
stain EM micrograph of POPC:muCOX-2. (B) 2D k-means class averages of POPC:muCOX-2 
particles. 6,069 particles were windowed into 150 × 150 pixel individual images, aligned to each 
other, and subjected to ten cycles of multireference alignment and k-means classification. The 
numbers at the bottom right designate the number of particles used in each average and the box 
size of each image is 44nm × 44nm. The images suggest that the COX-2 homodimer lies at the 
edge of the nanodisc scaffold. However, this is due to the nature of the sample preparation for 
negative-stain EM analysis, which flattens the sample prior to analysis. (C) Model depicting 
muCOX-2 (PDB id 3HS5) bound to one leaflet of the POPC nanodisc. Nanodisc scaffold proteins 
and POPC lipids are colored green and gray, respectively. The muCOX-2 homodimer is colored 
blue, with the MBD of each monomer colored red. 
 
 
 
 
